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Over the past two decades, we have seen impressive gains in the global fi ght against tuberculosis (TB). 
An estimated 41 million people have been successful-
ly treated, and 6 million deaths have been averted. Yet 
there remain serious challenges to reach all people who 
need quality TB care. Every year as many as 4 million 
people with TB fail to receive such care, and their illness 
is never documented, and 400 000 MDRTB cases are not 
having access to proper diagnosis and treatment.
Operational research – which aims to develop interven-
tions that result in improved policies; better design and 
implementation of health systems, and more effi cient 
methods of service delivery – is critical to reaching the 
unreached people who need TB care. It produces evi-
dence that lays the groundwork for improving current 
strategies and introducing new tools and new partners. 
For this reason, the Stop TB Partnership has included a 
new section on operational research in the Global Plan to 
Stop TB 2011–2015. 
In 2010, the Stop TB Partnership, the World Health Or-
ganization Stop TB Department and the Global Fund to 
Fight AIDS, Tuberculosis and Malaria jointly organized an 
expert meeting and workshop on operational research, 
followed by international consultations. The goal was to 
identify priority areas in which knowledge gaps hamper 
optimal implementation of TB control activities. The out-
come of these activities formed the basis for this publi-
cation.
We have identifi ed fi ve priority areas; and for each of 
these, we provide a list of the critical questions that must 
be addressed to improve TB care and control at the 
community, national, regional and international levels. In 
addition, for each of the critical questions, we provide 
a synopsis of a suitable study design and the methods 
required to identify and test suitable solutions. 
In making this material widely available we hope to en-
courage national TB control programmes and research 
institutions in countries with a high burden of TB to lead 
operational research projects that will help them dimi-
nish the impact of TB on their populations. All concer-
ned stakeholders, including civil society and affected 
communities, should participate in the development of 
operational research agendas. We also have high hopes 
that international funders will better understand the clear 
value of operational research and reinforce their commit-
ments to supporting it. 
Reaching every person who needs TB care is one of 
the primary goals of the Stop TB Partnership. There are 
multiple paths to reaching that point, and they must ulti-
mately converge. Operational researchers should now 
have what they need to forge those paths. The present 
publication, driven by the Stop TB Partnership Research 
Movement, will be the appropriate vehicle for this.
Dr Lucica Ditiu
Executive Secretary
Stop TB Partnership
Geneva
PREFACE
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Enabling and promoting research is a key compo-nent of the Stop TB Strategy, and it should be pur-
sued vigorously. Despite dramatic progress on global TB 
control in recent decades, many challenges remain. The 
fi ght against this ancient scourge must now accelerate. 
Clearly we need new and better tools for the prevention, 
diagnosis, treatment and care of TB and its associated 
conditions and complications. However, that will not be 
enough. We also need to continue to develop innovative 
approaches to ensure equitable access to these tools for 
all who need them. And those approaches need to be 
adapted and fi ne-tuned based on local epidemiological 
and health system context.
Most innovations cannot be translated into effective local 
action without careful planning and adaptation. Well-plan-
ned and conducted operational research, in addition to 
routine surveillance, is required to assess the national and 
local epidemiological and health system situation, as well 
as to evaluate different implementation modalities for lo-
cally relevant interventions. There are, however, many bar-
riers for this essential step in the chain of events from basic 
research to meaningful practice. Countries and national TB 
programmes often have limited capacity for operational 
research, and a strategically developed research agenda 
is often missing. There is, therefore, a need for guidance 
on which questions to address, how to do it, and how to 
strengthen the capacity for operational research.
Fostering better and more relevant operational research 
and ensuring careful evaluations of local experiences will 
not only help local implementation. It will also greatly assist 
the development of global policy. As we have learnt over 
the years, ideas for global solutions often stem from local 
innovations. Local experience was essential, for example, 
in the development of global policy on TB/HIV collabora-
tion, engagement of all health-care providers, management 
of drug-resistant TB, community involvement, and current-
ly on the adoption of new rapid tests for TB and MDR-TB. 
We learn from countries, and countries learn from each 
other. Time and again, essential knowledge on the effec-
tiveness, cost-effectiveness, feasibility, unintended conse-
quence, affordability and health systems requirements for 
the implementation of various tools and approaches have 
come from high quality operational research.  
However, this only works when a good system for ope-
rational research prioritization, planning and implementa-
tion is in place. We know that many opportunities to test 
new approaches and to learn from successful local expe-
riences have been missed because of a lack of strategic 
thinking. This publication will help national programmes, 
researchers and other stakeholders to identify key ques-
tions for operational research, do the needed planning 
and capacity strengthening, and raise the required re-
sources. Through its dissemination and use we anticipate 
a further strengthening of the global TB research move-
ment and, ultimately, to better, evidence-based global 
policy and local practice. 
Dr Mario Raviglione
Director
Stop TB Department
World Health Organization
Geneva
Much progress has been made in global efforts to improve TB care and control over the past 20 years, 
and the incidence and mortality rates of tuberculosis 
are now declining globally. A substantial increase in fun-
ding from both domestic and international sources has 
enabled these successes. However, these trends need to 
be sustained and accelerated if the TB related Millennium 
Development Goals (MDGs) are to be achieved and the 
burgeoning problems of TB/HIV co-infection and multiple 
and extensively drug-resistant TB are to be effectively 
addressed. 
2011 marks a critical point for TB control as we enter the 
last fi ve years of the journey towards the MDGs. The new 
Global Fund Strategy for 2012–2016 emphasizes a signi-
fi cant expansion of TB control, more strategic focus of 
investments where they are most needed, and ambitious 
scale up of actions to contain and treat MDR-TB. 
The Global Fund is committed to increasing uptake of ope-
rational research to improve TB control in order to maxi-
mize the impact of its investments. In this regard, countries 
are encouraged to allocate up to 10% of total grant bud-
gets to activities related to monitoring and evaluation inclu-
ding system strengthening, data management, operational 
research, and programme and impact evaluation.
Priorities in operational research to improve tuberculosis 
care and control is very timely for building the evidence base 
for effective implementation of TB programmes. It provides 
a clear road map of priorities in operational research to help 
countries improve implementation of TB control activities 
in critical areas. The priority operational research questions 
outlined in this report are also aligned with the Stop TB Par-
tnership’s Global Plan to Stop TB 2011–2015.
Through a consultative process led by the Stop TB Par-
tnership Research Movement and funding from the Glo-
bal Fund, fi ve key areas were identifi ed in which knowle-
dge gaps hamper effective implementation of TB control: 
access, screening and diagnosis of MDR-TB; develop-
ment of sustainable collaboration with all practitioners; 
prevention and treatment of TB in people living with HIV; 
optimal access and delivery of treatment for susceptible 
and drug-resistant TB; and operational research capacity 
building. New tools that offer prospects for substantially 
improving TB control are now available. Operational re-
search is critical in generating evidence on the accelera-
tion of the uptake of new interventions, diagnostic tools 
and technologies.
This publication is an important addition to the key re-
sources for national TB control programmes to address 
the technical and structural challenges that impede opti-
mal prevention, detection and treatment of all forms of 
TB. It will contribute greatly to the conduct of robust ope-
rational research,  helping to identify major challenges 
and determine the solutions to address them. 
Professor Rifat Atun
Director 
Strategy, Performance and Evaluation Cluster
The Global Fund to Fight AIDS, Tuberculosis and 
Malaria
Chair, Stop TB Partnership Coordinating Board
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EXECUTIVE SUMMARY 
For the past 15 years, global tuberculosis (TB) 
control efforts have generated impressive results, 
and the implementation of the World Health 
Organization (WHO) Stop TB Strategy (1995–2008) 
is estimated to have cured 36 million people with TB 
and averted 6 million deaths worldwide. However, 
despite these important achievements, the burden 
of TB continues to rise, and current control efforts 
need to be greatly improved if eliminationa is ever 
to be achieved. For this, new highly effective and 
widely accessible diagnostics, drugs and vaccines 
are needed to support TB control globally, and 
technical and structural challenges that impede 
optimal detection, treatment and prevention of all 
forms of TB must be overcome. Ensuring the smooth 
and wide uptake of control tools and the resolution 
of barriers to TB control is the role of operational 
research, which helps to identify the solutions that 
will have a signifi cant impact on case detection and 
cure rates, and help improve the effectiveness of 
TB care services.
Operational research is increasingly recognized 
as an essential element of global TB control. In its 
broad sense, operational research covers a large 
spectrum of activities, from local setting-oriented 
research to improve TB control programme 
performance, to international policy-guiding 
research, including the fi eld evaluation of new 
interventions to improve TB control. At the national 
level, an enabling environment for conducting 
operational research is key to achieving optimal 
TB control performance, and managers should 
be aware of the benefi ts of building research 
capacities through collaboration with research 
institutions, universities and nongovernmental 
organizations. At the international level, a robust 
evidence base is increasingly required for guiding 
policy-making (including the use of systematic 
reviews and GRADEb evaluation), often relying 
on operational research projects that give rise to 
changes in international policy. 
New funding opportunities are emerging to 
improve the use of existing control technologies 
(e.g. increased case-fi nding, simplifi ed treatment 
monitoring, etc.), and to evaluate the impact of 
introducing new tools in various health systems 
and epidemiological settings. In this context, the 
TB Research Movement of the Stop TB Partnership 
and the Global Fund to fi ght AIDS, Tuberculosis and 
Malaria jointly initiated a process to identify ways to 
promote rational operational research for TB control. 
This included an expert meeting and a workshop, 
accompanied by wide stakeholder consultations. 
The objective was to critically address the increasing 
need for improved and rational operational research 
in TB control, and identify key areas where evidence 
was lacking for proper implementation of new and 
existing technologies, as well as novel service 
delivery models. 
As a result of this process, carried out in 2010, 
fi ve key areas were identifi ed in which knowledge 
gaps hamper optimal implementation of TB control 
activities. These are:
1. Access, screening and diagnosis of TB;
2. Sustainable collaboration with all care-
providers for TB control;
3. Prevention of TB in people living with HIV, 
and joint treatment of HIV and TB;
4. Access to and delivery of treatment for 
drug-susceptible and M/XDR-TB;
5.  Capacity-building for operational research.
In each of these fi ve areas, critical and outstanding 
questions to improve TB care and control at the 
national and international levels were identifi ed. 
The objective of this publication is to help 
programme managers, consultants and researchers 
who intend to conduct TB-related operational 
research to identify the appropriate methods to 
be used according to the questions that are being 
addressed, and prepare for grant applications to 
donors (including the Global Fund) for operational 
research support. 
- In the fi rst part of the publication, the fi ve 
above areas are reviewed, with identifi cation 
of the priority questions to be addressed 
and their rationales. 
a Defi ned in the Stop TB Partnership Global Plan to Stop TB 2011–2015 as ≤ 1 TB case per million population per year.
b See: Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group: 
http://www.gradeworkinggroup.org
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- In the second part (the annexes), after 
a broad description of the main study 
designs used in operational research, the 
methods of the suggested research to be 
conducted to address each question are 
succinctly described, using the following 
standard synopsis:
o objective(s)
o design outline
o setting/study population
o methods: recruitment of subjects 
(eligibility criteria); intervention (as 
appropriate)
o expected endpoints
o analysis
o guidance for sample size calculation 
(and estimated number of participants)
o expected duration/timeline
o suitable scale
o estimated budget range.
The main outstanding questions in the fi ve priority 
areas are listed thereafter. 
1. Improving access, screening and diagnosis 
of TB
TB diagnosis in most endemic countries still 
relies mainly on direct sputum smear microscopy, 
and the diagnostic services for drug-resistant 
TB (DR-TB) are based on complex technologies 
that require sophisticated, biosafe laboratories 
with highly-trained staff. New tools are becoming 
available and, since 2007, WHO has endorsed 
the use of over 10 new TB diagnostic tools 
(technologies or approaches) that, if used wisely, 
could improve TB control considerably. In 2010, 
WHO endorsed a new automated real-time 
nucleic acid amplifi cation technology (NAAT) 
for rapid and simultaneous detection of TB and 
rifampicin resistance (the Xpert MTB/RIF system) 
that offers the prospects of drastically improving 
the diagnosis of active TB and MDR-TB. In 
general, there is insuffi cient evidence available 
to determine which package of current and 
newly-developed diagnostic tests would work 
best in a given set of circumstances, and there 
is as yet little guidance to countries on what new 
diagnostic tools, or combinations of tools, should 
be implemented in particular epidemiological/
health system settings or for different risk groups, 
and at what level of the health service it should 
be done. Operational research with collection 
of multiple country experiences should be the 
starting point to better guide diagnostic scale-up, 
and respond to the current outstanding questions 
for optimization of TB diagnosis, including:
i. how to improve access to TB diagnosis?
ii. how to improve screening of patients and 
high-risk groups?
iii. how to use the introduction of new tools to 
improve service delivery practices?
iv. how to improve active TB case-fi nding?
v. how to build accessible, effective and 
effi cient diagnostic services with new 
diagnostic tools?
2. Developing sustainable collaboration with all 
care-providers for TB care and control
In many countries, a signifi cant proportion of TB 
suspects and cases, including those from poor 
and vulnerable populations, present themselves 
to a range of public or private care-providers that 
are not linked to national TB control programmes. 
Evidence shows that TB diagnosis and treatment 
practices of many non-programme care-providers 
are inappropriate and that care-seeking from 
diverse care-providers hampers access to 
quality TB care, causes delays in TB diagnosis 
and imposes fi nancial burden on patients. 
Several ‘Public–Private Mix’ (PPM) projects have 
demonstrated the feasibility, effectiveness, cost-
effectiveness and scalability of engaging non-
programme care-providers in TB care and control 
in diverse country settings. To be further scaled 
up, the following outstanding questions need to be 
addressed for optimization of collaboration with all 
practitioners:
i. How to improve and scale up existing 
approaches to engaging all care-providers?
ii. How to measure the contribution of different 
provider groups to TB care and control?
iii. How to encourage involvement of as yet 
unengaged providers?
iv. How to encourage involvement of the non-
public sector in MDR-TB management and 
TB/HIV collaborative activities?
Priorities in Operational Research to improve Tuberculosis Care and Control
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v. How to develop and assess responses to 
changing involvement of diverse providers 
in TB care and control?
vi. How to encourage introduction of 
regulatory approaches to collaborating 
care-providers?
3. Prevention of TB in people living with HIV 
(PLHIV) and joint treatment of TB and HIV
Optimal control of TB in high-HIV burden areas 
requires implementation of collaborative TB/
HIV interventions through a sound policy 
and programme environment that gives due 
consideration to the local context, the respective 
epidemiology of TB and HIV, as well as the health 
system infrastructure that determines service 
delivery models. System-wide differences between 
HIV and TB care-providers and stakeholders – 
and operational diffi culties for providing effective 
and appropriate interventions – have contributed 
to sub-optimal implementation and scale-up of 
collaborative activities. It is therefore important 
to identify measures that would facilitate wider 
implementation and scaling up of collaborative 
TB/HIV interventions through effective service 
delivery models, including community-based 
interventions. Collaborative TB/HIV interventions 
include the prevention of TB in PLHIV, the joint 
treatment of TB and HIV in people dually infected, 
and improved infection control and prevention. 
Operational research is needed to optimize 
prevention and treatment of TB in PLHIV and 
address the several barriers that may occur at 
the level of screening, diagnosis, treatment and 
prevention. Particularly in high-burden countries, 
the following outstanding operational questions 
need to be addressed for improved TB/HIV core 
group activities: 
i. What are the barriers to TB diagnosis, and 
how to overcome these barriers?
ii. What are the barriers to initiation of isoniazid 
preventive therapy?
iii. What are the barriers to optimal combined 
TB/HIV diagnosis and treatment, and what 
are the  optimal models for joint TB and HIV 
care activities?
4. Treatment of drug-susceptible and M/XDR-
TB: optimal access, delivery and community 
participation
Access to health care is the cornerstone of TB 
control programmes, as all diagnosed cases must 
receive a full course of treatment. This includes 
establishing effective treatment as well as effective 
strategies to support the process of care from 
detection of disease through to the completion of 
appropriate treatment. Limited access and poor 
adherence to treatment remain major obstacles in 
the global fi ght against TB. This is particularly true 
for MDR-TB, as only a small fraction of the tens 
of thousands of diagnosed patients are receiving 
appropriate care. Operational research is thus 
critically needed to improve access to treatment 
for drug-sensitive (DS-) and drug-resistant (DR-TB) 
patients, and ensuring that appropriate support 
is being offered to patients to ensure adherence 
and address adverse treatment effects, taking into 
consideration the particular needs of combined 
treatment whenever needed (antiretrovirals, 
diabetes, etc). The following outstanding questions 
need to be addressed for optimization of treatment 
of DS- and DR-TB:
i. What are the reporting gaps and defi ciencies 
in fi rst-line management of TB cases?
ii. How to address these defi ciencies and 
improve management of drug-sensitive TB?
iii. What are the drivers of drug-resistant TB at 
individual and programmatic levels?
iv. What are the potential strategies for 
integration/scale up of drug-resistant 
TB management within TB control 
programmes?
v. How to reinforce PPM collaboration for 
treatment of DS- and DR-TB?
vi. How to improve decentralized and fully 
integrated access to TB and antiretroviral 
treatment ?
5. Capacity building for operational research
Despite international interest in operational 
research, very little research is conducted or 
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published from resource-limited settings where 
the greatest burden of TB occurs. Building and 
sustaining the necessary capacity to conduct 
operational research at country level is a primary 
aspect to be considered while projects are being 
developed. National TB control programmes 
may lack essential expertise, infrastructure, staff, 
funds, policy cycle, and/or professional culture, 
and there may be only weak linkages between 
programmers and researchers. The key questions 
to be addressed in this area are:
i. What are the existing models of operational 
health research capacity?
ii. What is the impact of existing training 
models in terms of products, outputs and 
outcomes? 
iii. How to ensure sustainable operational 
research capacity at the national level?
For each of the questions being addressed in the 
fi ve priority areas above, suitable methods for 
operational research are described in the second 
part of the publication, together with a summary 
of the main operational research methods, 
statistics and defi nitions used in operational 
research.
The Stop TB Partnership, the WHO Stop TB 
Department and the Global Fund to fi ght AIDS, 
Tuberculosis and Malaria are jointly committed to 
the promotion of operational research as one of 
the keys to improving TB control and developing 
appropriate policies on implementation of new 
tools for TB control. In this respect, Priorities 
in operational research to improve tuberculosis 
care and control bridges the information gap on 
priorities for TB operational research for reference 
during grant application and implementation. 
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I. INTRODUCTION
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A rational framework for 
operational research in 
tuberculosis
For the past 15 years, global tuberculosis (TB) control 
efforts have generated impressive results. The 
implementation of the World Health Organization 
(WHO) Stop TB Strategy (1995-2008) is estimated 
to have cured 41 million people with TB and averted 
6 million deaths worldwide (1). The global case 
detection rate (CDR) of sputum smear-positive 
TB rose from 15% to 61% over the period of the 
strategy, the treatment success rate increased from 
77% to 87%, and the Millennium Development Goal 
(MDG) related to TB incidence is on target. However, 
despite these important achievements, the burden 
of TB continues to rise, and current control efforts 
need to be greatly improved if elimination (defi ned 
as ≤ 1 TB case per million population per year) is 
ever to be achieved. While the estimated incidence 
of TB has been declining globally since 2004, the 
present rate of decline (less than 1% per year) is 
insuffi cient to reach the elimination of TB by 2050, 
and the absolute numbers of TB cases continue to 
rise: in 2009, there were an estimated 9.4 million 
TB cases globally (1). Reported data indicate huge 
gaps in the performance of national TB programmes 
(NTCP). Thus, it is estimated that 3.7 million TB 
cases, including 1.6 million with sputum smear-
positive disease (39% of incident cases), were 
not reported by DOTS-based programmes; of an 
estimated 440 000 cases of multidrug-resistant TB 
(MDR-TB), only 30 000 (7%) were diagnosed and 
few of these had access to optimal treatment; lastly, 
of the estimated 1.1 million people co-infected 
with human immunodefi ciency virus (HIV) and 
Mycobacterium tuberculosis, only 140 000 (12.7%) 
received antiretroviral therapy (ART) (1).
Highly effective and widely accessible diagnostics, 
drugs and vaccines are needed to support TB 
control globally. There are technical and structural 
challenges, however, that impede optimal detection 
and treatment of all forms of TB, as well as 
prevention. Nevertheless, such barriers can be 
overcome by robust operational research to identify 
the solutions that have a signifi cant impact on case 
detection and cure rates, and that help improve the 
availability and effectiveness of TB care services.
Promoting research is a key component of the 
Stop TB Strategy, which includes conducting 
“programme-based operational research” and 
“research on introducing new tools into practice” 
(2) (see Box 1). The importance of programme-
based operational research is increasingly 
recognized and was recently identifi ed as a major 
area on which global action is urgently needed 
(3, 4). In its broad sense, operational research 
covers a large spectrum of activities, from local 
setting-oriented research to improve TB control 
programme performance, to international policy-
guiding research, including the assessment of new 
interventions to improve TB control (4). The most 
appropriate type and scale of operational research 
is largely dependent on the type of questions being 
addressed, the level and type of care services and 
the users concerned, as well as the anticipated 
general relevance of the results (4) (see Figure 1). 
At the national level, TB control programmes should 
carry out setting-oriented operational research 
projects involving partners, in order to address 
local or regional problems, and identify appropriate 
solutions (5). At the international level, a robust 
evidence base is increasingly required for guiding 
policy-making (including the use of systematic 
reviews and GRADEc evaluation). Multicentre 
operational research projects are required to meet 
needs, address gaps in TB control, and to give rise 
to changes in international policy (4). 
 A broad-based, concerted effort is needed to 
develop operational research capacity, allocate 
appropriate resources, and encourage all actors/
c  See: Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group: 
http://www.gradeworkinggroup.org 
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protagonists to work together (6). The capacity to 
conduct operational research within NTCPs is often 
limited, due to lack of expertise, infrastructure, 
staff or funds. Research may also be constrained 
by the nature of the policy cycle, or an absence 
of the critical performance questioning what 
operational research entails. Investment in capacity 
building, which includes continuous training to 
undertake operational research, and interpret 
and act upon results, is essential to improving 
service delivery, and also to understanding where 
and why programmes do not work, as well as to 
guiding optimal implementation of new methods 
and strategies (7). An enabling environment for 
performing operational research is key to achieving 
the full potential for TB control programme 
improvement at all levels, and managers should be 
aware of the benefi ts of building research capacities 
through collaboration with government research 
institutes, local universities and nongovernmental 
organizations (NGOs). Lastly, and importantly, the 
conduct of effective operational research relies on 
the availability of effi cient monitoring and evaluation 
systems that can collect routine data reliably in 
order to analyse how the systems work and what 
can be done to improve on potential problems that 
are identifi ed. 
FIGURE 1. THE SCOPE OF TB OPERATIONAL RESEARCH
Relevance
Local Global
Generalizability
Setting-specific Across settings
Objective
Feasibility Impact/effective-
ness
Setting
Routine Research
Design
Observational
qualitative
Interventional
quantitative
Adequate funding is crucial for quality operational 
research to provide results that are relevant to 
policy-makers. According to the Treatment Action 
Group (TAG) (8), only US$ 34 million (6.8%) of the 
US$ 510 million invested in TB research and 
development in 2008 (by more than 70 reporting 
organizations) were for operational research, 
showing that only a limited proportion of funding is 
available for operational research compared to that 
for tool research and development research (i.e. 
diagnostics, treatment and vaccines). As operational 
research receives increasing attention, however, 
new funding opportunities are emerging to improve 
the use of existing technologies (e.g. increased 
case-fi nding, simplifi ed treatment monitoring etc.) 
and to evaluate the impact of introducing new tools 
in various health systems and epidemiological 
settings. Among these opportunities, the United 
States President’s Emergency Plan for AIDS Relief 
(PEPFAR) increasingly contributes to integrated TB 
and HIV activities in areas with high dual incidences, 
and the recently launched ‘Phase II’ states that 
“study proposals are encouraged to focus on 
bringing evidence into practice to improve service 
delivery and outcomes” (9). Of equal note is the 
Wellcome Trust initiative to strengthen research 
capacity in Africa (10).
The Global Fund to Fight AIDS, Tuberculosis and 
Malaria (Global Fund) is the largest international 
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funder of activities for TB control, accounting for 
60% of all external fi nancing of TB programmes. 
The Global Fund explicitly states that up to 10% 
of country proposal budgets should include 
monitoring, evaluation and operational research. 
The proportion of grants including an operational 
research component has increased from 19% 
in rounds 1–5 to 58% in round 7, showing the 
importance of operational research in TB control 
programmes. This provision of funds is sometimes 
not optimally used, however, due to limited local 
capacity for conducting operational research, 
or the absence of coordination mechanisms at 
country level to conduct appropriate research with 
suitable collaborators (11). In this context, there 
is an urgent need to identify operational research 
priorities in order to help donors target the most 
pressing needs. 
On this basis, the Stop TB Partnership Research 
Movement and the Global Fund initiated a process 
in February 2010 to identify ways to improve and 
rationalize operational research for TB control. This 
stepwise process included a systematic review, 
an expert meeting and a workshop, accompanied 
by wide stakeholder consultation. The objective 
was to critically address the increasing need for 
improved and rational operational research in TB 
control, to identify key areas where evidence was 
lacking for proper implementation of new and 
existing technologies, as well as novel service 
delivery models. As a result, fi ve key areas were 
identifi ed in which knowledge gaps hamper proper 
implementation of TB control activities:
(i) Access, screening and diagnosis of 
drug-susceptible and multi/extensively 
drug-resistant TB (M/XDR-TB);
(ii) Development of sustainable collaboration 
with all practitioners for TB care and 
control;
(iii) Prevention and treatment of TB in 
persons living with HIV;
(iv) Optimal access to and delivery of 
treatment and retreatment of drug-
susceptible and M/XDR-TB; and 
(v) Operational research capacity building.
In each of these fi ve areas, critical questions were 
identifi ed to improve TB control at the national and 
international levels, and to reach the Global Plan to 
Stop TB targets by 2015.
This document is the culmination of this undertaking 
and is intended to help countries to carry out 
operational research and prepare for grant 
applications to donors for operational research 
support. For each of the fi ve areas above, a list of 
priority questions and corresponding rationales is 
provided, along with a synopsis of suitable methods 
to conduct operational research projects in respective 
areas. The document is intended to help programme 
managers, consultants and researchers who wish to 
conduct operational research to improve TB control 
at national, regional and international levels. We 
recognise that the priority research questions may 
differ depending on the country, the epidemiological 
setting, the health system, etc. We do not propose 
here a “one-size-fi t-all” method for each of the 
potential research questions that may arise, but 
rather propose a “tool-kit” of potential methods to be 
used to address specifi c operational questions that 
may be considered critical to improve programme 
performance, optimize patients’ care, or adopt new 
TB control techniques. 
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1. Pursue high-quality DOTS expansion and enhancement
• Secure political commitment, with adequate and sustained fi nancing 
• Ensure early case detection, and diagnosis through quality-assured bacteriology 
• Provide standardized treatment with supervision, and patient support 
• Ensure effective drug supply and management 
• Monitor and evaluate performance and impact.
2. Address TB-HIV, MDR-TB, and the needs of poor and vulnerable populations
• Scale-up collaborative TB/HIV activities 
• Scale-up prevention and management of MDR-TB 
• Address the needs of TB contacts, and of poor and vulnerable populations.
3. Contribute to health system strengthening based on primary health care 
• Help improve health policies, human resource development, fi nancing, supplies, service delivery 
and information 
• Strengthen infection control in health services, other congregate settings and households 
• Upgrade laboratory networks, and implement the Practical Approach to Lung Health 
• Adapt successful approaches from other fi elds and sectors, and foster action on the social 
determinants of health.
4. Engage all care providers
• Involve all public, voluntary, corporate and private providers through Public–Private Mix 
approaches 
• Promote use of the International Standards for Tuberculosis Care.
5. Empower people with TB, and communities through partnership
• Pursue advocacy, communication and social mobilization 
• Foster community participation in TB care, prevention and health promotion 
• Promote use of the Patients’ Charter for Tuberculosis Care.
6. Enable and promote research
• Conduct programme-based operational research 
• Advocate for and participate in research to develop new diagnostics, drugs and vaccines.
BOX 1: THE SIX COMPONENTS OF THE WHO STOP TB STRATEGY
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II. METHODS FOR 
DEVELOPING THIS 
DOCUMENT
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1. Expert group meeting
An expert group meeting was convened in Geneva, 
Switzerland on 22nd February 2010, to refl ect on the 
need to rationalize operational research in TB control 
and address the translation gaps for implementation 
of new technologies and service designs for TB 
programmes, including TB/HIV and MDR-TB 
control. During the meeting, participants identifi ed 
key areas where evidence was lacking for optimal 
implementation of novel technologies and service 
delivery models, and explored how operational 
research could best inform policy-making for 
better TB control at all levels. One outcome was a 
proposed workshop to outline the main directions 
for improved and rationalized implementation 
research in TB, and defi ne the research priorities 
for better implementation of current and novel 
technologies. The following specifi c areas of focus 
were identifi ed by participants for priority attention:
1. Access, screening and diagnosis of drug-
susceptible and M/XDR-TB; 
2. Development of sustainable collaboration 
with all practitioners for TB care and control; 
3. Prevention and treatment of TB in HIV-
infected patients;
4. Optimal access and delivery of treatment 
and retreatment of drug-susceptible and 
M/XDR-TB; and 
5. Operational research capacity building. 
To prepare for the subsequent workshop (see 
below), an in-depth overview of the situation was 
prepared by one or two expert(s) in the area, which 
was complemented by background papers from 
two discussants in order to encourage discussions.
2. Systematic review
The second step was a systematic review of 
operational research projects conducted over the 
past 10 years on the following themes: (i) clinical 
algorithms for diagnosis of smear-negative TB; (ii) 
implementation of isoniazid preventive therapy (IPT) 
in contacts of TB cases, and in HIV-infected people; 
and (iii) provision of second-line treatment for MDR-
TB. The systematic review focused on studies of 
effectiveness (in contrast to effi cacy), delivery and 
cost-effectiveness of these interventions, addressing 
objectives, design, study setting and scope. It showed 
that few studies had been completed and published 
on these interventions and that they were highly 
concentrated on a limited number of geographical 
and epidemiological settings. Comparative designs 
had hardly been used. These results highlighted 
clear gaps in operational research with regard to the 
potential to inform policy-making, and the need for 
coordinated action at regional and global levels. 
3. Workshop
A workshop was convened on the 10–11th May 
2010 in Geneva, Switzerland and assembled a 
wide group of scientists, public health specialists, 
national TB programme managers, clinicians, NGOs 
and community representatives. The objective 
of the workshop was to address the translation 
gaps for implementation of current and innovative 
technologies for TB control, and identify the priorities 
in operational research for improved TB control, 
including the improvement of current TB control 
methods and the uptake of novel technologies and 
service delivery models.
The areas identifi ed during the expert group meeting 
(see above) were explored. Participants examined what 
research was needed to address the identifi ed gaps 
(“what?”), the methods (“how”), the study population 
(“whom?”), and whether it should be conducted 
at local, national, or multicountry/international 
levels (“where?”). Results of the discussions were 
summarized by a rapporteur and discussed among 
all workshop delegates, resulting in the identifi cation 
of critical research gaps and subsequent priorities in 
each of the fi ve defi ned areas.
4. Stakeholder consultations
To invite comments and suggestions on these 
research questions, the report of the workshop (see 
above) was widely circulated to the working groups of 
the Stop TB Partnership.d Comments and suggestions 
received were included in the workshop report that 
served for the preparation of this document.
This document was developed in fi ve successive steps:
d Including the DOTS Expansion Working Groups and its subgroups: (Childhood TB, TB and poverty, Introducing new approaches 
and tools, Public–Private Mix); the TB/HIV Working Group; the Global Laboratory Initiative; the MDR/TB Working Group; the 
Working Group on New Diagnostics; the Working Group on New Drugs; and the Working Group on New Vaccines.
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5. Development of specifi c methods
Methods and research study designs to address 
each of the research priorities identifi ed above were 
developed as templates for use by NTCPs and their 
research partners. For each priority, the current 
document provides a synopsis of applicable research 
methods, according to the following outline:
• objective(s)
• design outline
• setting/study population
• methods: recruitment of subjects (eligibility 
criteria); intervention (as appropriate)
• expected endpoints
• analysis
• guidance for sample size calculation (and 
estimated number of participants)
• expected duration/timeline
• suitable scale
• estimated budget range.
Annex I provides a broad description of the main 
study designs used in operational research. The 
detail of these suggested methods and research 
study designs is provided in Annex II. In addition, a 
summary description of these various designs, with 
respective budgetary requirements, and estimated 
timelines is included at the end of each section in 
Annex II.
6. Scope of operational research 
projects
In pragmatic terms, TB operational research 
projects should be conducted with the aim of 
addressing three main objectives (1): (i) to improve 
programme performance and outcomes; (ii) to 
assess the feasibility, effectiveness or impact of 
new strategies or interventions on TB control; and 
(iii) to collect data to guide policy recommendations 
on specifi c interventions (see Figure 1).
The fi rst objective aims to assess defi ciencies in 
TB control programmes and identify causes that 
are amenable to improvement by technical or 
managerial intervention. In that situation, research 
questions are setting-oriented and results are 
setting-specifi c (1–3). Actors and protagonists are 
primarily TB programmes and/or the researchers 
commissioned for the studies, and the users are the 
health-care providers and/or programme managers. 
The scale can be local or national. Despite limited 
generalizability, methodological issues may be 
relevant to other high-burden countries or settings, 
so publication of the results is suitable for sharing 
of examples. Research questions are generated 
through the identifi cation of problems or challenges 
encountered in programme activities, based on 
the review of locally-collected surveillance or 
programme-based data (4), or upon outcomes of 
qualitative studies with properly defi ned methods 
that articulate the social, gender, cultural and 
economic aspects of the problem, in relation to 
where the research is undertaken (5–7). Questions 
may also aim at identifying specifi c risk factors 
or the causal effect of given variables. These can 
lead to testing targeted interventions aimed at 
improving TB control performance locally, for 
instance methods for increasing case detection 
(8, 9), improving treatment adherence (10) or for 
encouraging collaboration with the private health 
sector (11). Other disciplines such as health 
economics may also be useful (12). 
The second objective includes studies of new 
interventions to improve TB control, such as the 
effective and effi cient use of new tools (diagnostics, 
treatments and vaccines) (13), but can also assess 
novel algorithms or combinations of tools, or new 
approaches to care delivery (14). Once effi cacy of 
new interventions has been established in relevant 
trials or validity studies (that typically lead to approval 
by regulatory authorities and/or endorsement by 
international organizations such as the WHO), 
operational research needs to be conducted to 
determine the conditions/requirements under which 
these interventions can be effectively implemented 
through the assessment of their effectiveness, 
acceptability, feasibility and affordability, as well as 
their impact on the health system when applied under 
routine conditions (15–17). Actors and protagonists 
are primarily TB programmes and/or the researchers 
commissioned for the studies, as well as NGOs, that 
can play a role in the evaluation and incorporation of 
new tools into the health system, for example. The 
users include policy-makers, care-providers and/
or programme managers of the country where the 
study is undertaken, but also potentially in other 
countries with similar epidemiological patterns and 
health-care systems. The scale ranges from national 
to regional/international. Studies are therefore best 
done in several countries/settings, and reported 
in such a way that TB programme managers and 
policy-makers can use the results to adapt the tested 
implementation strategy to their own setting (1). 
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In relation to the third objective, operational research 
projects are being conducted to inform international 
policy recommendations. Initial evaluations of new 
interventions under controlled conditions (e.g. clinical, 
laboratory etc.) need to be complemented with 
evaluation in real-life, programmatic conditions (18) in 
order to examine the optimal possibilities for uptake 
and use of novel interventions in populations, and 
assess their potential impact on patient outcomes 
(e.g. reduced treatment delay, improved cure rate, 
quicker return to work, reduced risk of relapse and 
drug resistance), as well as on the organization and 
structure of health services (12). Relevant actors 
and protagonists are primarily researchers working 
in collaboration with TB programmes. The users 
are national and international policy-makers. These 
studies are conducted on a regional or global scale. 
Since generalizing conclusions across settings 
is of primary importance, the choice of study 
locations is dictated by how representative the 
setting is in terms of epidemiological patterns and 
health-system structure, as well as local research 
capacity to produce high-quality data. Although 
most research is carried out within NTCPs, there is 
also a need for additional research capacity (e.g. 
laboratory, clinical aspects, data management 
etc.). Rigorous methods must be used, driven by 
results from safety, effi cacy and demonstration 
studies, and should include Phase IV trials, cluster-
randomized trials, cost-effectiveness studies, and 
impact evaluation studies (19–22). By implementing 
similar study protocols in various countries, data 
can be compiled into combined databases and 
analysed across countries.
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III. PRIORITY AREAS 
FOR OPERATIONAL 
RESEARCH IN TB 
CARE AND CONTROL
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TB diagnosis in most endemic countries relies 
heavily upon direct sputum smear microscopy, 
as this is most often the only simple test that can 
be used below the reference laboratory level. 
Currently, however, only about 60% of all infectious 
TB cases are being detected with this test, and 
a proportion of patients with active TB (i.e. those 
listed in the laboratory registers as having at least 
one positive smear) do not collect their test results, 
so do not receive appropriate treatment (1). In 
addition, among the estimated half a million cases 
of MDR-TB that occur globally each year, only a 
tiny fraction are identifi ed and treated appropriately. 
From a diagnostic perspective, this is largely due to 
services not being accessible to patients. Diagnostic 
services for drug-resistant TB (DR-TB) are based on 
complex technologies that require sophisticated, 
biosafe laboratories with highly-trained staff, and 
so are rarely available outside of national reference 
laboratories. As transport of specimens from the 
periphery to the reference laboratory(ies) can also 
be problematic, TB diagnostic services may be 
non- or dysfunctional. Similarly, since direct smear 
microscopy is less sensitive in patients with HIV-
associated TB, further testing using complex 
technologies in sophisticated laboratories is 
needed to reliably diagnose HIV/TB co-infection (2). 
New, simple and inexpensive tools are needed to 
identify the various forms of TB (including DR-TB 
and HIV-associated TB), particularly at the lower 
levels of health services. 
New tools are becoming available (3). Since 2007, 
WHO has endorsed the use of over 10 new TB 
diagnostic tools (technologies or approaches) 
that, if used wisely, could improve TB control 
considerably. In 2010, WHO endorsed a new 
automated real-time nucleic acid amplifi cation 
technology (NAAT) for rapid and simultaneous 
detection of TB and rifampicin resistance (the 
Xpert MTB/RIF system) that offers the prospects 
of drastically improved diagnosis of active TB and 
MDR-TB. This test, however, requires signifi cant 
initial capital investment and subsequent running 
costs for sustainability. 
In a recent survey on the use of diagnostic tools in 
16 high-burden TB countries from 2007 to 2009, 
50% of these countries reported using TB diagnostic 
tools recommended by WHO; national TB control 
programme managers reported diverse challenges 
in the implementation of new diagnostics, but no 
impact assessment of their introduction on TB control 
was carried out (4). In general, there is insuffi cient 
evidence available to determine which package of 
current and newly-developed diagnostic tests would 
work best in a given set of circumstances, and there 
is as yet little guidance to countries on what new 
diagnostic tools, or combinations of tools, should 
be implemented in particular epidemiological/health 
system settings or for different risk groups, and at 
what level of the health service it should be done. 
Operational research with collection of multiple 
country experiences could act as the starting point 
to better guide diagnostic scale-up, and regional or 
global policy in the future. This requires the creation 
of an environment that is conducive for operational 
research around TB diagnostics and diagnostics 
services, preferably using a multi-disciplinary 
approach, starting with careful situation analysis. 
1. Improving access, screening 
and diagnosis of TB
Outstanding questions for optimization of TB diagnosis
i. Improving access to TB diagnosis
Based on the currently used TB diagnostic tests 
(sputum smear microscopy, chest X-ray, culture/
drug susceptibility testing (DST)), what are the 
various socioeconomic, health system-related and 
qualitative barriers that infl uence TB diagnosis at the 
patient and health-provider levels (in terms of timeliness 
of diagnosis, convenience and cost to the patient, as 
well as prevention of primary treatment default)? Which 
interventions (decentralization to primary level facilities, 
decentralization into communities, use of mobile clinics, 
etc.) would be most effective in overcoming these 
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barriers? How can diagnostic services be brought 
closer to the community (decentralization, active case-
fi nding, mobile systems, etc.), and how can they be 
integrated into the general health system, bearing in 
mind that the nature of the technology employed and 
how it is delivered will determine patients’ access to 
the service? 
ii. Improving screening of TB suspects 
and high-risk groups
Who should be screened, what should they be 
screened for, and how should they be screened? 
For this, higher-risk groups for different forms of TB, 
to which intensive case-fi nding can be targeted, 
must be identifi ed (e.g. people living with HIV 
(PLHIV), prisoners, vulnerable groups, MDR-TB 
suspects, patient contacts, people with risk factors 
such as diabetes, smoking, alcohol or drug use). 
Appropriate screening algorithms and test methods 
(e.g. symptom questionnaire, conventional or digital 
chest X-rays, light-emitting diode (LED) microscopy 
and/or front-loaded microscopy and/or other 
laboratory tools) must be defi ned. Similarly, reliable 
methods need to be established for ruling out active 
TB in various screening settings, including prior to 
IPT. For instance, recently revised WHO guidelines 
on IPT recommend the use of a simplifi ed screening 
algorithm based on the absence of all four clinical 
TB symptoms (current cough, night sweats, fever 
and weight loss) to help identify PLHIV who have 
less likelihood of active TB disease and hence are 
eligible for IPT (5). This simplifi ed symptom-based 
algorithm should be used for all adults living with 
HIV, including pregnant women, people who are 
receiving ART, and those who have successfully 
completed TB treatment. However, the way in which 
these symptoms are confi rmed or excluded is likely 
to be context-specifi c, and screening approaches 
may vary among risk groups and so will the yield 
of screening approaches. Subsequently, data are 
needed to evaluate the performance of the new IPT 
guidelines locally.
iii. Assessing the role of new diagnostics 
tools to improve practices
As mentioned above, WHO has recently endorsed 
optimized smear microscopy approaches, a variety 
of commercial and non-commercial options for 
culture and DST (e.g. microscopic-observation drug 
susceptibility (MODS) assay, colorimetric redox 
indicator and nitrate reductase assay), and most 
recently the Xpert MTB/RIF system. How should 
these new tools be introduced into health systems? 
What would be the appropriate screening and 
diagnostic algorithms in different settings and for 
various risk groups? What would be their contribution 
to improved case detection and treatment of drug-
sensitive (DS) and DR-TB? But, also, what will be 
the human resource implications of introducing new 
tools (training, number and cadre of staff)? What are 
the infrastructure implications (such as equipment, 
laboratory layout and safety installations)? What 
will be the projected impact of going to scale with 
a new tool (e.g. cost savings to patients in relation 
to income, cost savings to health providers or the 
health system, effects on transmission of improved 
infection control as a result of the new tool)? At a 
broader scale, how can TB diagnostic services 
be integrated with other diagnostic services for 
infectious as well as noncommunicable diseases? 
The delivery of these services will clearly depend upon 
the existence of a functional and interconnected, 
tiered health system. Operational research must 
address the issues associated with dysfunctions in 
specimen and patient referral systems, as well as 
the communication of and response to laboratory 
results. 
iv. Active case-fi nding
Introducing optimal combinations of diagnostic 
tools at all levels of health care and improving 
access to early diagnosis for all TB cases are key 
to decreasing the period of infectiousness before 
diagnosis as well as improving patients’ outcomes. 
Active case-fi nding (ACF) has high potential to rapidly 
improve TB control. Recently, ACF in communities 
has shown high potential to substantially improve 
case detection, with rapid declines in undiagnosed 
TB (6) and increased numbers of TB cases 
diagnosed when ACF was added to routine facility-
based DOTS (6–9). However, with the exception of 
TB screening in PLHIV, there has been very little 
research into ACF in high TB burden countries, as 
this was not part of international policy until very 
recently. Further operational research is needed 
to identify how best to introduce ACF in different 
epidemiological settings. 
The choice of ACF strategy should be guided by 
the local epidemiology of undiagnosed TB disease. 
In high-prevalence settings (e.g. southern Africa, 
crowded urban communities, prisons) an untargeted 
approach that regards all adults as being at high 
risk may be more appropriate than one that relies 
on identifi cation of individual risk factors for disease 
such as HIV infection, diabetes or recent close 
Priorities in Operational Research to improve Tuberculosis Care and Control
16
contact with infectious TB cases (especially if these 
risk factors are themselves mostly undiagnosed). 
However, in low and medium TB burden settings, 
an untargeted approach is likely to have a very low 
yield in most communities.
Even when defi nitions of TB suspects and 
diagnostic algorithms are identical to those used in 
facility-based DOTS (sputum microscopy in patients 
self-reporting chronic cough), community-based 
interventions (e.g. using mobile outreach vans or 
temporary microscopy clinics) can still have high 
yield and impact (6). More intensive approaches to 
seeking out people with unreported cough (such as 
door-to-door enquiry) may be, paradoxically, less 
effective – perhaps through imposing unwelcome, 
unannounced visits to people’s homes. Not all 
patients with undiagnosed TB have chronic cough, 
however, and so strategies that successfully 
investigate everyone, regardless of symptoms, 
or use a broader defi nition of TB symptoms, will 
have a higher yield if well implemented, but will be 
more challenging and resource intensive. In this 
respect, cost-effectiveness studies that compare 
various approaches in specifi ed settings based 
on observed data (e.g. from pilot projects) can be 
extremely informative.
v. Building accessible, effective and 
effi cient diagnostic services with 
new diagnostic tools
The major question across all the above areas is: 
What combination of diagnostic tools should be 
introduced and what determines the appropriateness 
of particular combinations to given national 
programmes/health services? Until this question is 
addressed, most of the work in areas i–iii above will 
remain unfocused. This requires a broad approach 
to revising existing clinical diagnostic algorithms 
and developing new algorithms incorporating 
existing and new diagnostic tests, taking into 
account the prevalence of HIV and HIV-associated 
TB, the prevalence of M/XDR-TB, as well as 
infrastructural issues such as transport and health 
systems assessment. Such changes would have 
major implications for the administration of NTCPs 
and ministries of health. Starting work in this area 
will require the identifi cation of ‘best-fi t’ packages 
of particular diagnostics that might be used 
effectively and effi ciently in a given epidemiological 
and infrastructural situation, following clearly laid-
out algorithms that give the highest likelihood of 
correctly diagnosing patients with TB quickly and 
at reasonable cost. 
vi. Evaluation of the impact of new tests 
or new approaches
Determining the impact of any new diagnostic 
test (or package of tests) not only requires the 
assessment of the test’s sensitivity and specifi city 
with all forms of TB and in all populations affected 
by TB (including those co-infected with HIV), 
but also its effect on important patient outcomes 
(such as cure rate and mortality), accessibility 
(particularly to poor and vulnerable TB suspects), 
affordability (to the health system and to the patient) 
as well as staffi ng and infrastructure requirements. 
These data can be collected through national 
level operational research, and should be collated 
to help inform decisions on whether and how a 
test can be incorporated into current policy and 
practice. An Impact Assessment Framework has 
been developed to help guide this process and is 
shown in Annex III (10). 
The outstanding research questions have been 
prioritized to facilitate operational research that 
leads to improvements in the accessibility, quality 
and scope of diagnostic services for TB. Knowledge 
is needed at all levels from local to international and 
the research questions need to be asked at all levels. 
There may be different answers at different levels, 
but overall, there is a logical series of successive 
research projects to be conducted, as shown in 
Figure 2.
Priority areas for operational research
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1.1 Situation analysis
This comprises the baseline assessment. Studies 
need to be conducted to identify the local barriers 
to access to diagnosis of TB in order to allow better 
use of existing systems for diagnosing all forms 
of TB in various populations (including diffi cult-
to-reach populations) and specifi c risk groups 
(TB suspects, DS-TB, retreatment, DR-TB, PLHIV, 
children, people with diabetes or other risk factors). 
1.2 Identifying new programmatic 
approaches
This step is aimed at determining the best 
approaches that include revised clinical algorithms 
for TB diagnosis, and help in defi ning the most 
effective use of new diagnostic tool(s) in specifi c 
settings and populations (i.e. screening or 
confi rmatory, rule-in or rule-out, etc.) so as to 
maximize their impact. 
The example of Xpert MTB/RIF system is informative 
here. In the third quarter of 2010, WHO convened an 
expert group meeting to evaluate existing accuracy and 
operational data about Xpert MTB/RIF and reported the 
fi ndings to the WHO Strategic and Technical Advisory 
Group for TB (STAG-TB). Following STAG-TB’s 
recommendation to endorse the new diagnostic tool, 
WHO organized a wide-scale consultation to inform roll-
out of Xpert MTB/RIF. A roadmap for implementation 
was prepared, that included operational research to 
validate interim screening and diagnostic algorithms, 
inform anticipated changes in TB case and outcomes 
defi nitions, and provide early data on programmatic 
aspects and impact information.e Other examples 
of such approaches include: the development of 
improved clinical algorithms for smear-negative TB in 
high, medium and low HIV prevalence settings with 
and without access to (digital or conventional) chest 
X-ray; or the identifi cation of specifi c risk factor profi les 
for MDR-TB in different settings, that could be used 
for the presumptive identifi cation of suspect MDR-TB 
cases or identifi cation of MDR-TB risk groups. 
FIGURE 2. CYCLE OF RESEARCH ACTIVITIES FOR IMPROVED ACCESS, SCREENING AND 
DIAGNOSIS OF TB
1.1
Situation analysis
1.2
Identifying new 
programmatic approaches
Research 
cycle
1.3
Piloting implementation of a new 
diagnostic tool or package of tools in 
various settings:
   1.3.1 
   Through existing diagnostics services
   1.3.2 
   Through active case-finding
1.4
Evaluating the scale-up
and impact of a new test 
or new package of tests 
and algorithms
e Recommendations are as follows: 
 i. In high MDR-TB settings: persons at risk of MDR-TB (e.g. treatment failures, other retreatment cases, close contacts of MDR-
TB cases) should be tested using Xpert MTB/RIF as the primary diagnostic test; 
 ii. In high HIV prevalence settings: PLHIV with signs and symptoms of TB, those seriously ill and suspected of having TB 
regardless of HIV status, and those with unknown HIV status presenting with strong clinical evidence of HIV infection, should 
be tested using Xpert MTB/RIF as the primary diagnostic test;
 iii. In other settings: Xpert MTB/RIF is recommended as the primary diagnostic test where available, including in PLHIV in these 
settings, or as a follow-on test (at a higher level of the health service) after screening by sputum smear microscopy (at lower 
level of the health service) or after screening by chest radiography.
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1.3 Piloting implementation of a new 
diagnostic tool or package of tools in 
various settings
1.3.1 Through existing diagnostic 
services (routine health service 
provision)
Identifi cation of new programmatic approaches 
leads to questions regarding which infrastructure and 
delivery systems are appropriate for implementation 
of a new diagnostic test in a given country: Does the 
new test perform as well as expected for diagnosing 
patients who would otherwise remain undiagnosed or 
be diagnosed much later (effectiveness)? Are health-
care providers willing and able to utilize the new test? 
Does the new test facilitate equitable access for all 
patients? Will it reduce diagnostic delay? What is the 
impact on the main patient treatment outcomes? 
What are the feasibility and conditions for scale-up? 
What is the cost-effectiveness of the new tool using 
locally-relevant costing and outcome data and what 
is the most cost-effective positioning of the test in 
a diagnostic algorithm given epidemiological and 
economic conditions? 
In the epidemiological context of predominant DS-TB, 
the example of the recently endorsed Xpert MTB/RIF is, 
here also, informative: What will be the impact of the 
introduction of the cartridge-based NAAT or the rapid 
culture, or a combination of those? What is the role 
of chest X-ray in the diagnostic pathway in situations 
where MDR-TB and HIV associated TB is of lesser 
concern? What proportion of newly-detected cases 
will have access to treatment services? How cost-
effective is the new combined approach in routine 
settings? What would be the impact on treatment and 
patient management? What would be the impact on 
access to care by different socioeconomic groups? 
As the answers to these questions largely depend 
on specifi c settings, global/regional expert meetings 
can provide guidance to countries in identifying the 
likely provisional algorithms for particular settings 
(see section 1.2 above). 
As scale-up of Xpert MTB/RIF is likely to take time, 
and the tool may not be used everywhere, other 
approaches for detecting new TB cases that have been 
endorsed by WHO and which have not yet been widely 
implemented through research can be investigated - 
for example through the following sequence:
(i) Improving technical performance of sputum 
smear microscopy services for TB: WHO 
recently endorsed a more sensitive defi nition of 
a smear-positive TB case and endorsed tools 
to reduce the workload in smear microscopy 
labs (two-specimen approach) and increase 
sensitivity of sputum smear microscopy (using 
LED-based fl uorescence microscopy). Can 
a combination of these reduce the workload 
in smear microscopy labs and increase the 
number of sputum smear-positive cases 
detected in routine settings? Does it increase the 
TB notifi cations and number of patients cured? 
How cost-effective is the dual approach?
(ii) Improving treatment access for sputum 
smear-positive TB cases detected: Can 
same-day smear examination (with or without 
same-day reporting and treatment initiation/
referral) reduce initial patient default? Does it 
lead to improved access to treatment? How 
cost-effective is the approach? Are there 
opportunities for improvement of infection 
control practices through reorganization of 
patient fl ow in waiting rooms?
(iii) Improving the presumptive (non-
bacteriological) detection of smear-negative 
TB (including HIV-associated TB) through 
smear-negative clinical algorithms: With 
improved sputum smear microscopy services 
and access to treatment, can improved 
clinical algorithms be applied in routine 
settings to increase the number of TB cases 
detected and their access to treatment? 
In the context of high MDR-TB rates, the question 
may be different. For example, how to improve the 
detection of MDR-TB cases using rapid culture-
based techniques and/or NAAT (including line probe 
assays (LPA) and cartridge-based polymerase chain 
reaction (PCR))? What increase in confi rmed MDR-TB 
case detection will result from the introduction of rapid 
identifi cation of M. tuberculosis isolates and rapid DST? 
What proportion of detected cases will have access 
to and use second-line treatment? How cost-effective 
is the approach in routine settings? Here again, the 
situation will be highly dependent on the prevalence 
of HIV-associated or DR-TB, together with the level of 
laboratory and other infrastructure (including transport 
and communication infrastructures) available in 
different settings. Global and regional expert group 
meetings should provide guidance to countries in 
identifying the likely provisional ‘best-fi t’ packages of 
interventions for specifi c settings.
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1.3.2 Through active TB case-fi nding
In addition to the introduction of combinations of new 
and current diagnostic tools at all health-care levels, 
enhanced and active TB case-fi nding activities must 
be developed and strategized in order to improve 
case detection. The following related operational 
research questions should be addressed.
(i) Defi ning TB suspects and evaluating 
different screening algorithms: The cost 
and yield of using different ACF strategies 
to defi ne who and how to screen needs 
systematic evaluation. This includes 
evaluation of standard community-based 
interventions using traditional approaches 
(e.g. smear microscopy to investigate 
self-reported chronic cough) as well as 
comparison with promising alternatives, 
such as mobile digital radiography. Cost-
effectiveness/cost utility analyses should 
be an important part of these evaluations.
(ii) Service delivery to the community: 
Ideally ACF should be integrated into 
existing community-level services rather 
than delivered as stand-alone ‘vertical’ 
interventions. However, some notable 
examples of disappointingly low yield 
have been reported when an integrated 
approach has been taken (11, 12) (see 
Annex V). Therefore, different models of 
service delivery need to be developed and 
compared in urban and rural settings with 
high and low TB burdens.
(iii) Sustained effect on TB incidence of ACF in 
high and medium/low TB burden countries 
and communities: ACF in the general 
community has potential to provide the 
rapid gains in TB control that are needed 
to accelerate global TB control, but many 
uncertainties remain. Careful operational 
research to measure the effect of ACF on 
TB incidence needs to go hand-in-hand 
with sustained implementation of ACF 
strategies that are found to be effective 
(increased numbers of cases diagnosed 
initially) in different settings. 
1.4 Evaluating the impact of scale-up of 
a new test or new package of tests
After a new test (or package of tests) has been 
implemented through research, as outlined in 
section 1.3 above, policy-makers have to make 
decisions about whether to go to full scale with the 
new algorithms or modifi cations of these. At this 
stage the systematic presentation of data obtained 
through application of the Impact Assessment 
Framework (see Annex III) during the implementation 
studies can promote rational decision-making about 
whether and how to go to scale. It is important that 
data are generalizable at this stage, so that policy-
makers can assess the potential contribution to 
overall improved case detection and treatment of DS- 
and DR-TB. Operational modelling is helpful at this 
stage to evaluate the likely inputs and costs of going 
to scale, and transmission modelling can indicate 
the likely impacts on TB transmission, and, over 
time, the impacts on TB epidemiology. Combining 
these two approaches (as proposed in Layers 4 and 
5 of the Impact Assessment Framework) can make 
it possible to present different costed options for 
the process of fi nal scale-up to policy-makers to 
facilitate the decision-making process. 
Once a decision has been made to go to full, national 
scale with a new test or package of tests, the overall 
public health and societal consequences need to 
be documented.  Projections can then be checked 
and fi nal benefi ts and challenges documented. For 
this stage, implementation research that focuses on 
audit, before-and-after assessments, and monitoring 
and evaluation are appropriate (see Annex II).  
Note: it should be noted, however, that it is not 
always necessary to conduct detailed research in 
all areas of the research cycle, if there is suffi cient 
knowledge in existing situation analyses (see 1.1 
above) and identifi cation of new programmatic 
approaches (see section 1.2) for a country to 
proceed to implementation through research (see 
section 1.3). The Xpert MTB/RIF system provides 
a potential example to illustrate this. It is widely 
documented in resource-poor settings that the 
repeat visits to health facilities required for sputum 
submission for smear microscopy is a signifi cant 
barrier to diagnosis (13–17). The Xpert MTB/
RIF offers the potential to deliver an accurate TB 
diagnosis within two hours of submission of a single 
sputum specimen. WHO has developed potential 
algorithms for different epidemiological situations in 
which Xpert MTB/RIF can be used (see section 1.2). 
In this example, therefore, a given country might 
choose to proceed straight to implementing Xpert 
MTB/RIF through phased research that permits 
documentation of operational requirements/inputs 
as well as the clinical and epidemiological effects/
outputs (see section 1.3). 
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Global TB case detection is stagnating at around 
60% despite strengthened TB programmes. In 
many countries, a signifi cant proportion of TB 
suspects and cases, including poor and vulnerable 
populations, present themselves to a range of 
public and private care-providers that are not 
linked to NTCPs (18). These include informal and 
formal, commercial and non-profi t, individual 
and institutional private sector care-providers 
such as traditional healers, pharmacists, general 
practitioners, private clinics and hospitals, NGOs 
and faith-based organizations (FBOs), and employee 
health services by the business sector, as well as 
public sector care-providers such as general and 
speciality public hospitals, academic institutions, 
prison and military health services. Evidence shows 
that TB diagnosis and treatment practices of many 
non-programme care-providers are inappropriate 
and that care-seeking from diverse care-providers 
hampers access to quality TB care, causes delays 
in TB diagnosis and imposes fi nancial burden on 
patients (19). Furthermore, it is estimated that only 
about 5% of people with MDR-TB are managed 
within TB programmes. Several ‘public–private’ 
and ‘public–public’ mix’ (PPM) projects have 
demonstrated the feasibility, effectiveness, cost-
effectiveness and scalability of engaging non-
programme care-providers in TB care and control 
in diverse country settings. In some settings, PPM 
has also been shown to improve access, enhance 
equity, reduce diagnostic delays and reduce costs 
of care for TB patients. Consequently, WHO advises 
countries to undertake baseline and periodic 
national situation assessment (NSA) to determine 
the need and scope of implementing and scaling up 
of PPM. A tool to help conduct NSAs and guidance 
for PPM implementation is available and has been 
used effectively by many countries (20). By 2008, 
58 out of 93 active, TB-related country grants from 
the Global Fund had a PPM component, amounting 
to about 5% of the total allocation. 
2 Developing sustainable 
collaboration with all care-
providers for TB care and 
control
Outstanding questions for optimization of collaboration 
with all care-providers
i. Improving and scaling up existing 
approaches to engaging all care-
providers
While there are examples of PPM projects that are 
being taken to scale, knowledge gaps persist in 
relation to models or approaches for nationwide 
PPM scale-up. It remains unclear how to prioritize 
providers for engagement. More needs to be 
learnt also about specifi c models and approaches 
for scale-up, such as the use of incentives and 
enablers, the use of novel regulatory approaches, 
and the use of social marketing and franchising. 
Provider segmentation and adaptation of 
approaches to fi t specifi c groups of providers who 
are targeted to provide specifi c services – such as 
TB suspect identifi cation and referral, TB treatment 
support, etc. – need to be better understood, 
and the role of PPM in the broader aspects 
of ACF among symptomatic patients requires 
clarifi cation. Effectiveness and feasibility of PPM 
implemented as part of the Practical Approach to 
Lung Health (PAL) also need to be investigated. 
Better knowledge of issues related to quality in TB 
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care and control is needed as PPM initiatives are 
taken to scale, both in terms of adherence to the 
International Standards of TB Care,f and from the 
perspective of patients. 
ii. Measuring the contribution of 
different provider groups to TB care 
and control
Measurement of the contribution of diverse care-
providers to a variety of TB control tasks is diffi cult 
and may put an undue burden on recording and 
reporting systems. The components of PPM 
contribution that need to be measured at different 
levels (e.g. referral, microscopy, treatment, directly-
observed treatment, default retrieval) all need to 
be tailored to country contexts. Tied to this is the 
need to understand the resource requirements 
from the programme perspective for scale-up 
and, thus, the ability to weigh PPM outputs and 
outcomes against resource inputs, which can help 
to monitor PPM cost-effectiveness as initiatives 
are taken to scale.
iii. Encouraging involvement of as yet 
unengaged providers
Gaps exist in the provision of TB care at the national 
and local levels. To identify ways of fi lling these 
gaps, it will be helpful to determine what models are 
appropriate for the specifi c national/local context; 
whether there are additional providers (as yet 
uninvolved in PPM) that could provide services; and 
to assess the effectiveness of models that involve 
these providers.
iv. Encouraging involvement of the non-
public sector in MDR-TB management 
and TB/HIV collaborative activities
In some countries, much of the MDR-TB management 
is currently carried out by NGOs and private medical 
practitioners. Similarly, TB/HIV collaborative activities 
are being performed by multiple providers, with 
variable levels of coordination. It will be important to 
compile information on such approaches, and their 
quality and effectiveness.
v. Developing and assessing responses 
to changing involvement of diverse 
providers in TB care and control
As new TB diagnostic tests and drugs become 
available, it will be important to ensure they are 
used rationally by all providers. New diagnostics 
could mean the end of the distinction between 
pulmonary smear-positive and pulmonary smear-
negative TB, with consequent changes in treatment 
protocols and recording. New drugs may lead to 
different treatment schedules. While it is expected 
that within government provision use of the new 
diagnostics and drugs will be well-regulated, there is 
a need to ensure that private practitioners use them 
rationally, to avoid misdiagnosis and development 
of resistance to new drugs.
vi. Encouraging introduction of regulatory 
approaches to collaborating care-
providers
Countries are likely to have very different approaches 
to regulation of different aspects of TB care, including 
mandatory TB case notifi cation, certifi cation and 
accreditation, and restricting access to anti-TB 
drugs to collaborating care-providers. Some are 
already using regulation successfully; others have 
regulation but have problems with enforcement; 
while others have not yet attempted regulation. 
Clearer understanding of what works and what 
does not in different contexts will help countries to 
determine what approaches might be appropriate 
in their own settings; what enabling factors can be 
used; and whether potential disabling factors exist 
in their context.
f Available at: http://www.who.int/tb/publications/2006/istc/en/index.html 
Priority areas for operational research
The outstanding research questions have been 
prioritized to facilitate operational research that 
leads to optimization of collaboration with all 
practitioners (see Figure 3).
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2.1 Improving and scaling-up existing 
approaches to engaging all providers
The objective is to develop an evidence base of 
different PPM models and approaches to scale-up 
that include contextualized analyses of reasons for 
success/failure as well as mechanisms to create 
demand for quality services. This includes assessing 
enablers and incentives for various care-providers 
and the various mechanisms to fund scale-up.
2.2 Measuring the contributions of 
different provider groups to TB care 
and control 
As various care-providers (e.g. private, NGOs, 
FBOs, public health units outside the Ministry of 
Health, etc.) intervene in TB control, it is important 
to assess their contributions, as well as assess their 
respective abilities to improve user access, case 
detection and outcomes for underserved groups, 
and reduce diagnostic delays and costs of care. 
This will allow estimation of the needs and resource 
requirements for scale-up. 
2.3 Encouraging involvement of 
unengaged providers
It is important to assess potential models and 
approaches to involving various care-providers 
who are not yet engaged in a PPM framework. This 
includes identifying the potential new providers that 
could provide accessible and effective services, 
and assessing the effectiveness of models involving 
these newly-identifi ed care-providers. 
2.4 Encouraging involvement of the non-
public sector in MDR-TB management 
and TB/HIV collaborative activities 
The objective is to develop an evidence base of 
different models and approaches, through the 
identifi cation of potential providers that could 
provide accessible and effective services for MDR-
TB and TB/HIV management and the assessment 
of effectiveness of various models for PPM in MDR-
TB and TB/HIV care and prevention.
2.1
Improving and scaling 
up existing 
approaches to enga-
ging all providers
2.2
Measuring the contributions 
of different provider groups 
to TB care and control
Research 
cycle
2.5
Developing and assessing 
responses to changing 
diagnostic approaches and 
treatment patterns of diverse 
providers in TB care and 
control
Encouraging the involvement of:
2.3 
Unengaged providers
2.4 
The non-public sector in MDR-TB 
management and TB/HIV collaborative 
activities
2.6
Encouraging introduction 
of novel regulatory 
approaches to collaborating 
care providers
FIGURE 3: CYCLE OF RESEARCH ACTIVITIES FOR OPTIMIZING COLLABORATION WITH ALL 
CARE PROVIDERS
Priorities in Operational Research to improve Tuberculosis Care and Control
23
2.5 Developing and assessing responses 
to changing diagnostic approaches 
and treatment patterns of diverse 
providers in TB care and control 
The objective is to identify and assess ways to 
ensure rational use of new diagnostics and drugs in 
the private sector. 
2.6 Encouraging introduction of 
novel regulatory approaches to 
collaborating care-providers
This research process will require the development 
of an evidence base of regulatory approaches (such 
as mandatory TB case notifi cation, certifi cation 
and accreditation) that includes contextualized 
analyses of reasons for success/failure, and then 
assessment of the possibility to develop locally 
appropriate regulatory approaches. 
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Optimal control of TB in high-HIV burden areas 
requires implementation of collaborative TB/HIV 
interventions through a sound policy and programme 
environment that gives due consideration to the 
local context, the respective epidemiology of TB and 
HIV, as well as the health system infrastructure that 
determines service delivery models. System-wide 
differences between HIV and TB care-providers 
and stakeholders – and operational diffi culties for 
providing effective and appropriate interventions 
– have contributed to the lesser implementation 
and scaling up of collaborative activities (21). It is 
therefore important to identify measures that would 
facilitate wider implementation and scaling up of 
collaborative TB/HIV interventions through effective 
service delivery models, including community-
based interventions. 
Collaborative TB/HIV interventions include the 
prevention of TB in PLHIV, the joint treatment of 
TB and HIV in people dually infected and improved 
infection control and prevention in various health 
settings (22). In HIV-positive individuals, IPT has 
been shown to reduce the risk of TB (Relative Risk 
(RR): 0.64, 95% CI 0.51 to 0.81), with almost all of 
the protective effect in individuals with a positive 
tuberculin skin test (RR 0.38, 95% CI 0.25 to 0.57) 
compared to those who had a negative test (RR: 
0.83, 95% CI 0.58 to 1.18) (23). In this population, 
however, diagnosis of latent TB infection (LTBI) 
and exclusion of active TB are diffi cult, especially 
in resource-poor, high-prevalence settings (24). 
The WHO ‘Three I’s’ strategy (22) recommends 
that PLHIV are screened for tuberculosis, and, if 
tuberculosis is ruled out, IPT should be provided. 
Despite this recommendation, less than 1% of 
PLHIV were started on IPT in 2008 (25). Among 
PLHIV who develop TB disease, mortality remains 
signifi cantly higher than among HIV-negative 
patients. Early initiation of co-trimoxazole and 
ART can reduce mortality, but linking HIV-infected 
TB patients to HIV care and treatment has proven 
challenging. Recent data from South Africa have 
shown that a synergistic approach to delivery of 
IPT and ART may result in a decline in risk of active 
TB (26). Therefore, operational research is needed 
in high-burden countries to optimize prevention and 
treatment of TB in PLHIV and address the several 
barriers that may occur at the level of screening, 
diagnosis, treatment and prevention (27, 2). 
3 Prevention and treatment of TB 
in persons living with HIV
Outstanding operational questions for improved TB/
HIV core group activities 
i. Barriers to TB diagnosis
Among PLHIV who have active TB, in addition to the 
lack of sensitive and rapid diagnostic tools, barriers 
to TB diagnosis include the lack of awareness by 
HIV care-providers about why and how they should 
screen for TB disease, inadequate recording, 
reporting and monitoring of TB screening in HIV 
care and treatment settings, and limited access to 
TB diagnostics in HIV care and treatment settings. 
A simplifi ed screening algorithm was recently 
recommended by WHO to identify those PLHIV who 
have less likelihood of active TB disease and hence 
are eligible for IPT (5). This algorithm relies on the 
absence of the four main clinical symptoms (current 
cough, night sweats, fever, and weight loss), to 
identify those PLHIV who are eligible to receive IPT. 
This simplifi ed symptom-based algorithm should be 
used for all adults living with HIV, including pregnant 
women and people receiving ART, and should 
therefore be operationalized in various settings. 
Data are therefore needed on the local performance 
of this new guideline.
ii. Barriers to IPT initiation
Among PLHIV who have been screened and are 
deemed eligible for IPT, barriers to IPT initiation 
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remain formidable, despite the presence of 
substantial clinical research to address these. For 
example, many programmes remain unclear about 
whom they should prioritize for IPT (i.e. whether 
IPT should be offered to all HIV patients who do 
not have active TB disease, or whether it should 
be restricted to those with specifi c tuberculin skin 
test results or to patients above or below a specifi c 
CD4 count threshold). Similarly, there are questions 
about the optimum mode of delivery (e.g. in pre-ART 
and in ART clinics or through home care services; 
in HIV facilities or TB facilities), timing and duration 
of therapy, frequency and type of monitoring for 
adherence, toxicity, and breakthrough TB disease, 
and methods to train and motivate health-care 
workers for use of IPT in addition to ART and co-
trimoxazole therapy among PLHIV.  
iii. Barriers to optimal combined TB/HIV 
diagnosis and treatment
HIV testing has been scaled up rapidly among patients 
who seek care in TB clinics. Nevertheless, in many 
settings, particularly countries with concentrated or 
low-level HIV epidemics, major questions remain 
about whether or how to implement targeted, as 
opposed to universal, HIV testing of TB patients. 
When TB patients are diagnosed with HIV infection, 
they should immediately be evaluated for HIV care 
and treatment, particularly co-trimoxazole and ART, 
to reduce short-term mortality. Nevertheless, the 
optimum models for joint TB and HIV diagnosis 
and treatment remain ill-defi ned at the patient and 
public health level.
Priority areas for operational research
The outstanding research questions have been 
prioritized to facilitate operational research that 
leads to optimal control of TB in high-HIV burden 
areas (see Figure 4).
3.1
Optimizing linkages 
between TB and HIV 
programmes
3.2
Assessing validity of TB 
screening algorithms in 
different setting
Research 
cycle
3.5
Optimizing infection control 
to reduce TB transmission
For IPT:
3.3 
Optimizing timing of IPT in relation to 
ART
3.4 
Models to improve adherence to IPT
3.6
Reducing mortality in 
co-infected patients
FIGURE 4: CYCLE OF RESEARCH ACTIVITIES FOR COMBINED TB/HIV MANAGEMENT 
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3.1 Optimizing linkages between TB and 
HIV programmes
Key questions to address here are: What forms 
of cross-referral, co-location of services, and 
community participation would increase: (i) the 
proportion of PLHIV who are screened for TB; (ii) 
the proportion of PLHIVs in whom IPT is initiated; 
and (iii) the proportion of PLHIVs who survive during 
treatment of TB disease? Of note, specifi c attention 
should be paid to studying these questions in high 
priority populations, such as children, injection drug 
users and prisoners. Specifi c studies are required 
to determine the best linkages between TB and HIV 
programmes. In particular, the following questions 
need to be addressed: 
- What are the best strategies to integrate 
and deliver joint TB/HIV interventions, 
including ART, at the community- and 
health sector level to TB/HIV co-infected 
adults, children and their families?
- What are the optimal models of community 
participation (i.e. effective, feasible, 
acceptable and sustainable) for enhanced 
TB case-fi nding and early HIV detection, 
in order to reduce any delay in initiation of 
TB and HIV care, and reduce TB and HIV 
transmission?
- How can the cost-effectiveness of joint 
TB/HIV interventions delivered through 
community approach and through health 
facilities be estimated?
- What are the best delivery models of 
collaborative TB/HIV interventions for most 
at risk and special populations in all settings, 
including those with different TB and HIV 
epidemiology and epidemic states?
3.2 Assessing the validity of TB screening 
algorithms in different settings
In PLHIVs who attend health facilities, does 
implementation of the WHO-recommended 
algorithm for TB screening increase the proportion 
of subjects screened for TB, reduce the proportion 
of PLHIV who develop TB disease during IPT, and 
reduce mortality during TB treatment, compared 
with current policy or more intensive TB screening 
strategies (e.g. microbiologic evaluation of all 
PLHIV)? Specifi c attention should be paid to 
studying this question in different contexts in 
which TB screening might occur, such as HIV 
counselling and testing centres, HIV clinics, 
community-based case-fi nding, and household 
contact investigations. The following questions 
need to be addressed: 
- What is the best model to eliminate 
diagnostic delay, hasten treatment initiation 
for TB and reduce mortality, using existing 
tools including the effectiveness of the 
revised WHO algorithm for smear-negative 
TB among HIV-infected TB suspects?
- What are the best strategies to promote 
and scale-up integrated screening of HIV 
infection and TB infection and disease 
among household contacts of HIV-infected 
TB patients?
- What are the best operational models for 
active and enhanced case-fi nding of TB 
among PLHIV in HIV service facilities and 
at community level, in both high and low 
HIV prevalence settings?
3.3 Optimizing timing of IPT in relation to 
ART
In PLHIV eligible for both IPT and ART, what is 
the appropriate time to initiate IPT, and what is 
the optimal duration, safety, effi cacy and cost-
effectiveness of IPT – alone or with ART – in reducing 
the risk of active TB and mortality compared to ART 
alone among PLHIV, particularly under programme 
conditions?
3.4 Models to improve adherence to IPT
In PLHIV initiating IPT, what models of medication 
delivery, clinical monitoring and community support 
reduce rates of default during IPT, reduce the 
incidence of breakthrough TB, and reduce the 
occurrence of severe adverse events? What are 
the best operational models to scale-up IPT in 
HIV care settings, including frequency of symptom 
screening, monitoring tools and measures to 
maintain high adherence? The following questions 
need to be addressed: 
- What are the best strategies to obtain 
optimal medication delivery, community 
support and clinical monitoring of IPT in 
PLHIV in order to maximise adherence?
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- How to best model and forecast the 
operational requirements and full economic 
costs of going to scale in administering IPT 
in HIV care settings?
3.5 Optimizing infection control to 
reduce TB transmission
In HIV care and treatment settings, does a 
standardized package of infection control (IC) 
interventions reduce nosocomial TB transmission 
compared with current policy and practices? Do 
selected IC interventions reduce nosocomial TB 
transmission? For both of these questions, the best 
recognized indicator to measure (in operational 
research studies) is TB infection rates in health-care 
workers. With this in mind, the following operational 
research challenges need to be addressed:
- What are the best infection control 
interventions that effectively reduce M. 
tuberculosis transmission (both drug-
susceptible and -resistant) in health care-
settings, at home and in the community?
- What are the best operational models, i.e. 
practical, feasible, easily reproducible and 
effective, to implement and monitor infection 
control measures in health facilities?
- What are the best operational models to 
assess the impact of infection control measures 
in reducing the spread of M. tuberculosis to 
HIV-infected adults and children?
3.6 Reducing mortality in co-infected 
patients
In PLHIV treated for TB, what factors are associated 
with death during TB treatment and, among those 
who die, what are the most common causes of 
death? Although use of ART and co-trimoxazole 
have been clearly documented to reduce mortality 
during TB treatment, specifi c attention should 
be paid to identifying whether the absence of 
such treatment is responsible for ongoing, high 
mortality rates or whether additional, modifi able 
risk factors can be identifi ed.
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Access to health care is the cornerstone of TB 
control programmes, which must ensure that all 
detected patients receive a full course of treatment 
(29). This includes establishing effective treatment 
as well as effective strategies to support the 
process of care from detection of disease through 
the completion of appropriate treatment (30). 
Limited access and poor adherence to treatment 
remain, however, major obstacles in the global fi ght 
against TB. In 2008, 39% of TB cases were not 
reported or detected, 93% of MDR-TB cases were 
not diagnosed and even more were not treated 
with an approved Green Light Committee (GLC) 
regimen, and 93% of HIV-infected TB patients 
were not started on ART (25). Patient and health-
system factors contribute to these problems. 
Major diagnostic delays compromise treatment 
outcomes and increase TB transmission. In 2008, 
the treatment success rate for new patients with 
smear-positive pulmonary TB was 87%, but this 
apparent success masked a number of operational 
challenges: for MDR-TB, only 30 000 (7%) out of 
the 440 000 (95%CI 390,000–510,000) MDR-TB 
cases estimated to have emerged in 2008 globally, 
were notifi ed, and nearly 6000 of them (1.4%) 
were put on treatment (31). Treatment success of 
a cohort of 4500 MDR-TB patients treated under 
programmatic conditions in 2004–6 was 60%. 
Access to treatment for MDR-TB remains one 
of the major problems facing TB control today. 
Only a small fraction of the tens of thousands of 
diagnosed patients are receiving appropriate care. 
Even among the 72 000 patients approved for GLC 
treatment, only 19 000 have actually been enrolled. 
Operational research is thus critically needed to 
improve access to care for drug-susceptible (DS) 
and drug-resistant (DR) TB patients. We propose 
here a cycle of research that addresses both DS- 
and DR-TB aspects, also taking into account HIV 
co-infection, with actions that can be conducted 
in parallel, arising from a common basis of core 
activities i.e. identifi cation of the reporting gaps 
and identifi cation of defi ciencies in fi rst-line 
management of TB cases.
4 Treatment of drug-susceptible 
and M/XDR-TB: optimal access, 
delivery and community 
participation
The outstanding research questions have been 
prioritized to facilitate operational research that 
leads to improved access and delivery of treatment 
of drug-susceptible and M/XDR tuberculosis (see 
Figure 5).
Priority areas for operational research
Priorities in Operational Research to improve Tuberculosis Care and Control
29
4.1 Identifying reporting gaps
Reporting gaps exist at several levels and give false 
estimates of TB cases being detected and under 
treatment. For instance, it has been reported that 5 
to 15% of patients with smear-positive pulmonary TB 
are not entered into TB registers and fail to be counted 
(32). It is therefore important to determine treatment 
outcomes of new smear-positive pulmonary TB at 
different sources: comparing sputum laboratory 
registers with TB patient registers, for example, or 
comparing TB treatment outcomes by treatment 
cards, registers and quarterly reports. This should 
also be done for patients enrolled in TB re-treatment 
regimens. In addition, reporting gaps also arise from 
the lack of registration of TB patients detected and 
treated in the private sector or in public sectors 
outside the NTCPs, and efforts should be made to 
count them in (see section 2, above).
4.2 Carrying out investigational studies 
to address defi ciencies in fi rst-line 
management of TB
Avoiding missed treatment doses is benefi cial, 
since not all who receive irregular treatment will 
default but may be at high risk for acquired drug 
resistance. Similarly, defaulting from treatment 
may contribute to drug resistance. Efforts are 
needed, under programmatic conditions, to reduce 
irregular adherence or default from treatment; and 
to reduce selective pressure for resistant organisms 
among patients who take treatment irregularly, 
but do not default. Studies to understand reasons 
behind default (both primary and secondary), poor 
adherence, missed doses, and drug stock-outs 
will help inform strategies to reduce each of these 
challenges, and reduce the risk of drug resistance. 
4.1
Identifying reporting 
gaps through the use 
of registers and 
records, including 
drug resistance 
surveillance systems
4.2
Carrying out investigatio-
nal studies to address 
deficiencies in first-line 
management of TB cases
Research 
cycle
4.5
Defining and evaluating 
strategies for 
integration/scale-up of 
drug-resistant TB 
management within TB 
programmes
4.6
PPM collaboration studies
4.4 
Identifying drivers of 
drug-resistant TB
   4.4.1 
   At individual level
   4.4.2 
   At programmatic level
4.3 
Improving management 
of drug-sensitive TB
4.7
Improving decentralized 
and fully integrated 
access to HIV testing 
and combined TB and 
HIV treatment
FIGURE 5: CYCLE OF RESEARCH ACTIVITIES FOR IMPROVED ACCESS AND DELIVERY OF 
TREATMENT OF DRUG-SUSCEPTIBLE AND M/XDR TUBERCULOSIS
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4.3 Improving management of drug-
sensitive TB
Strategies should be developed, piloted, and rolled 
out to improve fi rst-line management of drug-
sensitive TB, based on the fi ndings generated in 
4.2 above.
4.4 Identifying drivers for drug-resistant 
TB
Studies conducted under 4.2 (above) will also provide 
information that will help identifying the various 
risk factors that contribute to the development of 
drug-resistant TB in the local or national context. 
One way of identifying these risk factors would be 
to investigate unexpected increases in numbers 
of MDR-TB patients, as observed through routine 
surveillance of multidrug resistance among risk 
groups, especially previously treated patients. Such 
investigations can provide important information 
as to which factors, operating at either individual 
patient level or at the health service (programmatic) 
level, are important drivers of the local/national 
increase in MDR-TB cases. Of particular importance 
are risk factors that are amenable to intervention. 
These factors will be investigated both at individual 
and programmatic level.
4.5 Defi ning and evaluating strategies 
for integration/scale-up of drug-
resistant TB management within TB 
control programmes
From the studies outlined above, optimal strategies 
can be developed to identify and target those 
patients most at risk of developing, or having, MDR-
TB. This includes evaluating the operational steps 
and time required to introduce new diagnostics for 
identifi cation of drug resistance, as well as optimal 
delivery of treatment in the context of programmatic 
management of DR-TB (for instance, models for 
maximizing adherence to treatment): What are the 
best strategies to scale-up DR-TB management 
into TB control programmes in relation to provision 
of 2nd-line treatment (e.g. inpatient vs. ambulatory 
treatment vs. community-based care, use of 
incentives and enablers to enhance adherence to 
treatment, social support, community involvement 
etc.)? It should be noted that different methods will 
require different technologies/infrastructure, but 
many processes will likely be identical.
4.6 PPM collaboration studies
Previous questions will address the role of private 
practitioners in the detection, diagnosis and 
treatment of both DS- and DR-TB. To achieve this, 
it is necessary to get realistic data on numbers of 
DS- and DR-TB cases treated in the private sector 
and about treatment outcomes and DR rates among 
those who failed or relapsed. Why do people use the 
private sector rather than the public sector? How to 
engage with the private sector for the treatment of 
DS- and DR-TB?  
4.7 Improving decentralized and fully 
integrated access to TB and ART 
treatment 
Previous sections addressed the challenges of 
detecting and treating both DS- and DR-TB most 
effi ciently. In addition, this has to be contextualized 
in relation to the HIV epidemic, as all TB patients, 
whether drug-sensitive or drug-resistant, should 
start ART early if they are co-infected with HIV, and 
the provision of both TB and ART drugs should be in 
the same facility. There are similar questions for both 
conditions: How can joint treatment be provided at 
health centres? How can communities be better 
engaged (structures, support, links with traditional 
systems)? Should TB programmes have their own 
stock of tests, co-trimoxazole and/or ART? Should 
they place orders to HIV programmes on behalf 
of patients receiving TB treatment, or should they 
have to refer patients to HIV programmes for all the 
above?
In addition, there are specifi c operational and 
epidemiological questions related to HIV-infected 
DR-TB, such as the precise causes of HIV-driven 
MDR-TB outbreaks if these occur, and the potential 
of IPT for inducing isoniazid-resistance and MDR-
TB in the long run. 
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Despite international interest in the subject 
of operational research, very little research is 
conducted or published from resource-limited 
settings where the greatest burden of tuberculosis 
resides. Yet major funders such as the Global Fund 
explicitly state that up to 10% of country proposal 
budgets should include monitoring, evaluation and 
operational research (33). There is a widespread 
consensus that operational research is important 
at local/national level to improve programme 
performance and at international level to guide 
policy recommendations (34). Questions remain, 
however, on the issue of where operational research 
should be located (e.g. NTCPs, governmental 
institutions, universities, NGO, or partnerships?), 
on the nature of research capacity to develop and 
approaches to capacity building, as well as on the 
evaluation of outcomes of training (34). NTCPs 
may lack essential expertise, infrastructure, staff, 
funds, policy cycle, and/or professional culture, 
and there may be only weak linkages between 
programmers and researchers. The key aspects 
of capacity building/strengthening in operational 
research at programme levels are the following: 
(i) operational research should be embedded in 
the NTCPs strategic plan; (ii) there should be an 
operational research focal point in programmes; (iii) 
operational research projects should conclude with 
clear results to alter/improve programme performance 
(see Box 2). It is particularly important to be aware of 
the distinction between capacity building (providing 
the ability to individuals, organizations or systems 
to perform and utilize health research effectively, 
effi ciently, and sustainably) (35) and training 
(which is an organized activity aimed at imparting 
information and/or instructions to improve the 
recipient’s performance or to help him/her attain 
a required level of knowledge or skill).g Training 
may be one component of capacity building that 
should encompass the generation of research 
agendas/topics as well as the uptake and utilization 
of research outputs. It can be helpful to envisage 
these as extremes of a spectrum with training in its 
simplest form at one end of the spectrum, most of 
the time unlinked to outputs such as peer-reviewed 
publications that enable an individual or organization 
to utilize health research. At the other end of the 
spectrum a country-based capacity-building 
programme could include direct participation of 
policy-makers who should directly utilize health 
research outputs. Between these two extremes, 
there may be training programmes delivering 
some elements of capacity building (such as peer-
reviewed publications) but without being suffi ciently 
embedded within a national system to deliver full 
changes to the functioning of an organization or 
system as a result. As a starting point, it might be 
helpful to use the needs assessment conducted 
with health professionals working with TB, TB/HIV, 
MDR-TB, who voluntarily complete locally-adapted 
questionnaires on preferred learning modes, 
research training needs, such as laboratory, clinical, 
epidemiology, biostatistics/data analysis, social 
science research, bioethics, and skills desired, 
such as grant writing and data management. This 
approach could be helpful to identify the further 
steps for the capacity building for operational 
research locally or nationally.
5 Capacity building for 
operational research
g See: http://www.businessdictionary.com/defi nition/training.html
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Priority areas for capacity building for operational 
research
FIGURE 6: CYCLE OF RESEARCH ACTIVITIES FOR IMPROVED CAPACITY BUILDING FOR 
OPERATIONAL RESEARCH IN TB
5.1 Assessing the impact of existing 
training models in terms of products 
and measurable outcomes 
Although there is a substantial literature available 
on different approaches to educational evaluations, 
few innovative interventions for work-based 
education of health professionals in developing 
countries have been adequately evaluated (37, 38). 
It is therefore important to evaluate the impact of 
existing models in terms of products and outcomes, 
such as the number and type of publications, the 
impact indicators for policy and practice, or the 
users’ satisfaction (e.g. patient, health-care workers, 
managers or community leaders). It is also important 
to track what happens to persons who attended 
training courses and whether they continue with 
research after the training and continue to undertake 
operational research and use this research to inform 
policy and practice. Accurate and reliable indicators 
of impact need to be defi ned to assess the quality 
of operational research projects and the capacity 
for translation into evidence-based programme 
practice. Examples of potential indicators are given 
in Annex VI.
5.2 Models of operational health 
research capacity building
Several models of operational research capacity 
building have been implemented, including 
country-specifi c experiences, and are detailed in 
Annex VI. Lessons learnt to date are summarized 
in Box 2. Prospective case study methodology can 
be used to learn further lessons from other models 
as they are introduced (36).
5.3 Sustaining operational research 
capacity at the national level
5.3.1 Identifying funding mechanisms 
for operational research capacity 
building at national level
What sort of funding mechanism (beyond Global 
Fund budgets) can allow operational research 
capacity to be built and sustained at the national 
level? Examples in the literature include money from 
central government training budgets, contributions 
from project participants towards the cost of 
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courses, income from selling consultancy services, 
and externally funded research grants (36).
5.3.2 What are possible ways of 
sustaining and retaining trained 
operational research staff within 
programmes?
Along with ongoing funding, sustained staff retention 
is another indicator of successful operational health 
research capacity building, and lessons for retaining 
and sustaining trained staff should be extracted from 
the evaluation described in section 5.1 (above). In 
the literature (36), indicators of sustainable capacity 
building increase in complexity as activities mature 
and include
• early engagement of stakeholders; explicit 
plans for scale up; strategies for infl uencing 
policies; quality assessments (awareness and 
experiential stages)
• improved resources; institutionalisation of 
activities; innovation (expansion stage)
• funding for core activities secured; management 
and decision-making led by southern partners 
(consolidation stage). 
(i) Operational research should be embedded in a national TB programme strategic plan;
(ii) In each national TB programme, there should be an operational research focal point (supported by 
other fi eld staff) that supports the programme manager and who coordinates and sets the national 
research priorities;
(iii) Programme staff engaged in operational research should be encouraged and motivated through 
‘on-the-job’ training and supervision, with dedicated time and opportunity for research activities, 
provided with opportunities to make presentations at national and international conferences, 
research bonuses and small grants;
(iv) There should be adequate operational research infrastructure (e.g. room space, computers, 
internet, stationary) and implementation support (e.g. motorcycles); 
(v) At the country level, there should be a shift towards a ‘partnership model’ in operational research 
that is inclusive of academic institutions, NGOs and community-based associations, so that the 
comparative advantages of each group are harnessed.
(vi) Operational research training should be based on strict selection criteria, must be output oriented, 
and should involve a strong element of mentorship. The operational research training model should 
be practical and geared towards providing practical skills for both conducting and publishing 
research (e.g. the UNION-MSF operational research approach to training);
(vii) There should be long-term career opportunities at programme level through operational research 
fellowships (junior and senior);
(viii) Operational research projects should conclude with clear results that can infl uence or alter/improve 
programme performance;
(ix) Funding and resources for operational research need to be built into the programme so as to avoid 
foreign or academic institutions developing a monopoly on funding, time and mandate for research 
and consequently, the associated power of decisions; 
(x) Programme researchers should be represented on the Global Fund Country Coordinating 
Mechanism so that the rationale for and decisions on research funding are made at the highest 
level.
BOX 2: TEN KEY ENABLING FACTORS FOR CAPACITY BUILDING/STRENGTHENING IN 
OPERATIONAL RESEARCH AT PROGRAMME LEVEL (FROM REFERENCE 34)
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IV. COMMUNITY 
INVOLVEMENT IN 
TUBERCULOSIS 
RESEARCH
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While communities at risk have been both drivers 
and partners in HIV research (1), their important role 
in TB research is yet to be fully realized. Involvement 
of communities in tuberculosis care and prevention 
is currently on the international agenda (2, 3). This 
creates opportunities and indicates the urgency to 
also engage communities in TB research.
In this section, the advantages of involving 
communities in operational research for TB care 
and control are presented, and strategies for 
engaging risk groups, (ex-)patients and high burden 
communities are proposed. We intend to provide 
researchers with some tools and ideas to help them 
collaborate effectively with communities in the 
identifi cation of research priorities, the conduct of 
research projects and dissemination of the results. 
‘Community involvement’ is more than the token 
inclusion of a former TB patient on staff or the 
setting up of a Community Advisory Board (CAB) 
for a clinical trial. It implies a fundamental shift in 
the way we think about and implement studies. 
Community involvementh in research is founded on 
the core principle that people who are affected by 
research have a right to have a say in what is being 
studied and how, and ensure that they can take 
advantage of the benefi ts of research fi ndings.
In addition to being a legal requirement in some 
countries (e.g. Brazil, Namibia, Kenya, Zimbabwe), 
capacity building and collaboration with members 
of risk groups enhances the quality of the 
research, because they are the experts on the 
challenges they experience and the solutions they 
require (4). The aim of community involvement 
is to recognize the public’s stake in determining 
the way research is formulated, commissioned, 
undertaken, disseminated and translated into 
policies and service delivery. Many TB researchers 
are embracing a TB version of the GIPA principle 
(Greater Involvement of People Living with HIV/
AIDs) called GIPT (Greater Involvement of People 
with TB) to refl ect their belief that TB patients have 
been neglected stakeholders for too long.i 
‘Communities at risk’ refers to both vulnerable groups 
such as the malnourished or people with diabetes 
as well as residents in geographical areas with a 
high TB prevalence. Some communities share a set 
of social, cultural, racial or linguistic characteristics 
that unite them. However other ‘communities’ are 
simply identifi ed by a common risk behaviour or 
shared geography such as injection drug users, 
prisoners, smokers, miners, or laboratory personnel. 
Some refer to ‘Most At Risk Populations (MARPs)’ to 
describe communities whose risks for TB are much 
higher than the general population. Often these 
communities are hidden due to stigmatization, and 
extra efforts and expertise are required to reach and 
to serve them well.
The following objectives of community involvement 
have been proposed (4):
• To ensure the relevance of research, 
• To assess and assure that research is 
culturally and practically acceptable in the 
context it is intended,
• To ensure that community disruption by the 
research project is minimized,
• To avoid injustice, by ensuring a fair 
distribution of the benefi ts of research, 
• To take into account the ethical hazards 
that may be part of the social, economic, 
and political landscape of the community 
(e.g. corruption),
• To ensure that research practices are in 
tune with local norms and values.
The requirements for successful community 
involvement include: a long-term commitment, 
an appreciation of the potential synergies, and a 
willingness to cross-train and support all the people 
involved (6).
One comprehensive model of collaboration is 
termed ‘community-based participatory research’ 
(CBPR). While, there are many defi nitions for 
CBPR, one defi nition is “a collaborative approach 
to research that combines methods of inquiry with 
community capacity-building strategies to bridge 
the gap between knowledge produced through 
h The terms ‘community engagement’ or ‘participation’ are considered synonyms for ‘community involvement’.
i http://www.worldcarecouncil.org/content/gipt-principles-new-driver-road-stop-tb
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research and what is practiced in communities 
to improve health” (7). In CBPR projects, the 
community participates fully in all aspects of the 
research process.
Communities can play key roles in many different 
activities in the course of a research project: 
(i) Priority-setting
(ii) Research design
(iii) Ethical evaluation
(iv) Protection of study participants
(v) Data collection
(vi) Interpretation of fi ndings
(vii) Dissemination of fi ndings
(viii) Translation into action
Community involvement in each aspect of research 
is considered in more detail below. 
(i) Priority-setting
The public and patients often have a more holistic 
view of health and wellbeing than disease-specifi c 
researchers. This may result in priority-setting that 
differs from that of health workers or researchers, e.g. 
more geared towards cross-cutting issues, quality 
of life, and social determinants. For example, while 
trialists may narrowly focus on improved treatment 
regimens for TB, communities may see the need to 
answer broader primary prevention questions such 
as how to address the structural conditions (e.g. 
poverty, malnutrition, marginalization) that put them 
at risk for a range of diseases.
The research questions that have been prioritised 
by experts in this document will be addressed 
at country level. During this country-level 
research process, it is recommended that at-risk 
communities are involved to confi rm their local 
relevance and priority. Various methods have 
been tested to involve the community (often 
ex-patients) in priority-setting. An example is 
the ‘Dialogue Model’ developed by Abma et 
al. for patient participation in health research 
agenda-setting (8). This model has six phases: 
exploration, consultation, prioritization, integration, 
programming and implementation. 
A key question is: Who should be responsible 
for involving the community in identifying priority 
research questions? Researchers may not have 
the knowledge or funding to organize community 
involvement and/or consultation. Furthermore, 
they often work on one specifi c dimension of TB 
and may not be suffi ciently knowledgeable of the 
whole fi eld to respond to community queries. Donor 
agencies increasingly seek guidance from most-at-
risk-populations when they prepare a new research 
programme or call for proposals. Also organizations 
of communities at-risk may take the lead, and may 
use the resulting, prioritized research agenda for 
advocacy purposes. Researchers should be aware 
that ex-TB patients and leaders of at-risk groups 
may not always be representative of all TB patients 
or people at-risk. Governmental organizations may 
also take a role especially in priority-setting that 
transcends one vertical disease program.
(ii) Research design
Reasons for involving the community in study design 
can be to increase participation and collaboration of 
the community; to improve the quality of research 
design; to ensure that study questionnaires pose 
questions in ways that are understandable and 
acceptable; to ensure that issues important to 
the community are included in the study design, 
etc. At-risk communities can play a pivotal role in 
developing recruitment and retention strategies 
or questionnaire design. When there are different 
study design options, community stakeholders can 
weigh in on which makes most sense locally. 
Communities that may appear homogeneous 
from the outside may in fact be very diverse. 
Understanding the heterogeneity, social codes, and 
hierarchies often requires an insider’s perspective. 
For example research with prisoners requires an 
insider’s knowledge of the parallel power structures 
that govern inmates’ participation in research 
endeavours (9). Acknowledging the heterogeneity 
of communities also means assuring that vulnerable 
sub-groups are heard, not just the main power 
brokers and gatekeepers. 
Types of community involvement in operational research
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There are several possibilities for involving at-
risk communities in research design: community 
members might be members of the steering 
committee or technical advisory committee of 
research studies, or community members might 
work in equal partnership with the researchers 
and other stakeholders on the research project. 
When involving (former) TB patients and members 
of stigmatized groups (men who have sex with 
men, ex-prisoners, sex workers, undocumented 
migrants, etc.) as researchers, it is important to 
respect their right to control to whom and how they 
disclose their member status.j 
A suitable way of involving communities is through 
the establishment of community advisory boards 
(CABs) - see the example of the Global Alliance 
for TB Drug Development.k These boards are often 
comprised of community members involved in local 
leadership, social services or health care delivery. 
They provide input on trial implementation and work 
towards greater community understanding of TB 
and the research process. Thus, a CAB established 
in KwaZulu-Natal, South Africa, contributed to 
promoting and facilitating relevant research and TB 
control activities (10). TB drug and vaccine trialists 
have engaged community leaders, traditional birth 
attendants, teachers, religious leaders, and parents 
in high-burden regions of Uganda, Kenya, and 
Mozambique in conversations about the potential 
need for invasive TB diagnostic procedures in 
children to anticipate and strategize ways to assuage 
their concerns in the pre-trial design phase (11). 
Participatory research and evaluation implies 
early and sustained involvement by target groups 
in assessing the outcomes of activities designed 
to help them. It is based on the premise that 
communities are ideally positioned to help national 
TB programmes and NGOs to do the work as 
well as to measure the outcomes. Participatory 
evaluation often involves the use of graphics, maps 
and interactive techniques, particularly where low 
literacy and language diversity may limit the utility 
of written measurement tools.
(iii) Ethical evaluation
Research protocols must be submitted for 
consideration, comment, guidance and approval 
to a research ethics committee before the study 
begins (according to Article 15 of the World 
Medical Association Declaration of Helsinki).l The 
Operational Guidelines for Ethics Committees 
that Review Biomedical Research,m published by 
the WHO/Special Programme for Research and 
Training in Tropical Diseases (TDR), suggests that 
an ethical committee should include a lay person. 
An ethical committee should include at least one 
member whose primary area of expertise is in a 
non-scientifi c area. The Council for International 
Organizations of Medical Sciences presumes that 
lay people qualifi ed to represent the cultural and 
moral values of the community, are included in the 
ethical committee.n They ensure that the rights of 
the research participants are respected. The Family 
Health International Offi ce of International Research 
Ethics has developed a curriculum to empower 
community representatives through training and 
education to act as a competent voice for research 
participants worldwide: Research Ethics Training 
Curriculum for Community Representatives.o
(iv) Protection of study participants
The Declaration of Helsinki states that in medical 
research involving competent human beings, 
each potential participant must be adequately 
informed of the aims, methods, sources of funding, 
any possible confl icts of interest, institutional 
affi liations of the researcher, the anticipated 
benefi ts and potential risks of the study and the 
discomfort it may entail, and any other relevant 
aspects of the study. This is generally done 
through obtaining informed consent from the 
individual to contribute to the trial/study.
Involving community members in the design of 
the informed consent process can ensure that 
potential participants have a better grasp of the 
real risks and benefi ts of a study. While scientists 
may know the physical risks of study participation, 
j See: http://www.aidsalliance.org/TechnicalThemeDetails.aspx?Id=34
k See: http://www.tballiance.org/aaa/endemic.php
l See: http://www.wma.net/en/30publications/10policies/b3/index.html
m See: http://apps.who.int/tdr/publications/training-guideline-publications/operational-guidelines-ethics-biomedical-research/pdf/
ethics.pdf
n See: http://www.cioms.ch/publications/layout_guide2002.pdf
o See: http://www.fhi.org/en/RH/Training/trainmat/ethicscurr/retccr.htm
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community members are better positioned to 
understand and mitigate the potential social harms 
(e.g. stigmatization, loss of employment, etc.) that 
can come from joining certain types of research. 
The community can also have a role in monitoring 
the procedures for obtaining informed consent. 
For example, is the informed consent process 
implemented as rigorously as was planned? 
History shows that community activist groups may 
oppose research projects that bypass them in the 
ethical review process. For example, two tenofovir 
trials were suspended due to the failure to engage 
activists in compensation issues (12).
The International AIDS Vaccine Initiativep has 
developed an AIDS vaccine literacy toolkit (Vaxlit). 
One of the positive outcomes of the vaccine 
literacy initiative is that potential trial volunteers 
make informed, independent decisions regarding 
participation. 
(v) Data collection
Involving community members in the data collection 
phase may have advantages or disadvantages, 
depending on the kind of information that is 
being collected. Local expertise can prevent 
misunderstandings and increase participation and 
retention because at-risk groups are more sensitive 
to local social norms and the negative connotations 
that some TB terminology can have (e.g. ‘suspects’ 
implies suspicious and untrustworthy in some 
settings). Involvement of community members in 
data collection may ensure that the intentions of the 
proposed research projects are honestly portrayed. 
Also if community members are involved in data 
collection they might be better able to interpret 
results than external researchers. If problems 
arise during the course of a study, community 
members involved in the undertaking of research 
can troubleshoot the problems at an early stage. In 
some areas (e.g. slums) security can be an issue. 
Involving community members might increase the 
security of the research teams.
Potential disadvantages of involving community 
members in research can arise when TB research 
delves into sensitive or stigmatized issues – such 
as non-compliance with infection control norms, 
non-use or misuse of medicines, etc. Deductive 
disclosure can be a problem if community 
members are not suffi ciently aware of research 
ethical principles. Since community members may 
share cultural assumptions and terminology of 
the participants, they might not always probe for 
the meaning of local concepts when necessary 
because they may take certain ideas for granted or 
because the topic is too sensitive.
(vi) Interpretation of fi ndings
Rigorous qualitative methodology involves 
frequent confi rmations with community members 
to prevent any misinterpretation and enhance the 
‘groundedness’ (foundation of an argument, a 
belief, or an action; a basis) of fi ndings. Involving 
community members in the interpretation of 
quantitative fi ndings might also result in more 
applicable conclusions and recommendations. 
(vii) Dissemination of fi ndings
The fi ndings of research should be disseminated 
with and within the communities that participated 
in the research (see Declaration of Helsinki, 
above). This could be done using different 
methods: workshops; radio talk shows; community 
debriefi ngs; local news media; graphical and visual 
techniques; during community meetings etc. 
Community members can have an important role 
in the dissemination of the research fi ndings. All 
materials used for dissemination should use non-
scientifi c language that is easily understood by a 
general audience. 
(viii) Translation into action
When communities at-risk have a sense of ownership 
of research fi ndings, they can play a powerful 
advocacy role in assuring that research innovations 
translate into service delivery realities long after 
researchers have departed. Community activists 
can use “the facts” to assure that new guidelines 
and policies are implemented and life-saving 
technologies are rolled out and brought to scale.  
p See: http://www.iavi.org/
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Building capacity for involvement
As interest in community involvement in research 
has grown, so has the need for research training 
and support to ensure good practice in this area. 
At the start of each project the training needs of 
relevant community members should be assessed: 
Do they need enabling skills and/or research skills? 
Examples of training for community involvement in 
research are available (10). Of note, TB investigators 
may often need training (e.g. communication skills, 
cultural competency, participatory methods) as well.
Financing community involvement
Appropriate involvement of the community in 
research requires an adequate budget, e.g. for 
community training, and for meetings with the 
community. Adequate resources for community 
involvement should be an integral part of the overall 
research budget. Donors and regulators have key 
roles to play in fomenting effective collaboration 
with at-risk communities and have made this a 
requirement for some research funding streams and 
regulatory processes.
Other aspects of community involvement
How to Engage Communities?
The process of involving at-risk communities 
depends on the type of research intended. Often 
roles cannot be decided a priori, but should be 
mutually determined with community members. 
It is most strategic if communities are involved 
from the outset of research planning, but it is 
better to reach out during the study than not at 
all. The more hidden and stigmatized the risk 
group, the longer it may take to engage them 
and study timelines should reflect this. Here are 
the steps followed by TB vaccine trialists in the 
TBVACSIN network. 
Step 1: Initial consultation with 
stakeholders.
Given that communities are rarely homogenous and 
may comprise sub-groups with divergent interests 
and power, it is usually strategic to start with an 
array of stakeholder meetings where research 
ideas and priorities can be vetted and the social 
landscape can be mapped. These consultations 
are listening exercises to identify sensitivities and 
to discern the full range of potential collaborators. 
Be careful not to create unrealistic expectations or 
make promises you may not be able to fulfi l.
Step 2: Recruit and train study staff 
from communities at-risk
Once the funding and the objectives are confi rmed, 
identify individuals with the local roots to contribute 
to study design and implementation. Be sensitive 
to political, social, gender, and ethnic divisions and 
strive to form a diverse team to bridge divides. Be 
prepared to invest in human resource development 
and build this into budgets and study timelines. Staff 
are the ambassadors of the study and their behaviour 
refl ects on the study when at work and after hours. 
Step 3: Form an effective Community 
Advisory Board 
Gather stakeholders from a diverse range of 
grassroots organizations and community groups 
and train them in the roles of a CAB. Budget for 
transportation reimbursement or other modest 
recognition of the contribution of community 
members. Beware of creating expectations of 
payment or allowing misunderstandings and 
potential accusations of undue inducements or 
lack of independence. Gather their insights on how 
to protect participants from social and physical 
harms, how to ensure high rates of participation 
without coercion, and how to frame the risks and 
benefi ts of participation. 
Step 4: Pilot study tools and fi delity to 
procedures
Conduct focus group discussions with potential 
participants to ensure that the research tools are 
understandable as designed. When in doubt, 
conduct back translations of instruments to avoid 
misinterpretation. Directly observe role plays 
of study procedures to ensure that that study 
staff uphold research ethics principles in their 
interactions. 
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Step 5: Do the research together
Invite communities to collect data and involve 
them in the process to evaluate, refute, refi ne and 
interpret the fi ndings.
Step 6: Share the credit for good work
Cultivate a broad ownership and accountability for 
the dissemination and translation of the results by 
involving community leaders in the “marketing” of 
the fi ndings to the wider world. 
The United Kingdom National Institute for Health 
Research describes in a ‘How-to guide’ the advantages 
of involving the community (13), and provides guidance 
on how-to involve communities in research.
Conclusion
Involving communities in several or all stages of a 
research study is not only an ethical requirement 
refl ecting people’s right to have a voice in issues 
that affect them. With adequate capacity-building 
of both researchers and communities at-risk, these 
partnerships hold great potential for improving the 
quality of research and the uptake and sustainability 
of resulting innovations. 
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V. GLOBAL FUND 
INVESTMENT IN 
TB OPERATIONAL 
RESEARCH 
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The Global Fund, as one of major funders in global 
health, has been providing fi nancial support for 
country applicants to conduct operational research. 
It serves an important role in the grant assessment 
process. In 2002, the Global Fund Board requested 
its Portfolio Management and Procurement 
Committee to provide guidance to the Technical 
Review Panel (3rd Board meeting, October 2002) on 
operational research. Later, for Global Fund round 
10 proposals, the Board requested the Global Fund 
Secretariat to “urgently work with partners to adopt 
measures to identify gaps and to further improve 
the quality of Global Fund-supported prevention, 
treatment, care and support including operational 
research to identify effective scaling up strategies 
to improve outcomes.”q
In general, there are no existing policies or 
requirements for Global Fund country applicants 
to include operational research in their proposals. 
However, countries are encouraged to allocate up 
to 10% of the total budget for activities related to 
monitoring and evaluation (M&E) including system 
strengthening, data management, outcome and 
impact evaluation of programmes and interventions, 
operational research studies, and any other M&E 
related activities. Countries receiving Global Fund 
grants should consider potential research needs 
in their national planning schedules and earmark 
suffi cient resources to conduct such studies (1). 
The Framework for operations and implementation 
research in health and disease control programs (2), 
published in 2009, was developed in collaboration 
with other partners to provide a set of comprehensive 
guidelines for programme managers, implementers, 
researchers, and policy-makers to plan and carry 
out research that would inform implementation. 
Sound research studies have been proven to be 
a powerful tool to inform decision-makers on 
programme implementation issues. However, there 
has not been a systematic analysis of what type 
of research is supported by the Global Fund. This 
section attempts to provide background on the 
level of the funding and type of research activities 
undertaken by countries, together with a snapshot 
of the Global Fund operational research portfolio, 
through the review of the research studies included 
in the country grant proposals. It describes the type 
of research studies proposed by each disease area, 
and also gives a picture of the research funding 
allocated from a sample of grants in which fi nancial 
information was clearly identifi ed.
Programmatic indicator data entered as of the end 
of 2009 from grant rounds 1 to 8 were extracted from 
the Global Fund Strategic Information Database. 
Specifi c indicators of research performance were 
used to fl ag particular grants that had a relevant 
component. Examples of such indicators included 
“number of operational research studies conducted 
or funded”, “number of training conducted related 
to operational research”. Since there was no strict 
working defi nitions of research categories, any 
studies that countries considered as operational 
research were fl agged. The original proposals 
of these identifi ed grants were then specifi cally 
reviewed, and the level of resources allocated to 
research and the methodology and the topics of the 
studies were determined. Grant agreements were 
also reviewed in the event that fi nal agreed amount 
was different from the proposal. Individual principal 
recipients with different studies and budgets were 
considered as separate grants, even if they were 
funded in the same round for the same disease 
area.
q 19th Global Fund Board meeting, 5–6 May 2009.
Methodology 
Key fi ndings
Overall, 103 grants, among 54 countries, were found 
to have an operational research component in their 
proposals; out of which, 26 countries incorporated 
a TB operational research component. Among the 
63 (out of 103) grants with budgetary information, 
the majority (78%) allocated less than 5% of the 
total budget towards operational research, with an 
average of 3.8% (Global Fund Portfolio Analysis 
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r Includes three multi-country grants which are considered a separate ‘country’.
2010). The disease focus of the identifi ed research 
was distributed evenly with approximately one-third 
of grants in each of the Global Fund disease areas, 
along with 2 HIV/TB, 1 health system strengthening, 
and 1 integrated grant. 
This distribution refl ects the general geographic 
needs of specifi c disease areas. Approximately half 
the identifi ed proposals were from sub-Saharan 
countries: of the 54 relevant originating countries,r 
27 were from sub-Saharan Africa, (with 11 in West 
and Central Africa, 9 in southern Africa, and 7 East 
Africa). Only 4 grants originated in the Eastern 
Europe and Central Asia region. Rwanda had the 
highest individual number of relevant grants (5), 
followed by India (4), Namibia (4) and Sri Lanka (4).
The number of grants with operational research from 
each Global Fund round is displayed in Figure 7. Of 
note, the low number shown in Round 8 is due to the 
incomplete performance frameworks of a subset of 
the grants at the time of the data extraction.  
FIGURE 7: NUMBER OF GRANTS BY ROUND
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Level of funding 
How much effort and resources countries 
receiving Global Fund fi nancing are devoting to 
implementation and operational research studies 
has not been previously clarifi ed. While countries 
are encouraged to allocate up to 10% of grant 
funding to M&E and related research, there are no 
specifi c guidelines on quality of research design 
and rigour and appropriate budget levels to allocate 
to a priority research agenda once identifi ed. 
Not all of the grants reviewed provided detailed 
fi nancial information on their research budget. Of the 
total 103 grants reviewed, 63 grants had fi nancial 
information that could be extracted. These grants 
were distributed among 39 countries and include 
two multi-country proposals. The review found that 
the total budget allocated to operational research 
for these 63 grants was US$ 30 736 854, with an 
average of US$ 487 887 per grant. The overall 
amount allocated for operational research was not 
consistent over grant rounds, as shown in Table 1, 
with a peak occurring in round 6. On average, the 
reported operational research budget for AIDS, TB 
and malaria grants amounted to about 2.5% of the 
total grant budget in each round. While only about a 
third of the 63 grants were AIDS-related, funding for 
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AIDS-related operational research was about US$ 
16.7 million – or approximately 54% of the total 
budget. The allocation of funding for TB-related 
operational research was about US$ 5.7 million. 
Overall, more than half (56%) of the total operational 
research budget was allocated to grants submitted 
from sub-Saharan African countries. 
TABLE 1: AVERAGE REPORTED IMPLEMENTATION/OPERATIONAL RESEARCH BUDGET BY 
GRANT, BY ROUND
Rounds Total number of 
grants, reviewed 
by round
Total operational 
research, 
US$, by round
Average operational 
research budget by 
grant
Allocation to operational 
research as a 
percentage of total 
grant budgets
1 7 4 586 378 655 197 2.1%
2 10 2 738 043 273 804 3.1%
3 7 4 431 566 633 081 2.2%
4 5 1 585 000 317 200 1.0%
5 10 3 797 623 379 762 2.4%
6 15 9 297 810 619 854 3.7%
7 5 2 576 141 515 228 3.6%
8 4 1 723 293 430 823 2.8%
Total: 63 grants 
with fi nancial 
information
Total allocated 
to operational 
research 
30.7million
487 887 (Av.) Av. Of 2.5% of 
Total Grant Budget
In general, many programme interventions did not 
have in-depth epidemiological data on the targeted 
population in countries and it is probable that they 
would take this opportunity to establish baseline 
fi gures in order to set their targets for the coming 
years. Very few countries specifi cally proposed 
cost-effectiveness studies.   
For tuberculosis, portfolio analysis showed that 
behavioural surveys and disease surveillance were 
the primary themes of the proposed operational 
research. Of all the TB- and TB/HIV-related grants 
reviewed, thirteen countries included studies on 
MDR-TB; six reported studies on DOTS strategy 
and implementation; six reported studies on 
HIV/TB co-infection; and one focused mainly 
on research capacity building. While no specifi c 
study topic was proposed in the area of health 
system strengthening, a number of indicators 
related to the numbers of people trained in 
research and capacity building were reported in 
all disease areas.
Types of TB operational research
A call to action
The Global Fund has been active engaged in global 
discussions on the operational research agenda 
with WHO, UNAIDS, USAID and the US National 
Institutes of Health (NIH), but has not been directly 
involved in reviewing study proposals and tracking 
their progress. One of the limitations of this review 
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is that currently the Global Fund does not require 
countries to report on their research studies in 
detail, and there is not a systematic process to 
track the progress of studies conducted with 
funding from the Global Fund other than through 
grant performance frameworks, which often do 
not contain detailed information. There is also no 
consistent mechanism to assess the quality of the 
research design, methodology, ethics and results, 
and how the programmes would utilize such results 
to inform stakeholders or programme design. 
Because reporting of operational research activities 
is currently not mandatory, the results presented 
here are likely to under report the level of funding, 
scale and type of research currently conducted with 
Global Fund support.  
As clearly described elsewhere in this document, 
there are several research priorities to improve TB 
control. The opportunity for developing operational 
research to TB control starts during the Global Fund 
proposal development process and should involve 
in-country researchers and stakeholders. Additional 
opportunities can be explored through M&E system 
strengthening efforts, regional meetings, and 
special country case studies. 
The Global Fund is committed to the development 
of policies on implementation and operational 
research, and communication to implementing 
countries to increase awareness of availability of 
related resources. In partnership with technical 
partners including the WHO Stop TB department, 
the Stop TB Partnership and the Special Programme 
for Research and Training in Tropical Diseases 
(TDR), this report is an investment towards bridging 
the information gap on priorities for TB operational 
research for reference during grant application 
and implementation to improve performance and 
impact of Global Fund investments. 
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There are various defi nitions of operational research. 
These have been summarized and discussed 
in detail elsewhere (1, 2). From a TB control 
perspective, the objective of operational research 
is generally aimed at helping TB control managers 
to improve programme operations, and providing 
policy-makers with evidence-based answers to 
address service delivery problems. In pragmatic 
terms, it is generally agreed that operational 
research can accomplish the following:
• improve programme performance and 
outcomes by assisting programme managers 
and staff to understand how the 
programmes work, identify problems and 
solve them in a timely manner;
• help programme managers and policy-makers 
to take evidence-based programmatic /public 
health decisions;
• assess the feasibility, effectiveness or impact 
of new strategies or interventions on TB 
control; 
• collect data to guide policy recommendations 
on specifi c interventions. 
Annex I 
Operational research methods, 
statistics and defi nitions
Operational research
Research approaches
It is essential that the correct methodological 
design is selected to properly address the stated 
study objectives. We fi rst describe quantitative 
observational designs, which are often referred to 
as the ‘traditional epidemiological approach‘. These 
classically have a designated study arm which acts 
as a control; this arm usually occurs naturalistically, 
consisting typically of individuals who either did 
not experience an outcome of interest (e.g. were 
diagnosed as TB negative) or who were not exposed 
to a risk/aetiological factor of interest (e.g. did not 
have a TB contact in their home or did not smoke). 
We then focus on quantitative interventional designs. 
The most robust of these designs is the randomized 
controlled trial (RCT) that is aimed at assessing 
the effi cacy of a test intervention. RCTs require (at 
least) two designated groups: an intervention group 
in which individuals receive the test intervention, 
and a control or comparator group in which 
individuals receive either a standard intervention 
(e.g. standard clinical care or a placebo treatment) 
or, in certain circumstances, no treatment (e.g. if the 
study objective is to evaluate a community health 
education programme). Each study participant is 
placed in one of the study arms, usually through a 
random process. Traditionally RCTs have not been 
seen as part of operational research, but in recent 
years there has been increased recognition of the 
value of ’pragmatic‘ randomized controlled trials 
(PRCTs) within operational research. These are 
implementation studies, taking place as much as 
possible in the context of day-to-day health service 
provision and practice, and aim at evaluating the 
effectiveness of an intervention in the real world 
rather than in the ideal setting created in most 
conventional RCTs. 
In the third section we deal with qualitative research 
designs and approaches. These are invaluable at 
many stages in the research cycle, and particularly 
so in the situational analysis stage, where they often 
help shaping questions or hypotheses to be tested 
in later stages.
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Finally we defi ne some newer research approaches, 
including those with a particular focus on assessing 
equity and access, which are important given 
the links between TB care and control and the 
Millennium Development Goals.
With all of these approaches, it is important to 
emphasise that coordination between countries or 
regions can be advantageous to assist in regionally 
appropriate decisions. This is not to say that some 
operational research is, necessarily, context specifi c 
and solves local operational issues.
1. Quantitative observational (traditional 
epidemiological) designs
Cross-sectional study/survey
• A study to measure the distribution of a 
condition (such as the burden of a disease) 
at a given point in time (3), or to identify if 
there is a correlation between a possible 
determinant(s) and a specifi c disease at the 
population level and at a given point in time. 
• Data are collected across a selected 
population within a limited time-frame. For 
example, the primary objective of a survey 
might be to estimate the proportion of 
MDR-TB cases in a population at a given 
point in time, and to determine if this 
proportion varies across the population; a 
secondary objective might be to determine 
if there is a relationship (correlation) 
between being an MDR case and having 
potentially predisposing characteristics 
such as age, gender or occupation at that 
same point in time.
• A longitudinal element can be added by 
repeating the same survey in the same 
population over a series of time-points to 
investigate whether the proportion of MDR 
TB cases is changing in the population, and/
or to investigate whether the predisposing 
factors are changing with time.
Cohort study
• A study of (usually two) groups (cohorts) 
of individuals who are followed-up over a 
period of time to measure the occurrence of 
a defi ned outcome (e.g. the diagnosis of TB, 
or being identifi ed as having MDR-TB). 
• Conventionally, one cohort will consist 
of individuals naturally exposed to a pre-
defi ned aetiological or risk factor (i.e. 
potential determinant of the outcome) while 
the other cohort will consist of individuals 
not naturally exposed to the risk factor. If all 
individuals in a population are exposed to 
the risk factor to different extents, one cohort 
may be individuals with a high exposure level 
and the other cohort individuals with a low 
exposure level. Typical risk factors for TB 
include gender, HIV status or smoking.
• The rates of occurrence of the outcome are 
compared between the cohorts (3). If there is 
a relationship between the exposure to the 
risk factor and the outcome, the proportion 
of individuals in the cohort exposed to the 
risk factor who experience the outcome will 
be signifi cantly greater than the proportion of 
individuals in the cohort not exposed to the 
risk factor who experience the outcome.
• The cohort study design is the optimal 
observational design for obtaining evidence 
of a causal temporal relationship between 
outcome and risk exposure.
• Cohort studies are always longitudinal as 
they track the individuals in the cohorts 
over a period of time. They are usually 
prospective, with the cohorts followed 
forwards through time, but can also be 
conducted retrospectively.
• The cohort study design allows multiple 
outcomes to be related to exposure to 
a specifi c risk factor, allows accurate 
information to be collected on the level of 
exposure to that risk factor, and enables the 
study of relatively rare risk factors.
• The results of a cohort study can be reported 
as risk ratios or risk differences, which 
are intuitive and easy to understand. The 
STROBE statement gives guidelines for 
the conduct and reporting of observational 
studies (5).
• The cohort study design is not appropriate 
if the time between exposure to the risk 
factor and the occurrence of the outcome 
may be very long, if the outcome of interest 
is rare, if the follow-up of cohort members 
will be diffi cult, and/or if exposure patterns 
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may change over time (possibly making the 
results of the cohort study irrelevant). Cohort 
studies tend to be expensive to conduct.
Case-control study
• A study of two groups of individuals whose 
personal histories are examined to determine 
their levels of exposure to a pre-defi ned 
aetiological or risk factor (e.g. HIV status, 
diabetes).
• One group is defi ned as the cases – these 
are individuals who have experienced 
a defi ned outcome (e.g. an adverse TB 
treatment outcome such as failure, default or 
death). The second group is defi ned as the 
controls – these are individuals who have not 
experienced the same defi ned outcome (e.g. 
have had a favourable TB treatment outcome 
such as cure or treatment completion).
• The rates (frequencies) of exposure to 
the pre-defi ned risk factor are compared 
between the cases and the controls. If there 
is a relationship between exposure to the 
risk factor and the outcome, the proportion 
of cases exposed to the risk factor will be 
signifi cantly greater than the proportion of 
controls similarly exposed.
• Case-control studies are always longitudinal 
as they track both the cases and controls 
over a period of time. They are usually 
retrospective, with the cases and controls 
followed backwards through time – but can 
be conducted prospectively.
• The case-control study design allows 
exposure to multiple risk factors to be related 
to a defi ned outcome, enables the (rapid) 
study of outcomes that are relatively rare 
or have a long latency between exposure 
and manifestation, and are often relatively 
inexpensive to conduct.
• The case-control study design is not appropriate 
if the information on exposure to the risk factor 
is poorly remembered (recall bias) and/or 
incomplete (a problem that generally increases 
as the recall period increases).
• The case-control study design cannot 
provide correct estimates of either disease 
prevalence or the probabilities (risks) of the 
outcome occurring in individuals exposed to 
and not exposed to the risk factor. Results 
can only be reported as odds ratios (3), 
which are not intuitive and can be diffi cult to 
understand, and are a proxy measure of the 
relative risk of being a case when exposed to 
the given risk factor.
• The choice of an appropriate control group 
for the cases can be diffi cult, and the method 
of selecting individuals into the control 
group can be contentious. One option is to 
randomly sample eligible control individuals 
so that the distribution of characteristics/
risk factors in the control group refl ects the 
distribution of these characteristics/risk 
factors in the general population from which 
the cases arise.
• Commonly, controls and cases are matched 
according to important (confounding) factors 
such as age, gender and environment (place 
of residence).
2. Quantitative interventional
Pragmatic randomized controlled trial 
(PRCT): 
• A randomized controlled trial approach with 
the purpose to inform decisions about routine 
day-to-day practice (5). 
• A PRCT differs from an explanatory RCT in 
that it focuses on effectiveness (does the 
intervention work when used in the real world, 
i.e. under routine normal practice?) rather 
than on effi cacy (does the intervention work 
in ideal and fully controlled conditions?). 
• PRCTs are more suited to operational 
research than explanatory trials. Explanatory 
trials are necessary and extremely valuable 
in empirical research to demonstrate the 
potential usefulness of a new intervention 
by testing its effi cacy and/or safety under 
strictly controlled conditions, which might 
then be taken forward into a PRCT. 
• Although characterized as being different for the 
sake of this explanation, it must be recognized 
that there is a spectrum of trial type with pure 
pragmatic trials at one end of the spectrum 
and pure empirical trials at the other (6).
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• Quality criteria are well developed and 
documented for the conduct and reporting 
of randomized controlled trials in the 
CONSORT statement (5). An addendum to 
the CONSORT statement to improve the 
quality of PRCTs has recently been published 
(7). This published addendum includes a 
table describing the key differences between 
explanatory and pragmatic trials – which is 
summarised in Table 2.
TABLE 2: KEY DIFFERENCES BETWEEN EXPLANATORY AND PRAGMATIC TRIALS
Explanatory Pragmatic
Question Effi cacy: does the intervention 
work?
Effectiveness: does the 
intervention work when used in 
normal practice?
Setting Well resourced, rigorously 
controlled conditions 
Normal clinical or public health 
practice
Participants Selected. Participants who 
are poorly adherent are either 
considered as having a negative 
outcome or are not assessed 
Little or no selection
Intervention Strictly enforced and adherence 
is closely monitored
Applied fl exibly within the 
requirements of normal practice
Outcomes Often short term surrogates or 
process measures
Directly relevant to participants, 
funders, communities and 
healthcare practitioners
Relevance to practice Indirect: little effort made to 
match trial to decision-making 
needs of those in the usual 
setting in which the intervention 
will be applied
Direct: designed to meet the 
needs of those making decisions 
about intervention options in the 
setting in which the intervention 
will be implemented
Options for units of randomization in PRCTs
Randomization is arguably the most important 
element of a PRCT. Individuals are allocated to the 
study groups through a random process in order 
to prevent bias in the selection of group members. 
Conventionally, individuals are randomised into the 
study groups. However, if this is not possible or even 
desirable (e.g. if the intervention is to be delivered 
to entire communities), then groups (clusters) of 
individuals are randomized. Individual randomization 
is more suited to explanatory trials (see above).
• Individual randomization: Individual study 
participants are randomized to receive either 
a new intervention (e.g. a new diagnostic 
algorithm or a new treatment/monitoring 
modality) or an existing/alternative intervention.
• Cluster randomization: Clusters (or groups) of 
study participants are randomised. A cluster can 
be defi ned in various ways to suit the design of 
the particular study in question. Examples, in 
order of decreasing cluster size, include:
Administrative Districts (one cluster = all 
patients attending health services within a 
given health district)
Enumeration Area (one cluster = all 
individuals in a census enumeration area)
Health Units (one cluster = all patients 
attending a given health unit, be it a health 
centre or a hospital – as defi ned by the 
study needs)
Households (one cluster = all individuals 
in a household)
Time-defi ned (one cluster = all patients 
attending during a defi ned time period, 
e.g. one week, two weeks, one month, 
or several months) this is traditionally 
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used when an intervention is applied to 
all health unit attendees for a given time 
period, and then swapped back to the 
comparator intervention (so called “week-
on, week-off” or “month-on, month-off”).
Cluster randomization is more suited to pragmatic 
trials than individual randomization. Cluster 
randomized designs permit the capture of health-
system effects (both direct and indirect) and often 
make use of routinely collected data. 
Options for control or comparator arm allocation in intervention trials/studies
• Before-and-after design: This design does not 
include a separate control group to the intervention 
group. For all participants in this design, data 
on the outcome measures is collected over a 
baseline (pre-intervention) time period, the new 
intervention is then introduced, and fi nally data 
on the outcome measures is collected over a 
follow-up (post-intervention) time period:
In the absence of any other option, this design can 
provide important information about the possible 
effectiveness of an intervention. However, the 
absence of a contemporary control or comparator 
group means that any difference found between the 
pre-intervention and post-intervention study periods 
could be due to factors other than the intervention. 
Participants act as their own controls, but treatment 
(control and intervention) is confounded with time – 
so the interpretation of the results from this design is 
often problematic. Ideally, the baseline data should 
be collected prospectively, so that the data collection 
methods (and hence data quality) are the same in the 
pre- and post-intervention study periods. Alternatively, 
however, historical control data (data which has 
already been collected for other purposes) could be 
used as the baseline. 
This is the weakest of the interventional designs. 
The following designs all include contemporary 
controls or comparator arms and are amenable to 
randomization, so the intervention effects detected 
are considered more robust.
Cluster Pre-intervention study period  Post-intervention study period  
1 control intervention
2 control intervention
• Parallel groups design: Individuals or clusters 
are randomly allocated to the intervention 
and control groups concurrently, and data 
collection on the outcome measures occurs in 
both groups concurrently:
This gives a direct comparison of the intervention 
and control groups. If cluster randomization is to 
be used, the clusters can be matched in pairs for 
important characteristics (such as sex distribution, 
population size, distance from a health facility) and 
randomized within these pairs.
Cluster Study period  
1 intervention
2 intervention
3 control
4 control
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• Cross-over design: Individuals or clusters are 
initially randomly allocated to the intervention and 
control groups concurrently, and data collection 
on the outcome measures occurs in both groups 
concurrently over an initial study period. At the 
end of this period, all participants cross-over to 
the other treatment arm, and data collection on 
the outcome measures continues in both groups 
concurrently over a second study period:
This design usually requires fewer participants 
(and fewer clusters) than a parallel groups 
design, but a longer time duration is needed to 
complete the study. There may also be important 
considerations for a wash-out time at the cross-
over point so that any effects that occur in the fi rst 
study period do not carry-over into (contaminate) 
the second study period.
Cluster Study period  Study period  
1 intervention control
2 intervention control
3 control intervention
4 control intervention
• Stepped-wedge design (8): This is an important 
and ingenious modifi cation of the cross-over 
design, and is particularly useful in situations 
where the only other alternative is the before-and-
after study design. This PRCT design makes use 
of an implementation plan where an intervention is 
introduced to some areas or health facilities before 
others over time. Ideally the sequence by which 
these areas or facilities implement the intervention 
is randomized. Comparisons are then made over 
time between those areas of facilities receiving the 
intervention and those not yet receiving it:
As this is essentially a cross-over design, the stepped-
wedge design also generally requires fewer clusters 
than a parallel groups design, but requires more 
time to complete. It has the advantage of phasing-
in an intervention over time, as would happen with 
uncontrolled or non-randomized implementation, so 
no study areas are deprived of a new intervention if 
this proves to have an added value.
Cluster Study period
1 2 3 4 5
1 control intervention intervention intervention intervention
2 control control intervention intervention intervention
3 control control control intervention intervention
4 control control control control intervention
3. Qualitative approaches
Qualitative research: aims to gather an in-depth 
understanding of people’s attitudes, behaviours, 
values, concerns, motivations, aspirations, culture 
or lifestyles and the reasons that govern such 
behaviour. Various methods are used, including in-
depth individual interviews, participant observation 
and focus group discussions to saturation point 
(the point at which no new responses are elicited). 
Qualitative research is usually conducted on small, 
focused samples. In-depth individual interviews are 
usually conducted with fewer than 100 participants 
– usually patients or service users. A single focus-
group discussion is usually conducted with a group 
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of around 10 people who have been chosen to give 
a range of views on a particular topic. If several 
focus-group discussions are held, then there may be 
more than 100 individuals involved. Key-informant 
interviews tend to focus on service providers or 
policy makers and use in-depth interview techniques. 
These may involve fewer than 10 individuals.
Policy analysis: analysis and synthesis of evidence 
and social values in making clinical and policy 
decisions. Qualitative research methods are usually 
employed and can be retrospective or prospective, 
include semi-structured in-depth interviews of 
key informants, focus groups, document analysis 
and process evaluation of implementation. This 
is sometimes called Policy Transfer (or Policy 
Transfer Analysis).
Realist review: a model of research synthesis that is 
designed to work with complex social interventions 
or programmes, and that is based on the emerging 
‘realist’ approach to evaluation. It provides an 
explanatory analysis aimed at discerning what 
works for whom, in what circumstances, in what 
respects and how (9). 
Case studies: these are detailed descriptions of 
programmatic approaches that achieve a balance 
between detailed understanding of the context and 
generic lessons that can be learned (10). 
4. Other research approaches
Equity Analysis: This method is still in its infancy in 
the context of operational research. It is an approach 
that attempts to answer whether an intervention 
is fair: principally, does an intervention promote 
access for all people, especially by the poor and 
vulnerable? It involves collecting information on 
patients’ socioeconomic profi les and the costs 
they incur in accessing services. It is a quantitative 
approach and can be applied in both observational 
and interventional approaches (see above).
Health systems analysis: This is an approach that 
captures the health system requirements of a given 
intervention. It asks what is required in the way of 
infrastructure, utilities, human resources, quality 
assurance mechanisms, supply chain, procurement 
and disposal. Usually these are summarized 
in economic terms. The economic measures 
generated are a quantitative outcome (11). Health 
systems analysis can be descriptive in observational 
studies, but can also be applied in interventional 
studies, especially cluster-randomized trials, where 
the analysis can be comparative – for instance 
comparing health system requirements of an 
intervention versus a control or comparator.
Mapping: This refers to the use of geographical 
information systems (GIS) in which digitized, 
electronic maps are used to illustrate multiple layers 
of information of interest. For example, health 
facilities can be plotted onto these maps using 
geo-satellite referenced personal digitized assistant 
electronic devices. Such maps can be overlaid with 
programme-relevant information such as numbers of 
TB cases notifi ed, sputum specimens examined etc.
Operational modelling: This encompasses a wide 
range of problem-solving techniques and methods 
to model optimal or near-optimal solutions to 
complex decision-making. The potential for 
scale-up, relative benefi ts with regard to the new 
interventions and cost savings are assessed. 
Different options can be assessed using decision 
analytical modelling. More detailed assessments, 
e.g. exploration of strategies managing bottlenecks 
or barriers in systems can use supply chain and 
modelling software (such as Witness).s
Transmission modelling: Transmission dynamics 
(i.e. how infections spread) are modelled to identify 
better strategies for disease control. A number 
of methodological approaches can be used to 
investigate these dynamics including observational 
study and epidemiological analysis, mathematical 
modelling, and systems analysis.
Systematic review: A systematic review attempts to 
identify, appraise and synthesize all the empirical 
evidence that meets pre-specifi ed eligibility criteria 
to answer a given research question. Researchers 
conducting systematic reviews use explicit methods 
aimed at minimizing bias, in order to produce more 
reliable fi ndings that can be used to inform decision 
making.t (12)
Meta-analysis: Meta-analysis is a statistical technique 
for combining the fi ndings from several independent 
studies. Meta-analysis can offer an objective unbiased 
synthesis of the empirical data and assess the 
consistency of the results of studies included (12, 13).
s See: http://www.lanner.com
t See: http://www.thecochranelibrary.com/view/0/AboutCochraneSystematicReviews.html
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u See: http://www.rti.org/sudaan 
v See: http://www-users.york.ac.uk/~mb55/msc/trials/sampsz.htm
Sample size/statistical power
For both ethical and practical reasons, the optimum 
number of participants needed to properly address 
the stated study objectives should always be 
estimated before the study starts. If too few 
individuals are studied, important intervention 
effects or risk factors may go undetected, denying 
patient’s access to effective disease treatments or 
preventing risk factors being adequately identifi ed, 
which may call for targeted intervention to reduce 
disease incidence. If too many individuals are 
studied, some may be exposed to risk factors or be 
treated with an inferior intervention for longer than 
necessary (or even totally unnecessarily).
Predominantly qualitative research approaches 
require least attention to sample size, as it is often 
more important to purposively select a sample of 
individuals who will represent the widest possible 
range of opinions/experiences across the target 
study population. However, data saturation principles 
are often used to ensure that the optimum number 
of participants are studied (i.e. data collection is 
stopped when no new information is being obtained 
from study participants and/or no new themes 
are emerging). This usually occurs after 10-20 
individuals (depending on heterogeneity) have been 
interviewed. Similarly, focus groups are conducted 
until saturation is achieved: these typically comprise 
6-10 individuals, often grouped by one or two key 
demographic or health-related factors (e.g. age, sex, 
patients/suspects, using ART or not).
For quantitative cross-sectional studies/surveys, 
sample size is based on the precision with which it 
is desired to estimate the prevalence or incidence 
of the condition of interest, or the strength of the 
relationship between two measures. Precision in 
this context is most often defi ned as the width of 
the (95%) confi dence interval around this estimate. 
The formula for this confi dence interval (and 
hence for the estimation of sample size) becomes 
more complex as the study design becomes 
more complex (14), but the widely used SUDAAN 
statistical software packageu calculates sample 
size for many survey design options.
For comparative quantitative research projects 
(including cohort studies, case-control studies 
and PRCTs) sample size is based primarily on the 
nature of the primary outcome measure and the 
minimum difference between the groups that it is 
desired to detect (i.e. minimally important effect 
size). There are mathematical formulae available 
for most study design options and most types of 
outcome measure (15–18). There are also many 
software packages available, both commercially 
and (of more variable quality) as shareware on the 
internet. Many of the formulae are mathematically 
complex, and the software packages can be 
diffi cult to navigate, so it is usually advisable to 
seek expert statistical assistance. Before doing so, 
however, the website Sample size for clinical trialsv 
is worth reviewing, as it provides a very readable 
introduction to sample size calculation covering 
most simple situations – and, perhaps more 
importantly, includes an easy to use graphical 
method for calculating an initial (approximate) 
sample size estimate.
For all types of quantitative study design, the 
complexity of the sample size calculations increases 
considerably if sampling or randomization is by 
cluster rather than by individual, as the calculations 
have to take into account the likely size of the 
intra-cluster correlation (ICC); unfortunately, few 
published studies report their ICC so precedent 
is rare – typically ICC ranges between 0.001 and 
0.100, but can be larger. Cluster designs require 
calculation of the optimum number of clusters and 
the optimum number of individuals per cluster. 
Many different combinations of these two numbers 
will give the same level of statistical power, so 
the fi nal decision is usually a compromise based 
on practical considerations. In general, a large 
number of clusters with few individuals per cluster 
is better than a small number of clusters with a 
large number of individuals in each cluster (17). 
Specialist software is available for these designs, 
but should only be used with expert statistical 
guidance.
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Most of the information contained in the fi ndings 
of quantitative research, whether this is a survey, 
observational comparative study or an interventional 
study, can be extracted by the proper application 
of simple summary statistical methods and graphs. 
For more complex statistical analyses, researchers 
are strongly advised to seek expert statistical 
assistance.
In general, greater emphasis is given now to 
estimating effect sizes with (95%) confi dence 
intervals than to formal signifi cance testing, although 
both have an important role in the evaluation of 
clinical research data.
For simple cross-sectional studies/surveys, a 
fi rst analysis should attempt to provide estimates 
of the main outcome measure (mean values for 
continuous measures, proportions for categorical 
measures, correlation coeffi cients for measures of 
association) with their 95% confi dence intervals, 
both for the whole study sample and then for 
important sub-groups. For more complex designs, 
weightings may need to be applied to sub-groups 
of participants if, for example, different sampling 
proportions were used in these sub-groups – this 
is one point at which expert statistical advice may 
be required. Time trends in measures such as case-
detection rates can be evaluated using contingency 
table analyses, but Poisson regression modelling 
methods are usually more sensitive (see below).
For observational cohort studies, the proportions of 
people in each risk exposure group who experience 
the outcome of interest should be reported. Effect 
size is best represented by either the ratio of these 
proportions (relative risk/risk ratio) or the difference 
between the two proportions (risk difference), with 
their 95% confi dence intervals. Adjustment for the 
infl uence of important confounding factors can be 
made using stratifi ed analyses, Poisson regression 
models and/or log-binomial models. Odds ratios 
are still commonly reported for cohort studies, with 
adjustment for confounding factors using logistic 
regression; odds ratios are reasonable estimates 
of relative risk when disease incidence is rare, but 
otherwise they overstate the relative risk (often very 
considerably) – and adjustment using the Zhang 
and Yu formula can introduce bias (19).
For observational case-control studies, the 
proportions of cases and controls exposed to the 
risk factor of interest should be reported. Effect 
size can only be represented by odds ratios (with 
their 95% confi dence intervals). As for cohort 
studies, the odds ratio estimates can be adjusted 
for the infl uence of important confounding factors 
using standard unconditional logistic regression 
methods if the cases and controls are unmatched. 
However, if the cases and controls are matched, it 
may be more appropriate (but not essential) to use 
conditional logistic regression methods – these can 
be more diffi cult to compute and may require expert 
statistical assistance.
For standard interventional PRCTs in which 
individual participants have been randomized, the 
method of analysis is straightforward. If the outcome 
measure is continuous and can be considered to 
follow a normal (Gaussian) distribution, the mean 
difference between the intervention groups (with 
their confi dence intervals) is the best representation 
of effect size; important confounding factors can be 
adjusted for, using standard regression methods. If 
the outcome measure is categorical, the PRCT can 
be regarded as a cohort study in which exposure to 
the risk factor is determined by a random process, 
and the same statistical methods apply (risk ratios, 
risk differences, odds ratios), with standard or 
logistic regression analysis methods then used 
to adjust the effect size estimate for important 
confounding measures. 
Standard PRCTs assume that the responses 
of different participants to an intervention are 
independent of each other. Cluster-randomized 
PRCTs, however, assume that the responses 
of participants within the same cluster will be 
correlated (ICC) – and so require the effect size 
to be adjusted for this ICC. This increases the 
complexity of the statistical analysis, although the 
summary statistics and analysis methods for both 
types of PRCT appear similar when presented. 
Expert statistical advice should be sought when 
analysing cluster randomized PRCTs.
Most of the statistical methods described above 
can be carried out by careful application of any good 
standard statistical software package, although 
it may be wise to seek expert statistical advice to 
have a diagnostic check of the assumptions made 
when applying multiple regression methods. 
More complex statistical methods are now widely 
available in many statistical packages, but these 
should be used only with the support of expert 
Statistical analysis methods
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statistical advice. A detailed description of these is 
outside the scope of this document, but the most 
commonly applied include:
• actuarial methods and Cox regression if the 
outcome measure is time to an event (e.g. 
time between start of symptoms and TB 
diagnosis);
• Poisson or negative binomial regression if 
the outcome measure is a count (e.g. the 
number of new TB cases in an area in a 
given month);
Finally, Qualitative research requires content analysis 
and the drawing out of key themes. This should 
always be done by researchers who have experience 
in qualitative, social science research and who must 
be involved in the research from the beginning. For 
all quantitative study designs, if data is collected at 
different levels (e.g. if some data is collected from 
individual participants while other data is aggregated 
across communities and/or regions), multi-level 
modelling methods are required. These methods 
require more complex analytical methods than are 
readily available in most statistical packages, so 
again expert statistical advice should be sought.
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Note: In this annex, indications for expected duration and budget of the proposed research studies 
are being provided as follows:
Expected duration/timeline of study
Short-term: 6 to 18 months
Medium-term: 18 months to 4 years
Long-term: > 4 years
Budget
Low: <US$ 10 000 
Medium: US$ 10 000 to 250 000
High: US$ > 250 000 to 10 000 000 (NB. large multi-country pragmatic randomized controlled trials would 
be an example of the type of study requiring the upper limit of this budget range.)
Annex II 
Research methods to address 
priority areas
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1. Improving access, screening 
and diagnosis of TB
1.1 Situation analysis
Objective: To identify local barriers in accessing 
diagnosis of all forms of TB in various populations 
(including diffi cult-to-reach populations) and 
specifi c risk groups (e.g. TB suspects, DS-TB, re-
treatment, DR-TB, HIV, children).
Illustrative designs: 
a) Audit of existing programme registers (suspect or 
chronic cough registers, laboratory and treatment 
registers).
b) Cross-sectional descriptive qualitative studies 
with patients (including assessment of health-
seeking behaviour, delay to diagnosis, etc.).
c) Mapping of services provision and availability 
(e.g. health facilities) and diagnostic modalities in 
relation to population characteristics (e.g. density, 
socioeconomic factors).
d) Patient costing studies.
Setting/study population: Patients with all forms 
of TB recruited from health facilities in different 
settings (rural, urban, prison, refugee camp, etc).
Methods:
a) Retrospective review of facility registers to track 
cases from recognition as a suspect (in the chronic 
cough or TB suspect register) to submission of 
diagnostic specimens (in the laboratory register) to 
starting treatment (in the treatment register).
b) Qualitative research methods to identify fi nancial, 
geographical, socio-cultural and health-system 
barriers. Approaches with patients, including 
symptomatic patients identifi ed through TB 
prevalence surveys, will include critical incident 
narrative interview techniques to map patient 
pathways in seeking diagnosis, structured 
interviews, focus group discussions, gender 
analysis and case studies. Costs incurred and 
time spent by the patient for each care-seeking 
visit, provide useful additional data. Key informant 
interviews and focus group discussions with people 
in the community and health providers are important 
for context, triangulation and validation of fi ndings 
from patients.
c) Mapping of facilities and services onto 
geographical information systems (GIS).
d) Costing surveys using questionnaires informed 
by an understanding of barriers identifi ed through 
cross-sectional studies described in (a) above. An 
example of a patient costing tool is given in Annex 
IV (NB: this is a tool for capturing costs of diagnosis, 
relevant for this section, and also for documenting 
patient costs of accessing treatment).
Expected outcomes: 
a) Estimates of proportion of patients who drop out 
of the diagnostic pathway at different stages.
b) Ranked lists of barriers faced by different patient 
groups.
c) GIS maps illustrating the relationship between 
patients, communities and services.
d) Key barriers expressed in economic terms.
Analysis: 
a) Description of numbers of patients recorded 
in each register for a given time-period (eg. six 
months) along with cross-checking for duplicate 
entries. Documentation of the numbers of patients 
failing to proceed from one stage of the diagnostic 
algorithm to the next.
b) Evaluation of TB patient care-seeking pathways, 
drawing out major themes and describing barriers.
c) Mapping poverty indicators on geographical 
information systems in relation to additional 
data, where available, including TB notifi cation, 
population density, health facilities.
d) Analysis of patient costs incurred per TB diagnosis 
made. Further analysis can include breakdown of 
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major cost categories incurred by patients during 
diagnosis (e.g. transport, food, user fees). Where 
possible, this can be further broken down into costs 
per health-seeking visit, and comparisons between 
costs incurred and assets available can be made.
Guidance for sample size calculation: 
a) No formal sample size calculations are required 
for record reviews or audits, but a rough guide is 
to analyse the ultimate fate of approximately 500 
TB suspects. The number of months of register 
data required to reach this number will depend on 
the size and throughput of the facility or facilities 
being studied.
b) No formal sample size calculations are needed 
for purely qualitative research. Individuals are 
conventionally recruited using purposive sampling 
(i.e. individuals are recruited to provide a cohort with 
the widest possible range of opinions/experiences 
across the target study population) until saturation 
is achieved (i.e. until no new themes are emerging); 
this usually occurs after 10-20 individuals have been 
interviewed (depending on heterogeneity). Similarly 
focus groups are conducted until saturation is 
achieved: these typically comprise 6-10 individuals, 
often grouped by one or two key demographic 
or health-related factors (e.g. age, sex, patients/
suspects, using ART or not etc.); saturation is 
usually achieved after 3-4 focus group discussions 
with each stratum.
c) No formal sample size calculations are required for 
GIS mapping. It is usual to map a district or a given 
catchment area – usually covering a population of 
about 500,000.
d) For quantitative cost estimates it is usual to 
interview at least 100 to 200 patients.
Expected duration/timeline: Short-term.
Suitable scale: 
a) Local.
b) to d): Local, regional or national.
Estimated budget range: 
a) Low.
b) to d) inclusive: Medium.
Note: As a result of the situation analysis, practical 
steps must be taken to address identifi ed obstacles 
in accessing TB diagnosis. Suggested methods for 
identifi cation of new approaches are described below.
Illustrative references: (1–6). 
1.2 Identifying new programmatic 
approaches
Objective(s):
a) To understand factors facilitating or hindering 
effectiveness of existing diagnostic algorithms.
b) To document accuracy of new diagnostic tests or 
packages of tests.
c) To project a number of suitable options of 
diagnostic approaches or packages for potential 
implementation.
d) To select, at the international or country level, 
new or revised diagnostic approaches to be further 
piloted (see section 1.3).
Illustrative Designs:
a) Realist review of local experience (national or 
regional) by researchers.
b) Systematic review of new tool(s) or approaches 
(carried out at international level). 
c) Operational and transmission modelling.
d) Expert group review meetings at international, 
national or regional level (informed by results of (a), 
(b) and (c) above) to examine the results of individual 
studies, systematic reviews and realist reviews in 
relation to existing tool(s) and approaches that have 
been nationally or internationally endorsed. Where 
possible, results of locally-conducted studies 
(national or regional) should be included in order to 
identify the new approaches that are most suitable 
to the local context.
Setting/study population: National programme 
and local academic organizations – with international 
partnership as appropriate. 
Methods:
a) Realist reviews: Synthesis of programmatic 
implementation experiences alongside any available 
informative research fi ndings from work carried out 
in the situational analysis (see section 1.1).
b) Systematic reviews: These usually synthesise 
global evidence, but a country may identify an 
implementation question about a new or local 
programmatic approach that has not already 
been the subject of a systematic review. In this 
case a national body may wish to partner with an 
international organization with systematic reviewing 
expertise.
c) Operational and transmission modelling: 
Operational modelling can be used for virtual 
testing of new programmatic approaches, 
predicting likely health system requirements for 
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given workloads of different options or packages. 
If linked with transmission modelling, impacts on 
TB epidemiology may also be predicted. This can 
help in making rational choices of programmatic 
approaches to pilot, phase-in or scale-up.
d) Expert group revieww meetings convened at 
national or international level to examine the results 
of individual studies, systematic reviews, realist 
reviews, and modelling outputs (if available) in 
relation to existing nationally and internationally 
endorsed tool(s) and approaches. Where possible, 
results of locally conducted studies (national or 
regional) should be included in order to identify 
the new approaches or algorithms that are most 
appropriate to the local context.
Expected outcome(s):
a) Compilation of lessons learnt about factors 
facilitating or hindering effectiveness of existing 
diagnostic algorithms.
b) Synthesised data on accuracy of potential new 
diagnostic tests or combinations/packages of tests.
c) A number of suitable options of diagnostic 
approaches or packages giving estimates of 
resource requirements (e.g. infrastructure, human 
resources, procurement) and likely epidemiological 
impact (on TB transmission).
d) Local evidence-based formulation of a new 
programmatic approach (or diagnostic package) 
based on internationally and nationally endorsed tools 
or approaches. Ideally this approach would then feed 
into research activities in section 1.3 (see below).
Analysis:
a) Realist review: Refl ective, fl exible and 
participatory analysis of both qualitative and 
quantitative evidence to explain how complex 
interventions work (or why they fail) in particular 
contexts and settings.
b) Systematic review: Comprehensive review 
of published and unpublished materials; meta-
analysis and synthesis.
c) Operational Modelling: Creating national-level 
models of health systems and testing different 
potential placement of tests (or packages) or 
algorithms using software (e.g. Witness) and 
modelling expertise.
d) National or regional expert group meeting: typically 
convened at international level (e.g. by WHO) using 
the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE)x approach to 
generate evidence-based guidance. For some larger 
countries or a number of countries in a region, it 
may be appropriate that national or regional expert 
group meetings are convened.
Guidance for sample size calculation:
Formal sample size calculations are not required 
for the above approaches to synthesising existing 
evidence.
Expected duration/timeline: a) to d) inclusive: 
Short-term.
Suitable scale: a) to d): Local, national and 
international.
Estimated budget range: a) to d): Medium.
Note: On the basis of the above process, new 
diagnostic algorithms could be developed by 
international organizations (e.g. WHO) that include 
new diagnostics tools or approaches. These could 
include, for example: 
i) Development of improved clinical algorithms for 
smear-negative TB in high, medium and low HIV 
prevalence settings with and without access to 
(digital or conventional) chest X-ray.
ii) Identifi cation of specifi c risk factor profi les for 
MDR-TB in different settings, that could be used for 
the presumptive identifi cation of suspect MDR-TB 
cases or identifi cation of MDR-TB risk groups. 
Another recent example is the development of 
new diagnostic algorithms that is following the 
endorsement by WHO of the new fully automated 
NAAT, Xpert MTB/RIF; these algorithms will have 
to be tested and validated in various settings (see 
section 1.3 below), as part of a roadmap to roll-out 
the use of this new diagnostic tool. 
Illustrative references: (7–10)
w At international level, the Strategic and Technical Advisory Group for TB (STAG-TB) of the WHO provides technical endorsement 
and guidance on new tools and approaches.
x See: http://www.gradeworkinggroup.org
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1.3 Piloting implementation of a new 
diagnostic tool or package of tools in 
different settings
1.3.1 Through existing diagnostic 
services (routine health service 
provision)
Objectives:
a) To optimize implementation of a new diagnostic 
tool(s)/package(s) of tools (identifi ed in section 1.2, 
above) within the health care system structure of a 
given country using available resources. 
b) To determine required resources to facilitate 
equitable access and optimize patient diagnosis 
and outcome. 
Illustrative Designs: 
a) Operational and transmission modelling: If 
suffi cient data exist on operating characteristics of 
new tests or approaches in terms of accuracy, health 
system requirements, patient-important outcomes 
and costs, it may be possible to predict best choices 
for a given national setting, rather than invest in a full 
pragmatic randomised controlled trial (PRCT) (see 
below). In some circumstance, this may have already 
been achieved in section 1.2 (see above)
b) PRCT (cluster)y: If suffi cient data on accuracy 
are available, but there are insuffi cient data on 
operational requirements, patient-important 
outcomes, costs etc., it may be appropriate to 
carry out a PRCT (cluster) of the chosen approach 
or package, comparing against an existing package 
or an alternative package. This can be achieved 
through a ‘before-and-after’ design (see Annex 
I) for simplicity, but concurrency of observations 
and randomization is important to minimize bias 
and confounding and to obtain robust evidence 
on impact to inform the next phase of scale-up. A 
PRCT (cluster) can also be carried out as part of 
scale-up or phased implementation, employing a 
stepped-wedge design.
Setting /study population/data sources: 
a) National health-system data and predicted 
operating characteristics and performance of tests.
b) Within the health-care system, at the level 
predicted to be optimal by operational modelling, 
in different epidemiological situations (e.g. high or 
low MDR-TB, high or low HIV prevalence, high/low 
density populations, urban/rural etc.).
Methods: recruitment of subjects (eligibility 
criteria); intervention (as appropriate): 
a) Operational and Transmission Modelling (as 
described above in 1.2). 
b) PRCT (cluster) as described above and in Annex 
I. Clusters could be health units (e.g. hospitals or 
health centres) or whole health districts, depending 
on how extensive the algorithm being phased in is. 
For example, if a simple point-of-care test is being 
tested at the health centre level, then the health 
centre is the appropriate unit of randomization. If, 
however, an algorithm includes a new point-of-
care diagnostic test at the health centre level, and 
a laboratory-based diagnostic machine at district 
level, for example, then the district is the appropriate 
unit of randomization.
Expected outcomes:
a) Projected estimates of the effectiveness of the 
intervention and likely health system requirements.
b) Direct evidence on effectiveness, equity of 
access, acceptability to patients and providers, and 
likely health system requirements.
Analysis:
a) Comparison of different projected confi gurations 
of a new intervention or comparison of a projected 
new intervention with an existing system in terms of 
likely effects on chosen outcome measures (such 
as numbers of patients starting and completing 
therapy, numbers of laboratory staff, etc.). The 
IAF (see Annex III) can serve as a check list for 
generating a relevant list of outcome measures.
b) Direct comparison of selected outcome 
measures resulting from a new diagnostic algorithm 
or package with an existing diagnostic algorithm or 
package. Here also, the IAF can serve as a check list 
for generating a relevant list of outcome measures 
prior to fi eld implementation of the PRCT (cluster). 
Guidance for sample size calculation: 
The sample size is determined by the nature of 
primary outcome measure, the effect size to be 
detected (11), and whether individual participants 
or clusters of individuals are to be randomised (12). 
y Here, and in the rest of the annex, PRCT (cluster) refers to a pragmatic randomised controlled trial using the cluster design (as 
opposed to individual randomization).
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Sample size considerations are also slightly different 
for step-wedge designs (13). Annex I provides an 
overview of these methods.
Expected duration/timeline: 
a) Short-term.
b) Medium-term.
Suitable scale:
a) Local or national.
b) Regional, national or international.
Estimated budget range:
a) Low or medium.
b) High.
Illustrative references: (14–16). 
1.3.2 Through active TB case-fi ndingz
a) Developing and evaluating ACF approaches:
Objectives: To identify the most effective and 
affordable approach to ACF in different settings.
Design:
Several approaches are possible, from simpler 
to more elaborate options, and are not mutually 
exclusive.
i. Review of published studies on ACF in the 
general community and targeted populations.
ii. ‘Rapid surveys’ or more formal prevalence 
surveys for undiagnosed TB (providing 
assessment of likely impact of ACF) (17–
20). Ideally combined with assessment 
of whether or not ACF can be effectively 
targeted on individual risk factors (e.g. age, 
HIV status, diabetes, etc.) through estimate 
of the population-attributable fraction of 
risk factors. This can be one selected target 
population being considered for ACF, or 
a random cluster sampling of the general 
population (21) to give more generalizable 
results. 
iii. Prospective observational (one ACF strategy) 
or comparative study (two different ACF 
strategies) in a few high risk groups and 
communities known to have a high incidence 
or prevalence of TB. 
iv. More elaborate studies (cluster-randomized 
trials) will give better quality evidence, but 
require considerably more resources and 
should be preceded by pilot studies (as in ii, 
above) wherever possible. Cluster-randomized 
trials require considerable planning and data 
analysis, but can be delivered pragmatically 
(through community worker routine services) 
and are by far the best design for case-fi nding 
interventions against infectious diseases 
(owing to their ability to capture the secondary 
benefi ts from reduced transmission rates). 
However, the number of cases found will not 
provide an appropriate end-point in long-term 
interventions, because a highly successful 
intervention will lead to a fall in new incident 
cases. Examples of cluster randomized trials 
include references at district and sub-urban 
levels (22–24).
v. Most questions around the impact of ACF 
are not ideally tackled through individually 
randomized trials (because TB diagnosis in 
one individual provides benefi t to others from 
prevention of TB transmission). Such trials 
may, however, provide evidence of reduced 
mortality from early TB case-detection (25).
Setting /study population: High risk communities, 
such as high density urban communities known to 
have high TB case-notifi cation rates and/or access 
problems.
Methods: Cross-sectional surveys, with or without 
random sampling (using satellite maps, community 
health worker catchment areas and census 
data to provide the sampling frame), analysis of 
interventional research, ideally combined with 
qualitative research, will require analysis of the 
cumulative yield of cases, ideally including cases 
diagnosed from the same populations through the 
routine health services during the same time period. 
Expected outcomes: Estimated prevalence of 
undiagnosed symptomatic TB, patient diagnostic 
rate, cost-effectiveness (as measured by cost-per-
case found) and yield (cases per 1000 population, 
and percentage of cases found through ACF and 
routine services during a fi xed time period). Yield 
could be stated in terms of the ‘number needed to 
screen’ (NNS) to detect one case.
z Further background and resources about active case-fi nding (ACF) and measuring effects of ACF on TB incidence are available 
in Annex V.
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Analysis: Cross-sectional analysis (with adjustment 
for design effect if cluster-sampling or household 
sampling is used), cumulative yield of TB from ACF 
adjusted for population size, economic analysis 
(cost-benefi t and cost-effectiveness).
Expected duration/timeframe: Medium-term.
Suitable scale: Sub-national; single defi ned 
settings (e.g. slums, prisons)
Estimated budget: Low to high depending on 
approach chosen and study design.
Illustrative references: (17–25).
b) Assessing the effect of sustained ACF on TB 
incidence:
Measuring the effect on TB incidence of ACF 
strategies that have been chosen and supported 
for sustained implementation is essential for long-
term TB control strategies. Reduced duration 
of symptoms before diagnosis (patient delay), 
substantial numbers of TB cases diagnosed 
through ACF, and an increase in the total numbers 
of TB cases diagnosed (active plus routine) from 
the whole community can be used to show success 
initially. However, one-off interventions will not have 
any lasting impact on TB control, so long-term 
success requires a sustained intervention. So, after 
an initial peak of cases (corresponding to improved 
case-fi nding), the aim is to lead altogether to 
reduced numbers of total TB cases identifi ed 
through ACF plus routine services. A falling yield 
from ACF could mean either successful TB control 
or implementation/intervention failure, so it is 
important to ensure that delivery of the intervention 
is monitored and that trends in total case-
notifi cations are reliably measured. Alternatively, a 
‘before-after’ evaluation of undiagnosed TB can be 
used to measure effect on TB incidence. 
Objectives: To identify impact of sustained ACF 
interventions.
Design:
(i) Data analysis from TB control registers, so as to 
examine trends in overall TB case-notifi cation rates.
(ii) Cross-sectional prevalence surveys (before 
and after ACF implementation) to assess trends in 
undiagnosed TB in the community.
Setting /study population: Communities in which 
sustained ACF interventions are being implemented.
Methods: 
(i) Trends in TB case-notifi cations with evaluation to 
confi rm that trends provide a proxy indicator of true 
TB incidence.
(ii) ‘Before-after’ intervention cross-sectional 
surveys for undiagnosed TB, looking for a substantial 
decline during the course of the intervention.
Expected outcomes: Evaluation of the impact of 
ACF interventions on TB control (case-notifi cations 
or prevalence of undiagnosed disease).
Analysis: Time-trend analysis of TB case-notifi cation 
rates (combined ACF and routine services), or cross-
sectional ‘before-after’ prevalence survey methods, 
adjusted for confounding variables (including age, 
gender, HIV infection or other locally important 
individual risk factors for TB disease, and factors 
such as household crowding). Process evaluation 
of implementation of sustained ACF programmes. 
Guidance for sample size calculation: for (ii), 
sample size will be very large and highly dependent 
on baseline incidence. Outcome evaluation will be 
facilitated by taking a unit that is already used for 
TB monitoring and evaluation (e.g. a district).
Expected duration/timeframe: Medium- to long-
term – needs to be nested into ongoing ACF 
interventions.
Suitable scale: Sub-national.
Estimated budget: ACF intervention costs will 
determine overall budget. Additional time-trend 
evaluation costs are low; before-after survey for 
undiagnosed TB costs are high.
Illustrative (26). 
1.4 Evaluating the impact of scale-up of 
a new test or new package of tests 
1.4.1 Modelling expected impact and 
implications of scale-up
Objective: 
a) To model and forecast the operational 
requirements, full economic costs and the clinical 
and epidemiological effects of going to scale with 
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a new test or intervention package (including ACF 
approaches) that has been trialled in 1.3 (above) from 
the health system, patient, and societal perspectives.
b) To critically appraise a new intervention or 
algorithm (e.g. those piloted in Section 1.3) against 
other interventions available internationally or that 
may become available for uptake in the short- to 
medium-term.
Design:
a) Operational and transmission modelling.
b) Use operational and transmission modelling 
based on available data on new interventions at 
earlier stages in the diagnostic pipeline.
Setting/study population:
a) Population targeted for new diagnostic test(s) or 
intervention package in the health facility provision 
of the region or country.
b) As for a) but assessed against alternative 
diagnostic intervention options.
Methods:
a) Transmission and operational modelling as already 
described and defi ned, but now using actual data 
from an approach that has been trialled in section 1.3.
b) As a) but using existing data on alternative 
diagnostic intervention options.
Expected outcome:
a) Projection of operational requirements and costs 
along with expected impacts on TB transmission.
b) Facilitated decisions on uptake into policy and 
practice.
Analysis:
a) Operational and forecasting modelling along with 
health economic projections.
b) Comparison of available information on alternative 
diagnostics (including those that are still at early 
stages of development and not yet endorsed by WHO) 
with the test currently being considered for adoption 
(note: this may be a test that has recently been piloted 
through the process described in section 1.3 and is 
now being projected for national scale-up).
Guidance for sample size calculation:
a) N/A. Requires primary data from implementation 
research and demonstration studies carried out in 
section 1.3.
b) as for a).
Expected duration/timeline: a) and b): Short-term.
Suitable scale: a) and b) National or international.
Estimated budget range: a) and b) Medium.
Illustrative references: (27–29). 
1.4.2 Assessing the impact of a new 
test or new diagnostics package
Objective: To document the effects of going to 
scale with new intervention or package.
Design: Audit of NTCP diagnostic and treatment 
registers to examine numbers of patients starting 
treatment and achieving favourable treatment 
outcomes before and after going to scale with new 
diagnostic intervention.
Setting /study population: Full national datasets.
Methods: Cohort analysis: comparison of case-
fi nding (case notifi cation primarily, but case-
detection rate if possible), and treatment outcome 
indicators before and after going to scale with the 
new diagnostic intervention.
Expected outcome: Evaluation of case-fi nding 
(case notifi cation primarily, but case-detection 
rate if possible) and treatment outcome indicators 
against those expected or predicted in forecasting 
(see section 1.4.1).
Analysis: Comparison of patient cohorts before 
and after intervention.
Guidance for sample size calculation: Full 
national datasets could be used for this if raw data 
in electronic form are available, comparing at least 
a year before implementation with at least a year 
afterwards. If not, then randomized selection of 
registers from at least 10% of the diagnostic and 
treatment centres could be undertaken, but still 
comparing at least a year’s worth of data either side 
of an implementation date. This is very similar to 
usual programme evaluation.
Expected duration/timeline: Short-term.
Suitable scale: National or international.
Estimated budget range: Medium. 
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Objective(s) Methods Expected outcomes Expected 
Duration
Suitable Scale Estimated 
budget range
1.1 Situation analysis
Identify local barriers to 
accessing TB diagnosis
a) Audit and  
Retrospective 
review
Estimates of 
proportion of 
“drop-out” patients
Short-term Local Low
b) Qualitative 
research
Ranked lists of 
barriers
Local, regional or 
national
Medium
c) Mapping of 
facilities 
GIS maps Local, regional or 
national
Medium
d) Costing 
surveys
Economic barriers Local, regional or 
national
Medium
1.2 Identifying new programmatic approaches
a) To understand factors 
facilitating or hindering 
effectiveness of existing 
diagnostic algorithms
a) Realist review Lessons learned Short-term Local, national 
and international
Medium
b) To document accuracy 
of new diagnostic tests or 
packages of tests
b) Systematic 
review
Synthesised data
c) To project a number 
of suitable options of 
diagnostic approaches 
or packages for potential 
implementation.
c) Operational 
and 
transmission 
modelling
A number of 
suitable options 
of diagnostic 
approaches 
or packages 
giving estimates 
of resource 
requirements 
d) To select, at 
international or country 
level, new or revised 
diagnostic approaches to 
be piloted 
d) National or 
International 
level Expert 
Group Review 
meeting
Local evidence-
based 
programmatic 
approach
1.3 Piloting implementation of a new diagnostic tool or package of tools in different settings
1.3.1 Through existing diagnostic services
a) Optimize 
implementation of a new 
diagnostic tool/package
a) Operational 
and 
transmission 
modelling
Projected estimates 
of effectiveness 
and health system 
requirements 
Short-term Local or national Low or 
medium
b) Determine required 
resources
b) Pragmatic 
cluster-
randomised 
controlled trial
Direct evidence 
on effectiveness, 
equity of access, 
acceptability and 
health system 
requirements 
Medium-
term
Regional, national 
or international
High
TABLE 1: SUMMARY
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Objective(s) Methods Expected outcomes Expected 
Duration
Suitable Scale Estimated 
budget range
1.3.2 Through active case fi nding (ACF)
a) Identify the most 
effective and affordable 
approach to ACF in 
different settings 
a) Cross-
sectional 
surveys, analysis 
of interventional 
research 
including 
qualitative 
research
Estimated 
prevalence of 
undiagnosed 
symptomatic TB, 
patient diagnostic 
rate, cost-
effectiveness and 
yield   
Medium-
term
Subnational low to high
b) Identify impact 
of sustained ACF 
interventions 
b) Trends 
in TB case-
notifi cations 
and before-after 
intervention 
cross-sectional 
surveys 
Evaluation of the 
impact of ACF 
interventions on TB 
control 
Medium to 
long-term
Subnational low to high
1.4 Evaluating the scale-up impact of a new test or new package of tests
1.4.1 Modelling expected impact and implications of scale-up
a) Forecast operational 
requirements including 
costs and impact on 
transmission
a) Simulation 
and 
transmission 
modelling
Projection 
operational 
requirements 
including costs 
and impact on 
transmission
Short-term National or 
international
Medium
b) Critically appraise 
a new intervention or 
algorithm against other 
interventions
b) As for (a) 
but using 
existing data 
on alternative 
diagnostic 
intervention 
options
Facilitated 
decisions on 
uptake into policy 
and practice
1.4.2 Assessing the impact of a new test or new package of tests
Document effects of 
going to scale
Cohort analysis Evaluation of 
case-fi ning and 
treatment outcome 
indicators
Short-term National or 
international
Medium
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2. Developing sustainable 
collaboration with all care-
providers for TB care and 
control
2.1 Improving and scaling up existing 
approaches to engaging all providers
Objective(s): Develop an evidence base of different 
PPM models and approaches to scale-up that 
includes contextualized analyses of reasons for 
success/failure as well as mechanisms to create 
demand for quality services. 
Illustrative designs: 
a)  Realist reviews to consolidate evidence on 
the factors contributing to the success (or 
failure) of different PPM models in meeting 
PPM objectives and/or achieving scale-up 
(international). 
b) Case studies to describe how and why scale-
up of different models was or was not achieved.
Setting /study population: 
For realist reviews, the setting will be PPM 
programmes.
Methods: 
a) Realist review: Synthesis of evidence from peer 
reviewed literature, national reports and other 
documents detailing the implementation and 
outcomes from various PPM programmes. 
The evidence base will be expanded through 
national-level studies outlined below.
b) Case studies that can describe the type of PPM 
model implemented with information on the 
partners involved; the costs of the programmes; 
the successes and challenges encountered, 
together with the specifi c experiences with 
scale-up. Programmatic data from TB registers 
will help to quantify the effectiveness of the 
programme, but qualitative methods will also 
be required (e.g. key informant interviews 
with national TB programme managers, PPM 
focal points and private or other public sector 
partners; focus groups or individual interviews 
with patients).
Expected outcomes: Broader knowledge for 
different models of PPM with understanding of 
factors leading to success (on which to build) and of 
factors leading to failure (which should be avoided).
Analysis: 
a. Evidence synthesis (e.g. in partnership with 
members of the PPM subgroup of the Stop TB 
Partnership).
b. Case studies analysed by thematic area (e.g. 
use of private providers in case-fi nding, diagnosis, 
treatment, DOT; management of PPM programmes; 
quality assurance; training; issues concerning 
access to care etc.).
Guidance for sample size calculation: N/A
Expected duration/timeline: Short-term.
Suitable scale: International; national/provincial.
Estimated budget range: Medium.
Note: Areas of enquiry which feed into this objective 
include: i) assessing enablers and incentives for 
different care-providers; ii) assessing different 
mechanisms to fund scale-up; iii) identifying locally 
appropriate approaches to scale-up, including 
PPM/PAL integration; iv) assessing mechanisms 
to create demand for quality services; and v) 
assessing quality of TB care and control, using the 
International Standards for TB Care as the yardstick, 
as initiatives are taken to scale.
Illustrative references: (7, 30).
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2.2 Measuring the contributions of 
different provider groups to TB care 
and control 
2.2.1 Contribution of different care-
providers to TB control
Objective: To assess contributions of different 
care-providers to TB control. 
Design: Time series or cross-sectional analyses 
of existing data sources including the following: 
chronic cough, outpatient or other registers 
recording sources (types of provider) of referral at 
public and private sites together with laboratory 
and TB registers, TB prevalence survey datasets. 
Setting: TB referral centres, diagnosis and 
treatment registration sites; NTCP records database 
(if suffi ciently detailed).
Methods: User and provider surveys; surveys of drug 
sales; analysis of information from pharmaceutical 
companies; review of registers review of existing 
data in TB prevalence surveys indicating from which 
type of provider prevalent cases received diagnosis 
and are receiving TB treatment.
Expected outcomes: An understanding of relative 
sizes of contribution of different types of care-
provider to case detection indicators and treatment 
outcome measures.
Analysis:
a) Description of relative numbers of patients cared 
for by different types of provider.
b) Cohort analysis of patient groups originating 
from or cared for by different types of provider.
Guidance for sample size calculation: Whole 
population studies (i.e. 100% of patient data that 
has already been recorded in a given implementation 
area or prevalence survey for a set time frame (e.g. 
1 year)).
Expected duration/timeline: Short-term.
Suitable scale: National.
Estimated budget range: Low.
Illustrative references: (none yet identifi ed).
2.2.2 Ability of different providers 
to improve access to care for 
underserved groups 
 Objectives:
a) To assess the abilities of different providers to 
improve user access, case detection and outcomes 
for underserved groups, and reduce diagnostic 
delays and costs of care. 
b) To understand resource requirements for scale 
up. 
Design:
a) Prospective cohort studies of patients detected 
or registered for treatment by different types of 
provider.
b) Economic studies of patient and provider costs.
Setting (study population): 
Patients accessing TB services through different 
types of providers (public, private, for- and not-for-
profi t, formal, informal).
Methods: 
a) Follow-up of patients in laboratory and TB 
registers (and a chronic cough register if 
existing) to assess drop-out between stages 
of care and to assess outcomes from different 
types of providers.
b) Assess equity through patient questionnaire 
surveys using, among others, the costing 
tool (described in Annex IV) with patients on 
intensive phase of treatment (to ensure recall 
around referral and diagnostic processes), 
ideally followed-up to treatment completion. 
These will provide data on socioeconomic 
status, care-seeking pathways, costs and 
benefi ts of provider choice. Studies to assess 
the resource requirements of involving each 
provider-type can feed into economic models 
of the costs of scaling-up PPM activities.
Expected outcomes: 
a) Documentation of the extent to which different 
providers promote access by underserved patients 
(e.g. the poor and those with other characteristics 
of vulnerability or facing barriers to accessing 
services).
b) Documentation of the resource requirements of 
both underserved groups and different providers for 
improving access.
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Analysis:
a) For cohort studies, analysis will include estimates 
(with 95% confi dence intervals) of various treatment 
outcomes disaggregated by provider type, 
signifi cance tests of group comparisons.
b) Cost-effectiveness analysis comparing resources 
used by NTCPs/the public health system in 
engaging different provider types; evaluation of 
patient care-seeking pathways through different 
types of care-provider and assessment of patient 
costs incurred along care-seeking pathways.
Guidance for sample size calculation: Data on 
case notifi cations will be from registers and will 
include 100% of all patients seen in the intervention 
and control areas over the relevant period. For 
patient costs sample sizes of 100-200 for each 
provider type are usually suffi cient (depending on 
the homogeneity of the populations).
Expected duration/timeline: Short-term.
Suitable scale: National/local.
Estimated budget range: Medium.
Illustrative references: (5, 31). 
2.3 Encouraging involvement of as yet 
unengaged providers
This research can be conducted in two successive 
steps:
2.3.1 Assessing potential models and 
approaches involving as yet 
unengaged providers
Design:  
a) Literature or realist review to learn from other 
country experiences of working with a broader 
range of providers. Learning from the outcomes of 
different approaches outlined in section 2.1 (Refer 
to section 2.1 above for methods, costs etc).
b) Expert group meeting at national level to discuss 
results from a) in relation to local experience and 
suggest rational approaches for engaging additional 
provider groups or types.
Expected outcome: Ranked priority list of types of 
as yet unengaged providers to include in 2.3.2.
2.3.2 Evaluating effectiveness of 
models involving new providers
Objectives:
a) To locate potential new providers that could 
provide accessible and effective services.
b) To assess effectiveness of partnerships involving 
new providers. 
Design: 
a) Brainstorming with key stakeholders +/- GIS 
mapping of new providers.
b) Implementation study; potential for PRCT 
(cluster). 
Setting/study population: Population groups 
accessing TB care via selected new providers and 
populations accessing the public services directly.
Methods: 
a) Mapping of as yet unengaged providers, such 
as informal providers, or employers of large 
workforces and other organizations. Mapping 
may be a precise process using GIS tools, or less 
precise, with a brainstorming process with key 
stakeholders to think of potential providers and 
marking approximate geographical areas where 
they may be located. 
b) PRCT (cluster), to evaluate the extent to which 
changes in health care provision will be effective in 
the usual conditions under which these changes 
will be applied. As indicated in Annex I, the PRCT 
(cluster) design in this context may require expert 
statistical and epidemiological input (32). However, 
if health-care providers are reluctant to engage in 
a study where they may be randomly allocated to 
not receive the new changes in health provision, 
the option of using a ‘before-and-after’ design (see 
Annex I) with either a single or multiple clusters may 
have to be considered on practical grounds – but the 
disadvantages of not having a contemporary control 
should be carefully considered and discussed with 
the participating health providers. 
Expected outcomes: 
a) Compilation of potential additional providers.
b) Information on effectiveness of new providers 
in terms of case-detection indicators (e.g. case 
notifi cations; case referral rates) and treatment 
outcome measures (treatment success rates, mortality 
etc); as well as cost implications for the service.
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Analysis:
a) Gap analysis in mapping exercises.
b) Comparison of case-detection indicators and 
treatment outcome measures among population 
groups accessing TB care via new providers 
against the same indicators and measures among 
the population groups accessing public services 
directly. Then, conduct cost-effectiveness analysis 
comparing resources used by NTCPs/the public 
health system in engaging different provider types; 
evaluation of patient care-seeking pathways 
through different types of care-provider and 
assessment of patient costs incurred along care-
seeking pathways.
Guidance for sample size calculation: 
a) For qualitative research and mapping, conduct 
interviews and focus group discussions to 
saturation point.
b) For implementation studies, including PRCT 
(cluster) – see previous sections. 
c) For PRCT (cluster) or ‘before-and-after’ designs, 
a minimum of 100 cases/respondents per arm 
(where an arm may be an area with newly engaged 
providers or one without) is usually required to 
compare patient costs. This is usually only a 
proportion of the total number of participants in 
each arm of the study.
Expected duration/timeline: Short- to medium-
term.
Suitable scale: National/local.
Estimated budget range: Medium.
Illustrative reference: (33). 
2.4 Encouraging involvement of non-
public sector in MDR-TB management 
and TB/HIV collaborative activities 
Objectives: To develop an evidence base of different 
models and approaches through the identifi cation 
of potential providers that could provide accessible 
and effective services for MDR-TB and TB/HIV 
management; and to assess the effectiveness of 
models for PPM for MDR-TB and TB/HIV.
Design: 
a) Realist review (international level or national with 
international collaboration). 
b) Observational cohort study; potential for PRCT 
(cluster).
Setting/study population:
For realist reviews the population will be PPM 
programmes.
For cohort studies, the study population will be 
MDR-TB or TB/HIV co-infected patients in study 
areas pre- and post- implementation.
Methods: 
a) Realist reviews from section 2.1 (see above) 
may be used to assess which providers would 
be best suited for engagement in MDR-TB or TB/
HIV PPM programmes. Specifi c challenges related 
to MDR-TB or TB/HIV service delivery should be 
considered against reported challenges of the PPM 
programmes under consideration.
b) Implementation cohort studies will follow 
methods described in earlier sections (particularly 
section 2.3) and should include assessments of 
patient and health-system costs. The cohorts will 
be defi ned by clinical status (e.g. MDR-TB or TB/
HIV co-infection) and types of provider.
Expected outcomes:  
a) Compilation of potential PPM models suited for 
management of MDR-TB or TB/HIV co-infection, 
along with key facilitating factors.
b) Information on effectiveness of new providers 
in terms of case-detection indicators (e.g. case-
notifi cations; case-referral rates etc.) and treatment 
outcome measures (treatment success rates, 
mortality etc.).
Analysis:  
a) Capturing key features of success or lack of it in 
existing PPM models when appraised for suitability 
for TB/HIV or MDR-TB.
b) Descriptive statistics with their (95%) confi dence 
intervals for case-detection and treatment outcome 
indicators, and appropriate for comparing rates 
between patient and provider groups (e.g. Fisher 
exact test for simple group comparisons, logistic 
regression for adjustment for important confounding 
factors); and cost-effectiveness analysis.
Guidance for sample size calculation: 
a) N/A
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b) For implementation studies, including PRCT 
(cluster) – see previous sections. 
Within PRCT (cluster) or ‘before-and-after’ designs 
a minimum of 100 cases/respondents per arm 
(where an arm may be an area with newly engaged 
providers or one without) is usually required to 
compare patient costs. This is usually only a 
proportion of the total number of participants in 
each arm of the study.
Expected duration/timeline:  Short- to medium-
term.
Suitable scale: National/local.
Estimated budget range: Medium.
Illustrative reference: (33). 
2.5 Developing and assessing responses 
to changing involvement of diverse 
providers in TB care and control 
Objective: To identify and assess ways to ensure 
rational use of new diagnostics and drugs in the 
private sector. 
Design: Realist reviews/evaluations; qualitative 
studies.
Setting (study population):  Providers, drugs 
manufactures/distributors.
Methods: Methods include structured evaluation 
of existing approaches; qualitative research to 
better understand providers’ practices; ‘mystery 
client’ surveysaa to assess use of inappropriate 
techniques; cost-effectiveness studies with a 
sample of anonymized private providers.
Expected outcome: Promotion of rational use of 
appropriate diagnostics and drugs in the private 
sector.
Analysis: 
Evidence synthesis, cost-effectiveness analysis 
for individual studies; quality of care analysis from 
mystery client surveys.
Guidance for sample size calculation: For 
qualitative research key informant interviews, focus 
groups and mystery client studies will be conducted 
to point of new knowledge saturation (typically 
20-30 interviews); for cost-effectiveness studies 
number of providers interviewed will depend on 
range of services offered, but for homogenous types 
of providers at similar levels of service provision 4-6 
providers should be suffi cient.
Expected duration/timeline: Short-term.
Suitable scale: Local, national and international.
Estimated budget range: Mostly low.
Note: This area will be diffi cult to undertake 
comprehensively due to a potential lack of 
willingness to share commercially-sensitive 
information and to reveal practices of questionable 
quality. Social marketing organizations (such as 
Population Services International)bb have developed 
good techniques for assessing quality of care in 
private providers and so could support this area. 
Identifying the scale of the problem will be a particular 
challenge and may require some projections made 
from discussions of sales of diagnostics and drugs 
with company representatives or local pharmacists.
Illustrative references: (see footnote below)
2.6 Encouraging introduction of 
novel regulatory approaches to 
collaborating care-providers
2.6.1 Developing an evidence base 
of regulatory approaches that 
includes contextualized analyses 
of reasons for success/failure
Design: Realist review.
Setting/study population: National regulatory and 
enforcement bodies.
Methods: Includes structured evaluation of 
existing approaches (such as mandatory TB 
case notifi cation, certifi cation and accreditation) 
through realist review; qualitative research to better 
aa A mystery client survey involves an actor presenting him or herself as a TB suspect to a provider to assess aspects of the quality 
of care.
bb See: http:// www.psi.org
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understand providers’ practices. Lessons may be 
drawn from experiences in other countries or in 
other sectors in the same country (e.g. control of 
pesticide use by the ministry of agriculture).
Expected outcomes: Inventories of regulatory 
approaches that are present and functioning a) 
locally, and b) in other settings.
Analysis: Analysis of benefi ts of different regulatory 
approaches, challenges and costs associated with 
implementation and enforcement.
Guidance for sample size calculation: N/A
Expected duration/timeline: Medium-term.
Suitable scale: International and national.
Estimated budget range: Medium.
Note:  Full attention must be paid to contextual 
factors that support or inhibit the success of regulation 
implementation in other countries or sectors.
2.6.2 Developing locally-appropriate 
regulatory approaches
Design: Qualitative, consultative studies.
Setting/study population: Regulatory authorities, 
enforcers and service providers.
Methods: Qualitative research to understand 
providers’ practices, including participant 
observation, to understand practices and willingness 
to comply with regulation; policy analysis to assess 
ability of the state/others to encourage and ensure 
compliance with regulations.
Expected outcomes: Enforceable regulations that 
improve quality of care and public health outcomes.
Analysis: Political, social, cultural and legal.
Guidance for sample size calculation: N/A
Expected duration/timeline: Medium-term.
Suitable scale: National.
Estimated budget range: Medium.
Note: While regulations will have to apply on a 
national scale, different options for enforcement 
may be piloted.
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Objective(s) Methods Expected outcomes Expected 
Duration
Suitable Scale Estimated 
budget range
2.1 Improving and scaling up existing approaches to engaging all providers
Develop evidence-base 
of different PPM models 
and identfy factors that 
result in success or failure 
of PPM
a) Realist review Broader 
knowledge of 
different models 
of PPM and 
understanding 
of  factors which 
lead to success or 
failure
Short term International 
or national/ 
provincial 
Medium
b) Case studies
2.2 Measure the contributions of different provider groups to TB care and control
2.2.1 Contribution of different care providers to TB control
Assess contributions of 
different care providers
Surveys, review 
of exisiting data
Understanding 
of contribution 
of differrent care 
providers
Short-term National Low
2.2.2 Ability of different providers to improve access to care for underserved groups
a) Assess ability of 
different providers to 
improve access to care
a) Prospective 
cohort study
Documentation of 
the extent to which 
different providers 
promote access 
by underserved 
patients 
Short-term Local, national Medium
b) Understand resource 
requirements for scale up
b) Costing 
questionnaires
Documentation 
of the resource 
requirements of 
both underserved 
groups and 
different providers 
for improving 
access
2.3 Encouraging involvement of as yet unengaged providers
2.3.1 Assessing the potential models and approaches involving as yet unengaged providers
Assess the potential 
models and approaches 
involving as yet 
unengaged providers
a) Literature or 
realist review Ranked priority 
of types of as 
yet unengaged 
providers
Short to 
medium-
term
National Medium
b) Expert Group 
meeting
2.3.2 Evaluating effectiveness of models involving new providers
a) Locate potential new 
providers
a) Brainstorming 
with key 
stakeholders +/- 
GIS mapping of 
new providers
Compilation 
of potential 
additional 
providers
Short to 
medium-
term
Local, National Medium
b) Assess effectiveness 
of partnerships involving 
new providers
b) Pragmatic 
cluster-
randomised 
controlled trial
Effectivess of new 
providers
TABLE 2: SUMMARY
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2.4 Encouraginig involvement of non-public sector in MDR-TB management and TB/HIV collaborative activities
a) Identify potential non-
public sector providers
a) Realist review Compilation of 
potential PPM 
models suited for 
management of 
MDR-TB or TB/
HIV co-infection, 
along with key 
facilitating factors
Short to 
medium-
term
Local, national Medium
b) Assess effectiveness 
of PPM
b) Observational 
cohort study 
or potential 
for pragmatic 
randomised 
controlled trial
Effectiveness of 
new non-public 
sector providers
2.5 Develop and assess responses to changing involvement of diverse providers in TB care and control
Identify and assess ways 
to ensure rational use 
of new diagnostics and 
drugs in private sector
a) Structured 
evaluation 
of exisiting 
approaches
Promotion of 
rational use of 
new diagnostics 
and drugs in 
private sector
Short-term Local, national 
and international
Low to 
medium
b) Qualitative 
research
c) Cost-
effectiveness 
studies
2.6 Encouraging introduction of novel regulatory approaches to collaborating care providers
2.6.1 Developing an evidence base of regulatory approaches that includes contextualised analyses of reasons for 
success/failure
Develop an evidence 
base of regulatory 
approaches 
Realist review Inventories 
of regulatory 
approaches 
locally and in 
other settings
Medium-
term
National, 
international
Medium
2.6.2 Developing locally appropriate regulatory approaches
Develop locally 
appropriate regulatory 
approaches
Qualitative, 
consultative 
studies
Enforceable 
regulations that 
improve quality of 
care and public 
health outcomes
Medium-
term
National Medium
Objective(s) Methods Expected outcomes Expected 
Duration
Suitable Scale Estimated 
budget range
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3.1 Optimizing linkages between TB and 
HIV programmes
Objectives: For HIV-infected TB patients in different 
groups and epidemiological settings (adults, 
children, families, and special at-risk populations 
(e.g. injection drug users (IDUs), men who have sex 
with men (MSM), prisoners):
a) To determine optimal strategies to integrate and 
deliver joint TB/HIV interventions.
b) To determine optimal models of community 
participation for enhanced TB case-fi nding and 
early HIV detection.
Design:
For both a) and b) above:
i) Realist review of existing models and studies, 
extracting, where possible cost-effectiveness data.
ii) Prospective observational and case-studies with 
‘before-and-after’ assessment of key indicators 
(including HIV/TB-related detection and treatment 
outcome measures, costs etc.);
iii) Qualitative studies among providers and patients.
Setting/study population: General population; HIV 
clinics; special services for at-risk populations (e.g. 
IDUs, prisoners).
Methods: i) Realist review; ii) Observational case 
studies; iii) Focus group discussions, key-informant 
interviews, and in-depth interviews.
Expected outcomes: Documentation of successful 
and less successful models at health system and 
community level in different settings.
Analysis: 
(i) and (iii) : qualitative analysis
(ii) compare effectiveness estimates from before/
after assessment of HIV/TB-related case-detection 
and treatment outcomes (capturing patient/
community costs, and health-system costs).
Guidance for sample size calculation (and 
estimated number of participants): N/A
Expected duration/timeline: Short-term for (i) and 
(iii), and medium-term for (ii).
Suitable scale: National/regional.
Estimated budget range: Low for (i) and (iii), and 
medium for (ii).
Illustrative references (34). 
3.2 Assessing the validity of TB screening 
algorithms in different settings
Objective: To evaluate the effect of implementing 
the WHO-recommended algorithm (or other 
algorithms) for TB screening compared with current 
policy on TB screening in different groups of PLHIV.
Illustrative Designs: 
a) Observational (before/after) case studies.
b) PRCT (cluster) +/- stepped-wedge design.
Qualitative studies of patient and provider 
acceptability may be nested within a) and b).
Setting/study population: PLHIVs in different 
settings (these may be within health units or clusters 
for the purposes of the research design) where TB 
screening may occur including HIV counselling and 
testing, HIV clinics, community-based case-fi nding 
and household contact investigations.
Methods: 
Comparison of HIV- and TB-related case-
fi nding indicators (notifi cations, time to starting 
intervention) and treatment outcome measures 
(including mortality):
3. Prevention and treatment of TB 
in persons living with HIV
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a) At baseline and after implementation in 
observational studies.
b) Between different algorithms in PRCT +/- step-
wedge design.
Expected outcomes: Evidence of relative 
effectiveness of different algorithms, along with 
evidence of impact on access, acceptability and 
health system requirements.
Analysis:
a) Primary effectiveness analysis: number of 
additional cases starting TB treatment or IPT; 
change in time to starting TB treatment or IPT.
b) PRCT (cluster), to evaluate the extent to which 
changes in health care provision will be effective in 
the usual conditions under which these changes 
will be applied – the use of this design may require 
expert statistical and epidemiological input (32). 
c) Equity analysis: Stratifi ed analysis of patients 
being screened (gender, age, socioeconomic status) 
– particularly examining high-risk or vulnerable 
groups; acceptability of screening algorithm to 
patients (qualitative); health system analysis (e.g. 
human resources, logistics, infrastructure and other 
cost-incurring requirements for implementation of 
alternative algorithms).
Guidance for sample size calculation:
Sample size calculation will have to take account 
of the likely intra-cluster correlation (ICC) if cluster 
sampling/randomization is used; few published 
studies report their ICC so precedent is rare – 
typically ICC ranges between 0.001 and 0.100, 
but can be larger. Sample size varies considerably 
according to nature of primary outcome measure, 
effect size to be detected, ICC and number of 
available clusters – it is better to have many small 
clusters than a few large clusters (35). 
Expected duration/timeline: Medium-term.
Suitable scale: Regional, national.
Estimated budget range: Medium.
3.3 Optimal timing of IPT in relation to 
ART
Objective: To defi ne the optimal time to start, 
duration, safety, effi cacy and cost-effectiveness of 
IPT in patients eligible for IPT and ART.
Illustrative designs: 
a) Observational cohort study.
b) PRCT (individual) or PRCT (cluster).
Setting (study population): Patients eligible for 
both IPT and ART.
Methods: In both a) and b) this would be a 
comparison between patients on ART given IPT 
for varying lengths of time. In a) there would be 
no actual intervention and health provider-patient 
interactions would determine the duration of IPT 
based on local recommendations. In b) there would 
be a randomized assignment of patients or health 
units to the different IPT duration strategies. Both 
will require long-term follow-up to determine timing 
of adverse events.
Expected outcomes: Evidence on effectiveness 
and cost-effectiveness of different durations of IPT 
in patients receiving ART, as determined by the 
occurrence of pre-defi ned end-points (e.g. death, 
development of TB, etc.).
Analysis: 
a) Observational design (note: adjustment for 
unmeasured confounding will be required).
b) PRCT (cluster) design: effectiveness analysis 
(including actuarial methods/Cox regression 
models) – mortality as the main outcome measure. 
Equity analysis and health system analysis 
analogous to that outlined in section 3.3 above 
could also be added.
Guidance for sample size calculation:
a) Sample size for rate(s) of occurrence of pre-
defi ned end-points (e.g. death, development 
of TB) based on either precision required for 
estimate of rate(s) or on size of difference 
between patient sub-groups that would be 
considered clinically signifi cant.
b) Sample size for ‘time to’ measures based on 
difference in median time to end-point (e.g. 
death, development of TB) between groups that 
would be considered clinically signifi cant.
Expected duration/timeline: Long-term.
Suitable scale: Regional, national, international.
Estimated budget range: High.
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3.4 Models to improve adherence to IPT
3.4.1 Identifying optimal models
Objective: To identify optimal medication delivery, 
community support and clinical monitoring of IPT in 
PLHIV to maximize adherence. 
Illustrative Design: PRCT (cluster) with factorial 
design. 
Setting/study population: PLHIV initiating IPT.
Methods: The cluster here is a health unit. The 
choice of adherence support mechanisms should 
be based on existing synthesised evidence (36):
- clusters in Arm 1: receive no additional adherence 
support between routine clinic visits;
- clusters in Arm 2: receive community-peer support 
for adherence through patient-support groups;
- clusters in Arm 3: other support mechanisms (for 
instance, weekly text reminders via mobile phones).
Expected outcome: Evidence on relative 
effectiveness (most feasibly in terms of IPT default 
rates, but can also include pills count, self-reported 
adherence, or measurement of INH metabolites 
in urine), patient acceptability, health system 
requirements of different adherence support 
mechanisms.
Analysis:
- Effectiveness analysis (suggested outcome 
measure = IPT default rate. Incidence of TB disease 
is relatively rare and would likely require a very large 
sample size).
- Equity and health systems analysis – analogous to 
that described in Section 3.4 above.
Guidance for sample size calculation:
A large number of clusters (areas) and number of 
default patients is required to ensure generalizable 
results; many small clusters are preferable to a few 
large clusters. Stratifi cation by urban/rural areas 
may be appropriate.
Expected duration/timeline: Medium.
Suitable scale: Regional, national.
Estimated budget range: Medium.
3.4.2 Identifying operational 
requirements
Objective(s): To model and forecast the operational 
requirements and full economic costs of going to 
scale in administering IPT in HIV care settings.
Design: Modelling study.
Setting/study population: PLHIV initiating IPT.
Methods: Operational research modelling to 
include optimal frequency of symptom screening, 
monitoring tools and measures to maintain high 
adherence. This approach corresponds to layer 4 of 
the Impact Assessment Framework (see Annex V) 
and requires empirical data (including data on 
costs) from studies outlined in section 3.5.1.
Expected outcome: Assessment of operational 
requirements and costs.
Analysis: Operational modelling.
Guidance for sample size calculation: N/A
Expected duration/timeline: Medium-term.
Suitable scale: National.
Estimated budget range: Medium.
3.5 Optimizing infection control to 
reduce TB transmission
Objective: To determine the impact on nosocomial, 
congregate and household TB transmission 
in HIV-prevalent settings with the introduction 
of TB infection control measures based on 
recommendations from WHO.
Design: PRCT (cluster) trial with stepped-wedge 
design, ensuring that all units ultimately receive the 
WHO-recommended TB infection control measures.
Setting (study population): Health-care staff working 
at facilities that provide chronic HIV care; staff working at 
congregate settings with long-term (e.g. prisons) and 
short-term (e.g. jails and homeless shelters) duration 
of stay of dwellers and residents of households in 
which at least one HIV-positive person resides.
Methods:
• Intervention clusters: WHO recommendations 
on TB infection control. 
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• Control clusters: current policy and 
practice of TB infection control, until such 
time as the WHO recommendations can 
be rolled out to these. 
• Information on known TB exposure, if any, 
should be obtained using interviews, log 
books and staff rotas. TB infection rates 
should be monitored through serial testing 
in the control and intervention arms using 
either the tuberculin skin test (TST) or the 
interferon gamma release assay (IGRA).cc 
The ultimate end-point is the number of TB 
cases among exposed populations over a 
defi ned period of time.
Expected outcomes: Evidence on effectiveness of 
standardized pack of infection control interventions, 
along with acceptability to health-care workers and 
impact (costs) on health system.
Analysis: 
• Primary effectiveness analysis: Mean 
numbers of cases of TB in exposed and 
unexposed populations, rate ratio or 
rate difference (all with 95% confi dence 
intervals). Appropriate regression methods 
to adjust rates for important confounding 
factors. Analyses may have to be adjusted 
also for clustering effects. For details, see 
Annex I.
• Qualitative research with health-care 
workers/other staff to understand 
acceptability of IC interventions.
• Health system analysis, including cost-
effectiveness analysis (infrastructure, 
utilities, etc requirements.
Guidance for sample size calculation (and 
estimated number of participants):
Depends on size of clusters, value of ICC, 
background rate of TB incidence among health 
care-workers/other staff, and size of reduction 
in incidence of TB infection and disease that will 
constitute a clinically signifi cant effect.
Expected duration/timeline: Medium-term.
Suitable scale: Regional, national, multi-country.
Estimated budget range: High.
Illustrative references: (37, 38). 
3.6 Reducing mortality in TB/HIV co-
infected patients
Objective(s): To identify the risk factors associated 
with death and the causes of death in PLHIV being 
treated for TB. 
Design: Prospective (routine clinical surveillance) 
survey.
Setting (study population): HIV-positive patients 
pre-ART and on ART commencing treatment for TB 
(programmatically defi ned, or, if resources allow – 
microbiologically confi rmed).
Methods: Prospective clinical assessment (routine 
surveillance). If routine follow-up of patients is 
adequate and if records are suffi ciently complete, it 
may be possible to use retrospective case notes or 
health register data.
Expected outcomes: Proportions of patients 
surviving fi xed time periods (with 95% confi dence 
intervals); hazard ratios/medians (with 95% 
confi dence intervals) for survival times, stratifi ed 
on CD4 count results. List of major risk factors 
associated with mortality in PLHIV treated for TB 
(examples to consider should include objectively 
measurable indicators of clinical condition at the 
start of treatment, such as body mass index, pulse 
rate and respiratory rate, undiagnosed MDR-TB, as 
well as general performance indicator) (39). 
Analysis: Actuarial/Kaplan-Meier plots of survival 
times for all patients and for important sub-groups. 
Fisher exact tests to compare early death rates (e.g. 
during the fi rst two weeks or during the intensive 
phase) between sub-groups and logistic regression 
methods to identify risk factors associated with 
mortality rates at fi xed time points. Log-rank tests 
cc The issue with IGRAs on serial testing is whether an increment threshold is required to determine a negative to a positive test 
result. The advantage over TST is that there is no boosting effect as it is an ex-vivo test, but variability around the threshold could 
be an issue when conversion results are around the threshold. TST is not a great tool for serial testing because of the boosting 
effect and the fact that people are not keen on a regular in vivo test. If neither test is being used, transmission assessment will then 
be made only on incident cases, so the impact on infection rates will not be assessed.
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to compare (median) times to death between sub-
groups and Cox regression methods to identify 
factors associated with survival time (e.g. during the 
continuation phase); analyses should be terminated 
when numbers at risk fall below 30 (40). These 
methods may require expert statistical advice.
Guidance for sample size calculation:
Depends on completeness and reliability of 
information on deaths and causes of deaths, current 
death rate, and the risk factors on which data is being 
recorded. Sample size for mortality rates at fi xed 
time points based on size of difference that would 
be considered clinically signifi cant; sample size for 
times to death based on difference in hazard rates 
that would be considered clinically signifi cant and 
requires use of specialized formulae/software (41). 
Expected duration/timeline: Medium-term.
Suitable scale: Local, regional, national.
Estimated budget range: Medium.
Illustrative references: (42–45). 
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Objective(s) Methods Expected 
outcomes
Expected 
Duration
Suitable Scale Estimated 
budget 
range
3.1 Optimizing of linkages between TB and HIV programmes
a) Determine optimal 
strategies to integrate 
and deliver joint TB/HIV 
interventions
(for both 
objectives)
i) Realist review,     
ii) observational 
case studies and 
iii) qualitative 
research
Documentation 
of successful and 
less successful 
models at 
health system 
and community 
level in different 
settings
(i) and 
(iii) short 
term, (ii) 
medium 
term
National, 
regional
(i) and (iii) 
low, (ii) 
medium
b) Determine optimal 
models of community 
participation for 
enhanced TB case 
fi nding and early HIV 
detection
3.2 Assessing the validity of TB screening algorithms in different settings
Evaluate the effect 
of implementing the 
WHO recommended 
algorithms for TB 
screening in PLHIV 
compared to current 
policy
a) Observational 
studies including 
qualitative 
studies of patient 
and provider 
acceptability
Evidence of 
effectiveness and 
impact of different 
algorithms
Medium-
term
Regional, 
national
Medium
b) Pragmatic 
randomised 
controlled 
trial including 
qualitative 
studies of patient 
and provider 
acceptability
3.3 Optimal timing of IPT in relation to ART
Defi ne optimal duration, 
safety, effi cacy and cost-
effectiveness of IPT in 
patients eligible for IPT 
and ART
a) Observational 
cohort study
Evidence on 
effectiveness and 
cost-effectiveness 
of different 
durations of IPT in 
patients receiving 
ART
Long-term Regional, 
national, 
international
High
b) Pragmatic 
randomised 
(individual or 
cluster) controlled 
trial
TABLE 3: SUMMARY
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3.4 Models to improve adherence to IPT
3.4.1 Identifying optimal models
Identify optimal 
medication delivery, 
community support and 
clinical monitoring of 
IPT in PLHIV to maximise 
adherence
Pragmatic cluster-
randomised 
controlled trial 
with factorial 
design
Evidence 
on relative 
effectiveness, 
patient 
acceptability and 
health system 
requirements 
of different 
adherence 
support 
mechanisms
Medium-
term
Regional, 
national
Medium
3.4.2 Identifying of operational requirements
Forecast operational 
requirements and full 
economic costs of going 
to scale in giving IPT in 
HIV care settings
Operational 
modeling
Operational 
requirements and 
costs
Medium-
term
National Medium
3.5 Optimizing infection control to reduce TB transmission
Determine impact on 
TB transmission in HIV 
prevalent settings with 
introduction of WHO TB 
infection control policy
Pragmatic cluster-
randomised 
controlled trial 
with step-wedge 
design
Evidence on 
effectiveness, 
acceptability 
and cost of 
infection control 
interventions
Medium-
term
Regional, 
national, 
international
High
3.6 Reducing mortality in TB/HIV co-infected patients
Identify risk factors 
associated with death in 
PLHIV and being treated 
for TB
Prospective 
clinical survey
Identifi cation of 
modifi able risk 
factors
Medium-
term
Local, 
regional, 
national
Medium
Objective(s) Methods Expected 
outcomes
Expected 
Duration
Suitable Scale Estimated 
budget 
range
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4.1 Identifying reporting gaps
Objective:
To determine the validity of reported treatment 
outcomes of new smear-positive pulmonary TB, 
and re-treatment pulmonary TB.
Design:
Comparison of routinely reported treatment 
outcomes from programme cohort analysis with in-
depth audit of registers and records. For example, 
within a given diagnostic and treatment centre, 
detailed treatment outcomes can be re-calculated 
from the following primary data sources:
a) Individual patient treatment cards – a random 
selection of treatment cards can be extracted 
and treatment outcomes in the standard outcome 
categories defi ned so that outcomes can be 
estimated and compared with the overall cohort 
report from the same time period.
b) laboratory registers can be compared with 
treatment registers (for a selected time-frame) to 
identify patients who are documented as smear-
positive by the laboratory services but who do not 
start treatment (primary defaulters). This kind of 
analysis can highlight areas in the patient pathway 
to and through treatment that either needs stronger 
documentation, programme strengthening or both.
c) Reference laboratory registers can also be 
scrutinized for data on drug resistance.
Setting/study population:
Patients’ records: individual treatment cards, 
laboratory registers, treatment registers, and cohort 
reports.
Methods:
Record and register reviews. Analysis of treatment 
outcomes can be disaggregated by different 
patients’ populations: e.g. new/re-treatment, male/
female, urban/rural residence etc.
Expected outcomes: In-depth understanding of 
gaps in recording and reporting, improved accuracy 
of treatment outcome data, indicative areas 
requiring additional programme support.
Analysis: 
a) and b): Comparison of existing treatment outcome 
reports from routine cohort reporting with re-calculated 
treatment outcomes derived from in-depth analysis of 
different data sources (laboratory registers, treatment 
registers, patient treatment cards).
c): Descriptive statistics of primary and secondary 
drug resistance rates and patterns.
Guidance for sample size calculation:
A sampling frame of all eligible health units will 
be needed. Random samples of records/registry 
entries selected for audit and a decision made 
about what time-span the audit will cover. An 
appropriate proportion of treatment cards will need 
to be drawn from all of the registers in each selected 
health unit, using either random or systematic 
sampling methods; sample size determined by 
precision required for estimate of prevalence rates 
for different treatment outcomes.
Expected duration/timeline: Short term.
Suitable scale: National.
Estimated budget range: Low.
4. Treatment of drug-susceptible 
and M/XDR-TB: optimal access, 
delivery and community 
participation
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4.2 Carrying out investigational studies 
to address defi ciencies in fi rst-line 
management of TB within national TB 
control programmes
Objective: To understand reasons behind default 
(both primary and secondary), poor adherence, 
missed doses, and drug stock-outs.
Illustrative Designs:
a) Cross-sectional descriptive qualitative studies 
with patients and providers of fi rst-line TB treatment 
within NTCPs.
b) Mapping of service provision for treatment 
initiation and support in relation to population 
characteristics.
Setting/study population:
a) Patients currently on TB treatment, and NTCP 
staff or fi rst-line providers within the public health 
service who procure, distribute stock, prescribe, 
and dispense TB drugs. The primary focus would 
be on districts or health units with higher than usual 
adverse treatment outcomes, but identical studies 
in better functioning districts or health units are also 
worthwhile.
b) Clusters (health units or districts) with different 
treatment success rates.
 Methods: 
a) Qualitative research methods to identify factors 
behind known defi ciencies in NTCP function 
(default, drug stock-outs etc). Themes will be 
expected to emerge from both patient and health 
system perspectives.
b) Mapping of facilities and services onto GIS.
Expected outcomes: 
a) Context-specifi c understanding of reasons 
behind known defi ciencies in NTCP function.
b) GIS maps illustrating relationship between 
patients, communities and treatment services.
Analysis:
a) Selection of modifi able processes behind known 
defi ciencies in NTCP function.
b) Identifi cation of geographical and other 
modifi able gaps in provision of treatment initiation 
and support.
Guidance for sample size calculation (and 
estimated number of participants):
a) No formal sample size calculations required (see 
details described in section 1.1, above).
b) N/A
Expected duration/timeline: Short-term.
Suitable scale: Local or national.
Estimated budget range: Low.
4.3 Improving management of drug-
sensitive TB
Objective: To test effects of strategies emerging 
from studies in section 4.2 (above) to improve fi rst-
line management of drug-sensitive TB.
Design: 
a) Before-and-after studies.
b) PRCT (cluster) or PRCT (individual) with stepped-
wedge design.
Setting/study population: 
a) and b): districts or health units with high rates of 
adverse treatment outcomes.
Methods: 
a) Compare treatment outcomes at baseline (may be 
retrospectively) to changes in treatment outcomes 
over time after initiation of improved management 
strategy (e.g. improved recording of patient 
locators and strengthened drug procurement and 
distribution mechanisms).
b) Compare treatment outcomes between control 
districts that have not yet received improved 
management strategy with intervention districts 
that receive improved management strategy fi rst.
Expected outcome: Estimates of effectiveness 
of different strategies for improved fi rst-line 
management of TB.
Analysis: 
If routine recording data are being used and 
observation periods are all equal, comparison of mean 
numbers of adverse outcome events between clusters 
and/or observation periods is feasible. If observation 
periods are unequal and/or times to events are known, 
arctuarial/ log-rank methods may be possible. 
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Guidance for sample size calculation: 
Sample size for rate of occurrence of pre-defi ned 
outcome measures based on either precision 
required for estimate or on size of differences 
considered clinically signifi cant.
Expected duration/timeline: Long-term, to allow 
time for capture of treatment outcomes.
Suitable scale: National.
Estimated budget range: Medium.
Illustrative reference: (46). 
4.4 Identifying major drivers of drug-
resistant TB
It is important to identify the major drivers of the 
DR-TB epidemic so as to effectively target control 
interventions at regional or local level and in specifi c 
settings, and in order to monitor interventions for their 
impact on the DR-TB situation. Programme managers 
need to know the scale of the problem (prevalence, 
incidence), particularly among specifi c geographical 
or socioeconomic groups, the interaction with other 
diseases (e.g. HIV, diabetes) and other risk factors 
(e.g. malnutrition), and what is the relative contribution 
of transmission and acquisition of DR-TB. They 
need this information for the optimal planning and 
implementation of the TB control programme. 
Therefore, depending on the situation, the major drivers 
of DR-TB should be investigated either through the 
existence of routine drug resistance surveillance data, 
or through the conduct of drug resistance surveys. 
In both situations, data should be used to identify 
those drivers of the DR-TB problem that are relevant 
at the local or national level. These can be primarily 
of individual (e.g. treatment adherence, transmission), 
or of health service or programmatic nature (e.g. drug 
stock-outs or drug quality), and require different study 
approaches. 
4.4.1 At the individual level
Objective: To identify risk factors for development 
of drug-resistant TB at the individual level.
Design: 
a) Case-control study comparing new cases with 
drug-resistant isolates and new cases with drug-
sensitive isolates. (Note: this would primarily yield 
insight into risk factors for transmission of drug-
resistant M. tuberculosis).
b) Case-control study comparing re-treatment 
cases with drug-resistant isolates with re-treatment 
cases with drug-sensitive isolates. (Note: this would 
yield insight into risk factors for both transmission 
and acquisition of drug-resistant M. tuberculosis, 
e.g. through low treatment adherence).
Setting/study population: 
- Cases (a and b): patients whose specimens grow 
M. tuberculosis and which are tested for fi rst-line 
DST and found to have drug-resistant patterns. 
- Controls (a and b): patients whose M. tuberculosis 
isolates are fully sensitive to fi rst-line drugs.
Note: for the second case-control study, case and 
control patients should be matched by diagnostic 
category (i.e. treatment failure, return after default, 
relapse).
Methods: Clinical, demographic, socioeconomic 
variables should be collected in cases and controls. 
In particular, these should try to investigate risk 
factors for acquisition of drug-resistance (e.g. 
adherence to treatment, use of rifampin before 
current treatment, previous treatments – where, 
what, interrupted, switched, access to care), and 
potential determinants for transmission of drug-
resistance (e.g. HIV status, history of hospitalization, 
frequent outpatient clinic attendance, incarceration, 
drug use, homelessness, alcohol use, country/
region of origin, etc.). 
Two approaches are possible for these case-control 
comparisons: 
a) Within the context of a national MDR-TB survey, 
an investigational case-control study, when a 
prospective sampling plan is used to collect 
specimens from representative populations of 
new and re-treatment TB patients. In such a case, 
clinical, demographic, and socioeconomic variables 
are collected at the time of sample collection from 
all patients included in the survey. Alternatively, 
detailed data can be obtained by interviewing 
identifi ed case and control patients after the survey 
DST results are available. A comparison of these 
variables between those identifi ed with DR isolates 
and those with DS isolates is then possible.
b) Outside the context of a national MDR-TB 
survey, new patients who are identifi ed with DR 
isolates during the course of treatment or when 
treatment is identifi ed as having failed can be 
interviewed at the time that they are identifi ed as 
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having drug resistance and are switched to a new 
treatment regimen. The interview can then capture 
personal, demographic, clinical and socioeconomic 
variables. The treatment register can then be used 
to fi nd a case with drug-sensitive isolates who 
matches the index DR case. This same procedure 
can be followed for re-treatment cases identifi ed 
with DR isolates.dd  
Expected outcome: Identifi cation of major 
individual risk factors for DR-TB operating at the 
individual patient level.
Analysis: Odds ratios for individual risk factors with 
their (95%) confi dence intervals; logistic regression 
adjustment of odds ratios for important confounding 
variables. When large studies are done or data 
from various smaller studies are combined in order 
to explain regional/international differences, the 
effect of risk factors operating at different levels 
(e.g. individual, village/community, region, etc.) can 
be taken into account using multi-level modelling 
methods (see Annex I). 
Guidance for sample size calculation: 
Depends on background rates of MDR-TB, and 
prevalence of expected risk factors. Study power 
should be based on the detection of risk factors 
that are either strong or have a high prevalence 
in the study population (i.e. are strong in terms of 
attributable fraction). In general terms, risk factors 
with odds ratios of less than two will have limited 
clinical value; 150-200 cases and controls are 
needed to detect factors with odds ratios of this 
magnitude with 80–90% power.
Expected duration/timeline: Depending on 
the design: medium (surveillance-based) to high 
(survey-based).
Suitable scale: Local, national, international.
Estimated budget range: Low to Medium.
Illustrative reference: (47). 
4.4.2 Programmatic risk factors for 
drug-resistant TB
Objective: To identify risk factors for development 
of drug-resistant TB at the programmatic level.
Design: 
Case-control study comparing health units or 
districts with high rates of (M)DR-TB, with units or 
districts with low rates of (M)DR-TB.
Setting/study population: Patients and programme 
processes in health units or districts with differing 
(M)DR-TB rates.
Methods: Comparison of programmatic issues 
in health units or districts with differing (M)DR-TB 
rates. Example issues requiring attention are: the 
use of the WHO re-treatment regimen, frequency 
of drug stock-outs, changes in drug suppliers, 
changes/lapses in treatment regimens, use of 
fi xed-dose combinations, quality of reporting and 
recording (including patient-locator details (such as 
addresses) in diagnostic and treatment registers), 
hospitalization practices.
Expected outcome: Identifi cation of major 
programmatic risk factors for DR-TB.
Analysis: Odds ratios for individual risk factors with 
their (95%) confi dence intervals; logistic regression 
adjustment of odds ratios for important confounding 
variables. 
Guidance for sample size calculation: 
Depends on prevalence of expected 
programmatic risk factors. Study power should 
be based on the detection of high-impact 
factors, which by definition will have medium to 
high prevalence and clinically desirable impact. 
In general terms, risk factors with odds ratios 
of less than two will have limited clinical value; 
150-200 cases and controls are needed to detect 
factors with odds ratios of this magnitude with 
80–90% power. Study power may be increased 
by using two to four control health units/districts 
(with low rates of MDR-TB) for each district with 
a high MDR-TB rate.
Expected duration/timeline: Short-term.
Suitable scale: Local or National.
Estimated budget range: Low to Medium.
Illustrative reference: (47). 
dd The limitation of a case-control approach outside of the context of an MDR-TB survey is that many countries are currently not 
offering DST to new TB cases. This may change as drug sensitivity testing modalities are more widely offered.
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4.5 Defi ning and evaluating strategies 
for integration/scale-up of DR-
TB management within TB control 
programmes
Objectives: 
a) To develop algorithms for selecting patients 
eligible for DST and second-line treatment in 
different settings (to identify MDR-TB early).
b) To develop strategies for provision of second-
line treatment (including adherence and use 
of incentives and enablers, community-based 
ambulatory care and support).
c) To evaluate the effectiveness of existing infection 
control measures and strategies for implementing 
recommended infection control measures at 
community, household and health facility levels.
Design: 
a) For development of appropriate diagnostic 
algorithms, please refer to Section 1.2 (above), 
where the approaches outlined for diagnostic 
approaches can be followed, but with specifi c 
attention to early identifi cation of MDR-TB.
b) Case studies of community-based provision 
of complex, long-duration antibiotic therapies 
including injectable drugs. Lessons could be 
extracted from case studies of community-based 
provision of treatment in areas of the health sector 
other than TB care and control, and from novel 
pilots of community-based provision of TB care.
c) For evaluation of existing infection control 
measures in relation to new and recommended 
control measures, refer to section 3.6, above. 
Setting/study population: Health-care facilities, 
congregate settings and households.
Methods: 
a) See section 1.2.
b) Case-studies: giving detailed programme 
description and extracting key features of success 
from examples in other parts of the health sector 
as well as novel community-based MDR treatment 
programmes.
c) See section 3.6.
Expected outcomes: Options for provision of 
scaled-up MDR provision, which include: i) improved 
diagnostic algorithms for early detection of MDR-
TB, ii) accessible and practical community-based 
MDR treatment arrangements, and iii) adequate 
infection control procedures.
Analysis: 
a) (See section 1.2).
b) Case studies.
c) (See section 3.6).
Guidance for sample size calculation: 
a) (See section 1.2)
b) A single case study may be useful in drawing out 
context-specifi c lessons for going to scale with a given 
model in a given country. If case studies in different 
countries of different models are compared, there is 
the possibility to draw out more generic lessons for 
scale-up which may be more widely applicable.
c) (See section 3.6)
Expected duration/timeline: Medium- to long-
term.
Suitable scale: National, but with international 
support for case-study comparisons.
Estimated budget range: Medium to high.
4.4 PPM collaboration studies
Please refer to section 2.
4.5 Improving decentralized and fully 
integrated access to TB and ART 
treatment 
Objective: To understand factors that facilitate fully 
integrated service provision at the point-of-care for 
HIV-infected TB patients.
Design: Case studies giving detailed programme 
description and extracting key features of success.
Setting (study population): Settings with high HIV 
prevalence providing high levels of integration of 
TB and HIV service provision at the point-of-care 
(model programmes).
Methods: 
Integrated TB and HIV pilot programmes in countries 
with high dual burden of TB and HIV.
Priorities in Operational Research to improve Tuberculosis Care and Control
93
Expected outcomes: List of factors promoting 
integrated TB and ART service provision at the 
point-of-care.
Analysis: Case study methodology.
Guidance for sample size calculation (and 
estimated number of participants)
A single case study may be useful in drawing out 
context-specifi c lessons for going to scale with 
a given model in a given country. If case studies 
in different countries of different models are 
compared, there is the possibility to draw out more 
generic lessons for scale up which may be more 
widely applicable.
Expected duration/timeline: Medium.
Suitable scale: National.
Estimated budget range: Medium.
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Objective(s) Methods Expected outcomes Expected 
Duration
Suitable Scale Estimated 
budget range
4.1 Identifying reporting gaps
Determine validity of 
reported treatment 
outcomes of new smear 
positive PTB and re-
treatment PTB
Record and 
register reviews
Understanding 
gaps in recording 
and reporting and 
identifying areas 
for programme 
support
Short-term National Low
4.2 Carry out investigational studies to address defi ciencies in fi rst-line management of TB within NTCPs
Understand reasons for 
default, poor adherence, 
missed doses and drug 
stock-outs
a) Qualitative 
research
Context specifi c 
understanding of 
reasons behind 
defi ciencies in 
NTP programme
Short-term Local or national Low
b) Mapping of 
facilities 
GIS maps
4.3 Improving management of drug-sensitive TB
Test effects of strategies 
emerging from studies in 
4.2 to improve fi rst line 
management
a) Before and 
after study
Estimates of 
effectiveness of 
different strategies 
for improved fi rst 
line management 
of TB
Long-term National Medium
b) Pragmatic 
randomised 
(individual 
or cluster) 
controlled trial 
with step-wedge 
design
4.4 Identifying major drivers of drug-resistant TB
4.4.1 Individual risk factors for drug resistant TB
Identify risk factors for 
development of drug 
resistant TB at the 
individual level
Case-control 
study
Identifi cation of 
major risk factors 
for DR-TB
Medium to 
long-term
Local, national, 
international
Low to 
medium
4.4.2 Programmatic risk factors for drug resistant TB
Identify risk factors for 
development of drug 
resistant TB at the 
programmatic level
Case-control 
study
Identifi cation 
of major 
programmatic risk 
factors for DR-TB
Short-term Local or national Low to 
medium
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4.5 Defi ning and evaluating strategies for integration/scale-up of DR-TB management within TB control programs
a) Develop algorithms 
for selecting patients 
eligible for DST and 2nd 
line treatment in different 
settings
a) Refer to 
Section 1.2
Improved 
diagnostic 
algorithms for 
early detection of 
MDR-TB
Medium to 
long-term
National with 
international 
support
Medium to 
high
b) Develop strategies 
for provision of 2nd line 
treatment
b) Case studies Accessible 
and practical 
community based 
MDR treatment 
arrangements
c) Evaluate effectiveness 
of existing control 
measures and strategies
c) Refer to 
Section 3.6
Adequate infection 
control procedures
4.6 PPM collaboration studies
Refer to Section 2
4.7 Improving decentralised and fully integrated access to TB and ART treatment (refer to Section 3 also)
Understand factors which 
facilitate fully integrated 
service provision at 
POC for HIV infected TB 
patients
Case studies: 
extract key 
success features 
from integrated 
TB and HIV 
programmes
List factors 
promoting 
integrated TB 
and ART service 
provision at POC
Medium National Medium
Objective(s) Methods Expected outcomes Expected 
Duration
Suitable Scale Estimated 
budget range
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5.1 What is the impact of existing 
training courses in terms of products 
and measurable outcomes? 
Although there is a large literature on different 
approaches to educational evaluations, few 
interventions for work-based education of health 
professionals in developing countries have been 
adequately evaluated (48, 49). 
Objective: To assess the impact of existing training 
in terms of products/outputs and outcomes.
Design: Evaluations of training courses should be 
rigorous but also simple and feasible in a resource-
constrained setting. There are no specifi c evaluation 
tools available for evaluating training courses in 
developing countries, so it is important to design 
evaluations using published frameworks that 
incorporate criteria derived from different perspectives 
(50). Evaluations should assess whether or not 
course outcomes have been achieved and should 
include indicators of process (i.e. how the course 
was delivered), content (i.e. what was delivered) and 
outcomes (i.e. completed assignments and projects; 
improved competence and confi dence in applying 
research skills into practice)(51). Criteria for selecting 
the evaluation tools for different types of training will 
vary but in principle they should be selected from 
those published in peer-reviewed journals and be 
relevant to the course outcomes and for evaluating 
innovative educational interventions based on social 
learning (48, 49), and they could be applied within 
the available time and resource constraints. Ideally 
two different methods should be used to triangulate 
the assessment of each of the learning outcomes of 
the training.
Setting (study population): Existing training 
courses in operational research offered by 
international agencies, NGOs or academic 
institutions. 
Methods: Subjects should include students, tutors, 
institutional managers and other stakeholders 
including users of the course outputs. Examples 
of evaluation tools include: course assignments, 
questionnaires, surveys, self-effi cacy scale which 
asks learners to score a series of 11 statements 
about their research skills from 1 (= not at all 
able) to 10 (= very able) (this has good internal 
consistency and face validity across a range of 
professional programmes); ‘stages of change’ tool 
to assess progress in changing learners’ attitudes, 
intentions and actions in relation to research. 
Outcomes should also include operational research 
publications, mainly those leading to policy change 
at local, national or international level.
It is also suggested that an alumni association of 
participants trained in operational research is set 
up by training institution that should monitor on 
an annual basis whether these participants are still 
engaged in operational research, have completed 
studies, have written-up papers and are actively 
involved in training/monitoring others. 
Suitable scale: Individual training courses.
Estimated budget range: Low to medium (course 
evaluation approximately 10-15% of the total 
course budget for a rigorous, possibly publishable, 
evaluation).
5.2 Models of operational health 
research capacity building
Objective(s): Assessment of existing models of 
operational research capacity building and lessons 
learnt.
Design: Operational health research capacity 
building (OHRCB) is more than the provision and 
evaluation of training and evaluation as has been 
described in section 5.1. It is defi ned as an “ability 
of individuals, organizations, or systems to perform 
and utilise health research effectively, effi ciently, and 
sustainably” (see section on defi nitions in Annex I). 
A review of published and grey literature to collate 
information about models for OHRCB is required, or 
countries may wish to review publications if already 
in existence (52). 
5. Capacity building for 
operational research
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Setting (study population): All settings in which 
individual and/or institutional capacity building 
have been described should be included.
Methods: Studies identifi ed from: i) formal 
searches of health, education and management 
literature using pre-defi ned search terms; ii) 
websites of funders and users of health research, 
health consultancy organizations and academic 
institutions; iii) personal contacts involved in doing 
or evaluating health research capacity building; 
iv) review of institutional research repositories. 
The types of studies will include cases studies, 
realist reviews, expert opinions and theoretical 
frameworks for designing and/or evaluating health 
research capacity building.
Expected outcome: Different documented models 
for OHRCB which have been rigorously evaluated 
and shown to work in a variety of settings and 
which provide examples from which country-level 
TB programmes and partners can choose. 
Analysis: Studies that describe real-life health 
research capacity building projects and which 
include a formal evaluation using a pre-designed 
evaluation framework/indicators will be analysed. 
The analysis will involve developing a framework in 
collaboration with researchers and research users 
to ensure that the outputs meet the needs of a 
range of players. Key indicators in this framework, 
as indicated in the defi nition, include uptake and 
use of research and sustainability. Sustainability is 
usefully framed in terms of both funding sources 
and retention of trained staff (see also section 5.3). 
The framework will be populated with information 
from each of the eligible studies independently 
by two individuals and common lessons will be 
extracted by comparing across studies. 
Guidance for sample size calculation (and 
estimated number of participants) N/A. 
Expected duration/timeline: Short-term.
Suitable scale: International.
Estimated budget range: Medium (full-time post 
doctoral researcher, consumables and one meeting 
with stakeholders).
Illustrative references: (53-57). 
5.3 Sustaining operational research 
capacity at the national level
5.3.1 Identifying funding mechanisms 
for operational research capacity 
building at national level
Objective: To identify funding mechanisms to 
sustain operational research capacity at national 
level.
Design Some international funders are increasingly 
investing in capacity building (e.g. the European 
Commission, Wellcome Trust, International 
Development Research Centre) and have formed a 
collaboration to focus on how to evaluate capacity 
building (58). One element of operational health 
research capacity strengthening is securing of 
national ‘buy-in’ to the value of operational research 
for programme delivery, which may be expressed in 
allocation of national budgets.
5.3.2 What are possible ways of 
sustaining and retaining trained 
operational research staff within 
programmes?
Along with sustained funding, sustained staff 
retention is another indicator of successful OHRCB, 
and lessons for retaining and sustaining trained 
staff should be extracted from the OHRCB review 
described in section 5.2. 
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Objective(s) Methods Expected 
outcomes
Expected 
Duration
Suitable Scale Estimated 
budget 
range
5.1 What is the impact of existing training courses in terms of products/outputs and outcomes?
Assess impact of existing 
training
Evaluation Determine impact 
of existing training
Short-term Individual training 
courses
Low to 
medium
5.2 Models of Operational Health Research Capacity Building (OHRCB)
Determine existing 
OHRCB and lessons 
learnt
Review of 
published and 
grey literature 
(including case 
studies, realist 
review, expert 
opinion and 
theorectical 
frameworks)
Documented 
relevant models 
for OHRCB which 
have been shown 
to work in a 
variety of settings
Short-term International Medium
5.3 Sustaining OR capacity at national level
5.3.1 Identifying funding mechanisms for OR capacity building at national level
Identify funding 
mechanisms to sustain 
OR capacity at national 
level
Search for 
funding 
opportunities, 
advocacy 
for funding 
for capacity 
building 
in national 
budgets
Identifi cation 
of funding for 
capacity building
Short-term International Low
5.3.2 What are possible ways of sustaining and retaining trained operational research staff 
within programmes?
Identify mechanisms for 
sustained staff retention
Extract lessons 
for retaining 
and sustaining 
trained staff 
from OHRCB 
review 
described in 
Section 5.2
Identifi cation 
of mechanisms 
for sustainable 
retention of staff
Short-term International Medium
TABLE 5: SUMMARY
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The Impact Assessment Framework (IAF) (1) has 
been developed by a multidisciplinary team at 
the Liverpool School of Tropical Medicine and 
collaborators, including clinicians, laboratory 
specialists, health economists, social scientists 
and health systems analysts. It is based on a 
range of prior research activities in different 
countries that supported various elements of the 
evidence base (2–14). These elements have been 
combined to provide an overarching framework 
(the IAF) to indicate how suffi cient information 
for policy decisions could be collected in a 
systematic manner for all new diagnostic tools 
and approaches. The suffi ciency of information 
has been considered in line with the international 
targets of the Global plan to Stop TB and the 
Millennium Development Goals (MDGs) (15). The 
IAF, with references relating to different types of 
evidence, is shown in Table 3.
The IAF comprises fi ve interconnected layers: 
1. Layer 1: Effectiveness analysis
2. Layer 2: Equity analysis
3. Layer 3: Health systems analysis
4. Layer 4: Scale-up analysis
5. Layer 5: Policy analysis.
Layer 1: Effectiveness analysis
This layer requires evidence about the accuracy 
(sensitivity and specifi city) of new tools and 
approaches, but also fl ags the need to go further 
than this, and build evidence on effectiveness. 
Data on sensitivity and specifi city are universally 
provided by developers of new diagnostics and 
their positive and negative predictive values have 
been suggested by GRADE as proxies for patient 
important outcomes in the assessments of new 
tools. However, estimations of the number of 
patients who might start and complete appropriate 
treatment are typically calculated by extrapolating 
these parameters, rather than relying on evidence 
from fi eld trials to provide estimates of actual 
numbers. All too often, diagnostic evaluations 
assess new tests solely in terms of their diagnostic 
potential (accuracy), which may not always 
translate into appropriate clinical or public health 
management decisions for patients within the 
context of health services (effectiveness). 
Layer 2: Equity analysis
This layer examines who benefi ts from the new 
intervention. The Global plan to Stop TB highlights 
the need to “prioritize the needs of the poor and 
vulnerable” recognizing that the greatest burden 
of TB is found among poor people and they face 
the greatest barriers in access to care (8). Typically, 
however, the systematic measurement of equity in 
health and health interventions is either absent or 
sporadic. Although the fi rst MDG is expressed in terms 
of an equitable outcome, the health and other goals 
that are intended to contribute to this make no specifi c 
reference to equity or distributional issues (16). 
Layer 3: Health systems analysis
This layer examines the health systems requirements 
of a new intervention, for example human resources, 
infrastructure, operating procedures, quality 
assurance, procurement and maintenance. 
These data are sometimes collected during the 
demonstration studies (see Figure 1, in section I) – in 
optimized operational settings - of new diagnostics, 
but not in all cases. Even where they are collected, 
the improvement to operations necessarily provided 
through the demonstration study may mask issues 
that become apparent in implementation studies. This 
layer provides crucial data for assessing the feasibility 
of implementation and for identifying where key 
constraints, or bottlenecks, in the system may occur. 
Layer 4: Scale-up analysis
This layer projects and models the full economic costs 
as well as the clinical and epidemiological effects 
of going from demonstration or implementation 
studies to full scale (national or regional) with a new 
Annex III 
The Impact Assessment 
Framework for new diagnostics
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intervention. Health system, patient, and societal 
perspectives are all important here. Modelling 
techniques can provide information concerning the 
epidemiological benefi ts of scaling up and, when 
combined with patient costs from Layer 2, total 
additional costs or savings for patients. At the same 
time mathematical systems analysis techniques can 
outline the potential constraints to and resources 
required for scale-up. When combined with cost 
analyses from Layer 3, these can give an indication 
of total resources required as well as identify and 
quantify likely resource gaps. 
Layer 5: Policy analysis
This layer critically appraises the new intervention 
studied in layers 1-4 against other interventions 
that are available or may become available for 
uptake in the short- to medium-term. An important 
part of this layer is a scoping of the risk that a 
given new diagnostic test may be supplanted by 
newer technology within a short period of time. 
It requires a rapid assessment of data on other 
pipeline diagnostics from the previous four layers 
and a review of whether changes made for one 
diagnostic may provide a better platform for the 
next technology, or alternatively whether the 
new technology is ‘disruptive’ (17), or ‘market 
transformational’ (18), both terms are used to 
describe a technology that could radically alter the 
way in which TB diagnosis is achieved.
Using the IAF
The IAF can be used by diagnostics research teams 
during the ‘demonstration’ and ‘evidence for scale-
up, delivery and access’ phases of development 
shown in Figure 8. The latter may take the form of fi eld 
evaluation, or implementation studies in non-optimized 
settings, or other operational research activities. The 
framework can also be used by international policy-
makers during the policy development process to 
systematically assess a broader range of evidence 
and by national policy-makers to support adoption, 
implementation and scale-up decisions. 
The IAF has already been used for the development 
of protocols for a multi-country research programme 
to study the implementation of line probe assays 
(LPA), which were recommended by WHO STAG-
TB in 2008 (19). Clinicians and laboratory specialists 
from three countries (Russia, Brazil and South 
Africa), along with other members of the core 
group of the TREAT TB Diagnostic Tools Initiative,ee 
discussed the priority research questions they would 
like to answer with regard to the use of LPAs and 
mapped these questions to each layer of the IAF. All 
the questions that were raised mapped to one layer 
of the framework and all layers were addressed; the 
resulting framework is shown in Table 3. Each of these 
teams now has a different protocol for collecting the 
evidence, due to the stage at which their NTCPs are 
with regard to rolling out LPA. Nevertheless, each 
will provide data against the same set of outcome 
indicators, facilitating comparisons across different 
epidemiological settings. 
The recommended methodology to feed robust 
evidence into Layers 1 to 3 is prospective 
randomised, controlled trials (RCT). This design 
permits comparisons between the existing 
technology and approach (control) and the new 
(intervention) as follows:
For Layer 1: A comparison of effects on a) numbers 
of patients achieving important outcomes (including 
ee See: http://www.treattb.org
FIGURE 8: DIAGNOSTICS DEVELOPMENT PATHWAY 
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diagnosis, start of treatment, and treatment 
completion); and b) time to achieving these outcomes.
For Layer 2: A comparison of effects on different 
patient sub-groups (e.g poor compared with less 
poor, adults compared with children). Equity may 
be assessed based on outcome indicators among 
different groups, in terms of morbidity or mortality 
measures, or process indicators such as health 
service use (16). Analysis of socioeconomic status 
may use asset-based measures to defi ne different 
socioeconomic groups (20). Demographic and health 
surveys, and more recent TB prevalence surveys, are 
increasingly using these methods 21, 22). 
For Layer 3: A comparison of the health system 
inputs required. Data for this may be gained 
through economic analyses of standard versus new 
diagnostic interventions, focussing on the health 
system not just the tool, and through interviews 
with health systems personnel.
Data for these comparisons can be obtained across 
all study participants in both intervention and control 
arms, or through nested sub-studies on more limited 
numbers. For example, in-depth qualitative and 
quantitative research on patient costs incurred during 
a diagnostic process (either control or intervention) is 
time consuming and thus only collected for a sub-
group of study participants. Data from Layers 1 
to 3 can then be fed into the modelling and other 
methodologies required in Layers 4 and 5.
The type of randomized trial employed will depend 
on the stage of diagnostic development to which the 
IAF is being applied. During demonstration studies 
(which may be prior to STAG-TB approval) an 
explanatory RCT with well-controlled study conditions 
and data collection instruments is appropriate. 
During subsequent implementation or operational 
research a pragmatic RCT approach using existing 
health system data will be more suitable (for a fuller 
description of the difference between explanatory 
and pragmatic RCTs, see reference 23). There are 
concerns that RCT designs deny some patients 
(those in the control arm) the assumed benefi ts of 
a new technology – especially in implementation 
research of STAG-approved technologies. Such 
ethical concerns need to be addressed, for example 
by ensuring that the PRCT includes a scale-up plan, 
for example through a stepped-wedge approach in 
which all sites access the technology but in a phased 
manner to allow for comparisons between those with 
and without the technology. 
TABLE 3: A FRAMEWORK FOR IMPACT ASSESSMENT FOR NEW DIAGNOSTICS. 
Layer of 
Assessment Kinds of question(s) being addressed 
References to 
work addressing 
these questions
Layer 1:
Effectiveness 
analysis
How well does new tool work in terms of accuracy? 
How many additional cases will be identifi ed who would otherwise not 
have been identifi ed?
How many additional cases will actually (start and complete) treatment as 
a result of using new tool?
2
6
7
Layer 2:
Equity analysis
Who benefi ts from new tool?  (ambulant or hospitalized, poor/less poor, 
men/women, adults/children)
Why do these benefi ts accrue? (health system level in which new 
diagnostic is deployed, change time to issue of results, change in patient 
costs) 
8
13
Layer 3:
Health system 
analysis 
What are the human resource implications of introducing the new tool? 
(training, number and cadre of staff)
What are the infrastructure implications? (equipment, laboratory layout, 
safety installations)
What are the procurement implications? (reagents, consumables, 
documentation)
What are the implications for quality assurance? (internal and external) 
3
11
14
Layer 4:  
Scale-up analysis 
What are the projected impacts of going to scale with new tool? e.g.
a) cost savings to patients in relation to income 
b) cost savings to health providers/the health system 
d) Effects on transmission of improved infection control as a result of new 
tool
4
11
Layer 5: 
Policy analysis 
What other similar technologies are available or likely to become 
available?
How do similar existing or emerging technologies compare in their 
projected performance within each of the layers above? 
11
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The Tool to Estimate Patients’ Costs can help to 
assess the impact of TB on the welfare of households 
and individuals. More specifi cally, it helps to 
estimate the costs that TB patients incur before and 
during diagnosis and during treatment. It also helps 
to gather information on health-seeking behaviour 
patterns, individual and household income, coping 
behaviour, socioeconomic situation, gender-related 
issues and the social impact of TB.
The tool consists of a generic questionnaire 
designed to be adapted to local settings, a literature 
review, as well as guidelines on adaptation of the 
tool, interpretation of fi ndings, socioeconomic 
indicators, methods and sampling and possible 
interventions. In addition, an Epi-Info data entry 
template, an Excel-based summary sheet and 
an example Powerpoint showing how to present 
results are also included.
The tool can be downloaded as a pdf fi le. It is 
available at: http://www.stoptb.org/wg/dots_
expansion/tbandpoverty/spotlight.asp.
Please note that the data entry template is not 
provided in MS Access format, but in Epi Info 
format. Epi Info can be downloaded for free on the 
CDC Atlanta website.ff
Annex IV 
Tool for capturing patient costs
ff See: http://wwwn.cdc.gov/epiinfo/
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Typically, about half the burden of undiagnosed 
culture-positive TB will be found in the 5 to 10% of 
individuals who report chronic cough in any given 
community (this does not vary much by HIV status) 
(1–4). Many options exist for delivering active 
case-fi nding (ACF) services (see Figure 9 and 
Table 4). On this basis, different models should be 
developed and tested in various situations (urban 
and rural settings, high and low burdens of TB, 
presence or absence of strong community health 
worker programmes, etc.), as well as in important 
risk groups, such as PLHIV, contacts of TB 
cases, persons with diabetes and drug users. For 
instance, options include interventions delivered by 
multipurpose community workers (both successful 
and unpromising results have been obtained; 
see Table 4) and dedicated TB teams. In order to 
identify the best ACF delivery model, these would 
have to be evaluated and compared with regards to 
effectiveness (number needed to screen and cases 
diagnosed) and costs of the different approaches 
in deciding (i) whom to screen for undiagnosed 
TB in the general community (whole populations, 
all adults, adults who are symptomatic on direct 
questioning, adults who respond to the offer to 
report their symptoms, or adults known to have 
risk factors for TB); and (ii) how to screen them 
(different symptoms, smear microscopy, chest 
radiography, newer TB diagnostics). In addition, 
the effectiveness and costs of different approaches 
to delivering community-based services should be 
assessed.
Annex V 
Resources for developing and 
evaluating active case-fi nding 
approaches
FIGURE 9: VARYING LEVELS OF EFFECTIVENESS AND SUSTAINABILITY OF VARIOUS ACF 
SERVICES ACCORDING TO THE CHARACTERISTICS OF THE TARGETED GROUPS 
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TABLE 4: BROAD STRATEGIES AND REPRESENTATIVE EXAMPLES OF DIFFERENT APPROACHES 
TO PROVIDING ACF (SEE ALSO FIGURE 9)
Broad Strategy Representative examples Comments 
Screen whole 
groups  or 
communities for 
TB disease
 Most prevalence surveys (5)
 Mobile CXR in USA and 
Europe during last century (6)
 Annual CXR in S. African  
miners and in Korean civil 
servants (7–10).
Most commonly screening all adults with 
CXR, with or without a symptom screen.
One-off provides estimate of prevalence. 
If repeated provides trends (8,21) or ACF 
if repeated frequently (6). Residual burden 
of radiologically undetectable TB may limit 
impact of repeat CXR screening (22).
Screen whole 
groups or 
communities for 
TB symptoms 
(further 
investigate 
 ymptomatic)
 “Rapid surveys” for TB in 
urban/rural pops & prisons 
(11–15). Individual interview 
with all household members 
(11–14)
or door-to-door enquiry 
for chronic cough in the 
household (7).
 
CXR or smear used to investigate 
people reporting symptoms. Provides 
low cost estimate of prevalence (one-off 
implementation, symptomatic disease only) 
(11–15), and if repeated periodically 
provides ACF (7). More resource intensive 
than providing opportunity to report 
symptoms to outreach services and, in one 
study, less effective (≈20% case-detection per 
round (7)).
Provide whole 
groups or 
communities 
with the 
opportunity to 
be screened 
for TB in 
community 
 Outreach or community 
services delivered to 
all wanting screen, or 
symptomatics only, delivered 
through
- Periodic outreach clinic/van 
(7,16)
 - CHWs or lay volunteers  
providing continuous services 
(17–19)
- community-directed (20).
Relies on community mobilization/
dissemination, with community-level services 
providing sputum collection in the community. 
High impact on case-detection in some 
(7,17,19,20) but not all (16,18) examples. 
High impact on undiagnosed prevalent TB in 
one urban population (7).
Targeted ACF 
aimed at 
individuals or 
groups with 
known risk 
factors for TB 
infection or 
disease
 Screening in those with 
known TB risk factors (e.g. 
HIV/diabetes /IVDU /
immigrants) and 
Contact tracing (typically 
screen for TB infection & 
disease) 
Can be linked to IPT. Screening for TB 
linked to risk factors will be most effective in 
communities where there is a high population 
attributable fraction, good diagnostic and 
chronic care services.
Reaching the very poor will require 
community-level services to identify “at risk” 
individuals and provide screening 
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No sustainable operational research can be 
conducted within NTCPs unless suitable capacity is 
being established. From an NTCP perspective, this 
section focuses on: a) where exactly this operational 
research capacity should be located? b) what sort 
of capacity is needed? and c) how capacity building 
should be done? It will be illustrated through various 
case studies, based on experiences in capacity 
development and implementation of TB operational 
research in Malawi, Brazil, and Indonesia. 
Annex VI 
Capacity building for 
implementing operational 
research in a national 
tuberculosis control programme: 
where, what and how ?
Should this be within the NTCP, a government 
research institute, universities (local or international) 
or nongovernmental organization working with the 
NTCP? Each of these options creates potential 
opportunities and limitations, which are discussed 
below.  
1.1 Embedding operational research within 
the NTCP structure will promote research as an 
important health service delivery activity and could 
lead to improvements both in the monitoring of 
programme activities and the development and 
use of a suitable information system. Importantly, 
it could contribute to empowerment of programme 
managers to translate research fi ndings into policy 
and practice. However, spearheading operational 
research within the NTCP often faces a number of 
challenges (1,2). First, there is a lack of dedicated 
time to conduct operational research and often 
this is coupled with limited capacity. Second, 
programme managers might not recognize the 
relevance of operational research because they 
are concentrated on programme implementation 
and research questions might not be perceived as 
being of priority, or there might be no mechanism(s) 
for deciding on research priorities at the national 
level. Thirdly, individuals who study abroad and 
obtain Masters or other higher degrees are usually 
appointed to senior-level management posts and 
they often have no time or opportunity for research. 
These challenges are often worsened by lack of 
offi ce infrastructure and implementation support. 
There are, however, a number of enabling factors 
that could help overcome these problems. First, 
and foremost, a coordination mechanism should 
be established at national level to provide a clear 
strategy for setting-up (and revising) research 
priorities, which ensures that research questions 
are relevant to programme implementation and 
connected to service delivery. It is necessary to 
have a full-time competent research offi cer with 
suitable programmatic skills who can support the 
programme manager, and develop strategies to 
1. Where should operational research capacity be 
located?
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motivate programme staff (e.g. on-the-job training 
and supervision, research workshops). All this 
must be coupled with the provision of suitable 
infrastructure to support research, such as offi ce 
space, internet access, data management and 
analysis capacities, stationary and transport. Box 3 
gives an example of embedding research capacity 
and implementation in the NTCP in Malawi, and 
outlines the enabling factors that contributed to 
developing TB operational research in that country.
BOX 3: MALAWI CASE STUDY
Building capacity and implementation of TB operational research in Malawi
Technical assistance and dedicated funding for operational research
In 1996, the United Kingdom Department for International Development (DFID) began providing technical 
and fi nancial support for the Malawi National Tuberculosis Control Programme (NTCP) to develop, 
implement, write up and disseminate operational research. Between 1996 and 2003, in addition to 
existing support provided by The Union, other development agencies and international organizations 
entered into partnership with DFID to support the NTCP implementation of operational research. These 
included the Norwegian Agency for Technical Cooperation and Development (NORAD), the Royal 
Dutch TB Association (KNCV), WHO and the United States Agency for International Development 
(USAID). Resources were allocated to training that included in-service training during supervision, an 
annual research training workshop, an annual writing skills workshop and an annual review meeting to 
disseminate research fi ndings to national and international stakeholders.
Multistakeholder partnership
A multistakeholder partnership was set up whereby research ideas from within the NTCP, from local 
institutions (e.g. the Malawi Medical School, the National AIDS Programme) and from international 
organizations and NGOs (e.g. WHO, MSF and The Union) and academia (e.g.  the Liverpool School of 
Tropical Medicine) were discussed and endorsed at the six-weekly meetings of the Malawi TB Programme 
Management Group. After priorities were established, research activities were implemented by the various 
stakeholders. A good relationship was established with the Malawi National Health Science Research 
Committee that received and approved the annual research plan and programme before the start of the 
forthcoming year, and in turn expected an end-of-year report and copies of any published papers. At the 
end of every year, a report was written on research undertaken, studies completed, studies published and 
the effect that these studies had on infl uencing policy and practice (2–9).
The appointment of a Central Unit Offi cer, who worked closely with the Director of the NTCP, and was 
responsible for leadership, organization and implementation of operational research, was an important 
enabling factor in the development of an effective partnership and TB operational research programme 
in Malawi (1). 
Guiding principles to build a sustainable well-functioning TB programme with country-
wide, standardized case-fi nding, treatment and monitoring systems
From the outset, the NTCP developed guiding principles that underpinned the integration and 
implementation of research. The top priority was to have a well-run programme that incorporated all the 
essential elements of the DOTS strategy, and in particular to ensure that registers (particularly the sputum 
laboratory register and the district/hospital TB register) and TB treatment cards were well maintained. 
It was anticipated that these registers and treatment cards would form an important part of the data 
collection for operational research questions.  
Assessment and prioritization of research studies targeted at constraints to national 
and local setting TB control objectives, and integral to established TB systems
With the NTCP developing initial 3-year, and ultimately 5-year plans, the goal and purpose of national 
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TB control were served by a number of key objectives. Constraints were identifi ed that prevented these 
objectives being met, and research questions were asked to help address these constraints, by either 
clarifying or fi nding solutions to them. Research questions tended to be based around three main themes: 
i) Is there a lack of knowledge about the issue in question? For example, what is the prevalence of 
tuberculosis among prisoners?; ii) Is there a lack of a suitable tool or can a better tool be used? For 
example, will a package of HIV testing, counselling and co-trimoxazole preventive therapy for TB patients 
reduce case fatality rates?; iii) Are the tools used ineffi ciently or are the tools ineffective? For example, 
is it more cost effective for the health services to screen pulmonary tuberculosis suspects using two rather 
than three sputum smears? 
Thinking ahead
An annual research programme detailing research activities planned within the NTCP was included in 
the annual workplan and approved each year by the TB Programme Steering Group. A large number 
of studies were undertaken, completed and published between 1996 and 2003. The success of the 
operational research was judged in various ways: 1) Whether proposed annual targets in terms of 
projects initiated, projects completed, papers written and papers published were met; 2) Whether 
the research fi ndings infl uenced policy and practice; and 3) Whether the research helped to improve 
programme performance. 
Strong emphasis on dissemination, both nationally and internationally
Once research studies were completed, they were quickly translated into reports and papers, many of 
which were subsequently published in international peer-reviewed journals. It was felt that this was the 
best way to disseminate knowledge within Malawi and to a global audience, and it was felt that such 
publication would enable TB and TB-HIV operational research to obtain scientifi c credibility and respect. 
In this seven-year period, the NTCP wrote over 100 original research articles and about 30 review/
opinion and policy papers. Research publications from the Malawi TB Control Programme were collated 
each year into an annual report that was printed and disseminated to all districts in the country. 
A focus on results, translation into policy and practice
The operational research studies conducted led to key changes in national policy and practice. These included 
the creation of a prison tuberculosis control programme, which continues to this day (10,11);  improved 
recording and reporting of patients with previously treated TB (12);  a change of treatment regimens from 
hospital-based, 2-months intensive phase therapy centred around daily injections of streptomycin – to oral, 
ambulatory therapy given from health facilities or from family-based guardians (13); better management of 
patients who transfer between facilities (14); and routine HIV testing and counselling for all TB patients, and 
provision of co-trimoxazole preventive therapy to those found to be HIV-positive (15–18). At the international 
level, this research contributed to the development or modifi cation of guidelines on health-care worker safety, 
prison TB control, decentralized TB treatment from hospitals to health centres and beyond, management of 
HIV-associated TB and the eventual adoption by WHO of the recommendation to base diagnosis of TB on two 
rather than three sputum smears. 
Challenges and lessons learnt
Despite the achievements, not all operational research was successful. There were too few well-trained 
research offi cers with too much to do, and attempts to increase these numbers were only partially 
successful. Several projects started and implemented with NTCP funding were never completed because 
of poor study design, poor or unreliable data collection and poor supervision, and there was occasionally 
a failure to translate a few completed but complex projects into understandable and readable papers. 
Sometimes the research was completed and published showing that an intervention was feasible and 
benefi cial to the programme (19), yet for various reasons, policy and practice remained unchanged. 
A key lesson that emerged was that it is essential to put learning systems in place to capture emerging 
lessons from what works, where, why and how.
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1.2 Locating operational research capacity at 
a government research institute. This is the 
case, for instance in Kenya, for example, with the 
Kenya Medical Research Institute (KEMRI) taking a 
lead role in operational research. The advantages 
are that it acts as the fi rst point of reference for 
the Ministry of Health for public health research, 
serving other key national programmes and not just 
TB. Thus, it is well placed to stimulate government 
ownership and responsibility for research at a wider 
level; and it could also provide career opportunities 
for trained national researchers. However, there is 
at present limited practical experience on how to 
make this work in terms of functional links with the 
TB programme, and it relies on the need to obtain 
additional funding. In situations where such a 
structure does not already exist, it might be wiser 
to build a structure within the NTCP initially, with 
the long-term goal of integrating this into a cross-
programme research centre.
1.3 Universities provide potential operational 
research opportunities. They have skilled resources 
that can be particularly useful for specifi c research 
(e.g. qualitative, economics and social sciences), 
they have the methodology and publication skills and 
their involvement can stimulate a scientifi c culture 
within the TB programme. There is a risk, however, 
that outsourcing research to academic institutions 
may draw away researchers from programmes, 
thereby handicapping any existing capacity. Also, 
as implementation is not in the academic mandate, 
fi ndings may be handed to busy programme 
managers who do not have a sense of ownership. As 
a result, there may be limited or no impact in terms of 
getting policy and practice outputs. Many academic 
researchers also lack practical programme skills, which 
may make research rather academic and distanced 
from programme realities.  However, examples exist 
of a systematic process of linking research institutes 
to the NTCP, and strengthening research capacity 
outside the NTCP, such as in Indonesia - see Box 4
Building operational research capacity in Indonesia: linking research institutes 
to NTCP and strengthening research capacity outside of the NTCP
Multistakeholder partnership
The TB Operational Research Group (TORG) was established in 2003 with membership including 
researchers from leading universities in Indonesia, the National Centre for Health Research and 
Development (NCHRD), the NTCP and key funding agencies. Terms of reference for this group included: 
i) Development of a plan for operational research in Indonesia; ii) Promotion of information exchange 
between researchers and the TB programme; iii) Support to operational research at the national, 
provincial and district levels; iv) Promote research co-ordination at National level; v) Capacity building 
for TB operational research by actively supporting young researchers from universities and regional 
health offi ces; vi) Assessment of the relevance and quality of operational research proposals submitted to 
the NTCP either for endorsement or funding support.
Strategy for research capacity development: Decentralized training targeted at young 
researchers
The TORG developed a plan for operational research in Indonesia in 2008 linked to research institutes 
and a process of strengthening research capacity outside the NTCP. It subsequently organized operational 
research courses including:
Designing and Conducting Health Systems Research Projects
 - Volume I: Proposal Development and Fieldwork
 - Volume II: Data analysis and report writing;
The training is organized around four groups per course of fi ve persons (three from university and two 
from provincial or district health offi ce). Participants are selected from national/provincial/district TB 
programmes and local universities. 23 out of 33 provinces have already participated.
BOX 4: INDONESIA CASE STUDY
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Promotion of information exchange between researchers and the NTCP
A key feature of the programme is regular meetings and contact between the chair of the TORG and 
NTCP. The TORG also organizes national operational research dissemination conferences and sharing 
of results among the provinces participating in the TORG workshops.
Relevance, quality and prioritization of operational research
Over a two year period, TORG developed Guidelines for evaluation of research proposals that have been 
used to review 36 operational research proposals submitted to the NTCP; with 12 projects approved for 
funding. 
Strong emphasis on publication, both nationally and internationally
Since it was established, the TORG has yielded three publications in international peer-reviewed 
journals. 15 provinces completed operational research projects with dissemination of recommendations; 
10 provinces completed related projects, with recommendations implemented; 60% of participants (40 
people) have gone on to engage in other research projects after the course. 
Challenges and lessons learnt
Building capacity outside the NTCP is not without challenges. A number of researchers at universities do 
not have adequate knowledge or experience in TB programme implementation. This poses a potential 
risk of bias in the statement/formulation of research questions, which may be driven by interests of 
researchers, and not aligned to NTCP programme priorities. Externally-driven research may have limited 
stakeholder engagement, and as a result, implementation of research recommendations might be more 
diffi cult. Funding may be diffi cult to sustain given that the research outcomes may not be translated into 
policy and practice.
However, linking research institutes to the NTCP and strengthening research capacity demonstrated unique 
advantages. Researchers embedded in a scientifi c environment were well positioned to bring rigour and 
robust methodology to the research process. Research is the main activity of universities and research 
institutes, which were therefore able to dedicate human resources to development and completion of the 
research projects, while researchers in the NTCP often had (many) other duties. In addition, research 
undertaken by those outside the NTCP was perceived to be more independent, and this in turn allowed 
the NTCP to tap into research resources that were already available in-country. Given the commitment to 
research, building partnerships between research institutions and the NTCP forged TB research capacity 
that was sustainable, with a high feasibility of involvement of other disciplines (multidisciplinary research). 
This enabled the NTCP to have permanent access to problem-solving expertise at an affordable cost.
1.4 Nongovernmental organisations (NGOs) 
working with programmes can provide a number 
of opportunities. They work in specifi c settings and 
with vulnerable groups (e.g. prisoners, sex workers, 
MDR-TB patients etc) where researchers often have 
little or no access. An advantage is that those NGOs 
conducting operational research projects are usually 
involved in translating research fi ndings into policy 
and practice on a local scale, which is of added 
programme benefi t. NGOs that are relatively well 
resourced can bring in complementary human and 
material resources for implementation. In particular, 
NGOs can be strong in advocacy, which is of vital 
importance in raising the profi le of operational 
research and catalysing changes to policy and 
practice (3–5). A common problem with NGOs is that 
they may lack training and capacity in the research 
fi eld, as well as the culture and skills for interacting 
with national programs. Box 5 gives an example 
of an NGO in Brazil spearheading the process of 
promoting OR and research capacity development 
in an integrated manner (integrating implementers, 
academic institutions and community) to contribute 
to TB and TB/HIV control.
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BOX 5: BRAZIL CASE STUDY
Experience of Rede-TB in Brazil: Development and impact evaluation of new 
health system intervention tools for TB control, with particular focus on TB/HIV 
and DR-TB
Background
During the period of 1980–2000, there were no NGOs working on TB control in Brazil, and almost no 
interaction between the NTCP, academia and the private sector. Health professionals and researchers 
did not perceive one another as partners. Development of policies for TB control was not driven by 
scientifi c evidence, and effi ciency and impact of such policies was not monitored. The lack of investment 
in efforts to build research capacity was refl ected in the limited range and type of research conducted 
during this period.
Multistakeholder partnership 
In response to the lack of a systematic approach to development of research capacity in Brazil, a 
‘Foresight seminar on TB research and control’ was organised in Rio de Janeiro in March 2001. The 
aim of the seminar was to identify strategies that would enable the development and evaluation of new 
products, technologies and strategies for TB control. A number of stakeholders were invited in order 
to mobilize political commitment and establish a systematic, sustainable system for research capacity 
development. These included representatives from national and provincial TB and AIDS programmes; 
public and private laboratories; research/education institutions; biomedical associations; the national 
regulatory agency and health Council; and relevant NGOs and companies. In this seminar, a consensus 
was reached regarding the need for a Tuberculosis Research Network as an innovative strategy to 
facilitate coverage of all gaps.
Promotion of information exchange between researchers and the NTCP
The Brazilian TB Research Network (Rede-TB) was created in April 2001 to spearhead the effort of 
developing TB control research capacity at the national level. The main objective of Rede-TB was to 
promote research and educational activities in an integrated manner in order to contribute to TB and TB/
HIV control. 
Rede-TB is an NGO initially constituted by an interdisciplinary group of researchers and students working 
on health sciences, engineering and education, who were later joined by civil society partners and 
health service (TB and AIDS) representatives (from the federal, state, and municipality levels). Rede-TB is 
a membership organization of 160 members from 47 institutions, including researchers, policy-makers, 
and AIDS and TB managers. The strategy was to establish a network with self-organizing nodes called 
‘Coordination Areas’ or ‘Working Groups’ according to specifi c areas of research interest, linked to a 
common vision that formed the basis of a platform for membership engagement, identifi cation of gaps 
and research partnership building. 
Rede-TB played a key role in the creation of the Brazilian Partnership Against Tuberculosis (BPAT) in 2004. 
Rede-TB researchers were invited by the Ministry of Health (MoH) to help in the defi nition of a National 
TB Research Agenda in 2004, 2007, and 2010. It also led to the establishment of a number of research 
initiatives including the scientifi c and technological platform in TB diagnosis developed together with the 
Latin America Network for TB Control and WHO. Research institutes and universities are now engaged in 
the implementation of TB operational research, with good interaction between basic and clinical research 
using several laboratories with standardized procedures. This has led to prominent interaction between 
governmental institutions (NTCP, Central Laboratories, Sanitary Supervision Institutions) and industry.
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Strategy for research capacity development: Decentralized multilevel training in health 
systems research methods and operational research
With an award from the Science Technology Department of the MoH, Rede-TB piloted research training in 
Rio de Janeiro Province (2004). Building on this experience, the International Collaborative Operational 
and Health System Research on TB and HIV/AIDS (ICOHRTA) Research Capacity project expanded 
training to fi ve additional provinces using funding from United States National Institutes of Health and 
the MoH to implement research training on clinical, operational and health sector aspects. Health care 
workers and community leaders are invited to participate in research methodology courses of various 
duration and levels, according to their scientifi c background, and to develop their own research projects, 
based on their service experiences and issues. The best projects are supervised by Rede-TB researchers 
and funded by ICOHRTA and the MoH.
Strong emphasis on expansion of academic output
An evaluation of the trends of scientifi c articles focusing on TB in Brazil published between 1986 and 
2006 showed that among 1054 publications, only 6.8% were on operational research and 3.5% 
included qualitative evaluations (20). Rede-TB contributed signifi cantly to the expansion of the academic 
output in TB in Brazil over recent years. Analysis of CAPES (the Brazilian agency for graduate studies) 
databank on theses and dissertations on TB in 2004–2008 revealed that 42% of PhD theses and 37.4% 
of MSc dissertations were mentored by Rede-TB members. 
A focus on results, translation into policy and practice 
Following development of broad consensus that any guidelines modifi cation should be seen by guideline 
developers and policy-makers as a new opportunity for technology incorporation activity, TB and AIDS 
Programme coordinators (at federal, state and municipality levels) prioritized operational research to 
evaluate the effectiveness of existing tools used in TB control, and the impact of new tools before introduction 
into practice. Working in an integrated way, Rede-TB researchers have received signifi cant national and 
international funding for basic, clinical and operational research. Recently, Rede TB researchers took 
part in the development of protocols to evaluate the impact of the introduction in the public health system 
of new diagnostic tests (e.g. Xpert MTB/RIF, line-probe assays), and received funding to investigate 
the accuracy of a new molecular test for pulmonary TB diagnosis (DETECT TB) developed by Brazilian 
scientists in collaboration with national companies.
In addition, Rede-TB conducted a nationwide qualitative study to map performance of health services 
in the diagnosis of tuberculosis in 10 metropolitan areas of Brazil from the perspectives of patients, 
health professionals, managers of health units and civil society organizations. The investigation found 
low effectiveness of TB care, verifi ed by the low suspicion of TB by professionals (even those with high 
knowledge of TB disease), high number of referrals to hospital/emergency and primary care services, 
and a defi ciency in communication fl ow and referring activities between services at all levels (including 
the laboratory network) (21–23). Moreover, TB diagnostic tests were not performed routinely in the health 
facility initially visited by patients. Patient travel requirements until effective TB diagnosis were a factor 
that increased the time between symptom onset and TB diagnosis. This scenario occurred even in those 
cities with more decentralized health systems, where healthy family programmes have received high 
priority.
TB operational research led to key changes in national policy and practice described in the latest National 
Guidelines, released in March 2010. This included the creation of a TB control programme for vulnerable 
citizens (i.e. indigenous, homeless, prison inmates); the development of tools to be used for TB infection 
control in health settings (hospitals, prisons, and primary health services, etc); the adoption of routine TB 
culture for all HIV-infected TB suspects, drug susceptibility testing for drug-resistant TB suspects; and HIV 
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In summary, there are often many locations and 
partners intervening at national level, and each 
of them has comparative advantages. The best 
operational research option would be a partnership 
model led by national programmes that would 
promote better involvement, co-ownership and 
responsibility of programme staff with researchers. 
It is particularly important to integrate funding and 
resources for operational research into a national 
programme so as to get decisional power for setting 
the national research agenda on TB, evaluate how 
and when new technologies should be incorporated 
and decide on implementation. The latter has often 
been the monopoly of foreign institutions and this 
imbalance needs correction.   
testing for all TB suspects; a change of treatment regimens for newly diagnosed TB patients (using a fi xed-
dose combination with four drugs); and standardized drug-resistant TB treatment.
Challenges and lessons learnt
The creation of Rede-TB helped to create renewed bridges between academia, the health system and 
civil society. Engagement of academia strengthened the capacity of TB and AIDS managers, health 
professionals, health-system users and the national Industry in the production of scientifi c knowledge that 
responds to local demands, through operational and health system research approaches. 
Rede-TB is a unique example of NGO leadership and coordination of a national research capacity 
development process that has demonstrated signifi cant, measureable results. Challenges remain, however. 
Sustainability of achievements will require continued investments in research capacity development; 
funding research through the established research coordination areas; training health-care workers, 
managers, and community leaders towards a change in attitude and practices to improve conditions of 
access, the continuity of care, and communication fl ow between TB services (at all levels), as well as with 
the civil society. In addition, ongoing confusion with monitoring and evaluation will need to be resolved, 
and processes strengthened to incorporate research into the national TB programme.
2. What sort of research capacity is needed?
The ultimate goal of research capacity building is 
to provide the ability to individuals, organizations 
or systems to perform and utilize health research 
effectively, effi ciently, and sustainably (24). It is 
distinct from training (which is an organized activity 
aimed at imparting information and/or instructions 
to improve the recipient’s performance or to help 
him/her attain a required level of knowledge or skill). 
At the programme level, the following are required 
in the process of capacity building:
a) ability to defi ne the right research question(s);
b) knowledge of the steps needed to conduct a 
methodologically rigorous study;
c) capacity to collect, store, quality-assure, manage, 
and analyse data (both qualitative and quantitative);
d) capacity to write up the results for publication in 
peer-reviewed journals;
e) engagement of the appropriate range of 
stakeholders (including community and policy-
makers) in the whole process of research to facilitate 
ultimate utilization of the results.
While writing skills for publishing present a challenge 
widely acknowledged across a number of NTCPs, 
fundamental capacity gaps in defi ning critical 
research questions and in research methodology 
have been recognized. In this regard, this document 
attempts to provide a reference tool for NTCP 
managers and researchers to conduct operational 
research projects through brief synopses of suitable 
research methodologies for the set priorities (see 
Annex II). 
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3. How should capacity be built?
3.1 Training courses:
There has been much investment in operational 
research training by various organisations such as 
WHO, the US Centers for Disease Control (CDC), 
Médecins sans Frontières (MSF), Japan Anti-
Tuberculosis Association (JATA), The International 
Union Against TB and Lung Disease (the Union) 
and many others (this list is not exhaustive), but 
there has been limited evaluation of these models 
and of their impact on research and programme 
implementation. A recent publication from the 
Research Institute of TB in Japan showed that, of 
all participants attending an international training 
course in Japan between 2001 and 2007, only 40% 
started operational research projects, and none 
wrote a scientifi c paper (6). The main cited reasons 
for failure to implement and complete studies 
were: lack of time, lack of funds, disapproval by 
supervisors and lack of writing skills. In addition, 
weak or non-existent retention strategies and 
long-term career opportunities further contribute 
to attrition of trained researchers. Training can, 
therefore, contribute to capacity building, but 
unless it is suffi ciently integrated with development 
programmes or collaborations, or supported by 
other longer term capacity development initiatives, 
such as mentorship programmes, it may not result 
in changes in programme implementation such as 
improved patient care and public health.  
3.2 Integrated and targeted capacity 
development approaches:
Capacity development can be integrated 
within development programmes or research 
collaborations as illustrated in Boxes 2 (section III) 
3, 4 and 5 (Annex VI), resulting in research networks 
that support TB Programmes. Such integrated, 
country-based approaches can be supported by 
targeted and novel processes of learning, such as 
the one developed by The Union and MSF along 
with partners (7). The purpose of this training 
is to develop the practical skills for conducting 
operational research among doctors, nurses, data 
analysts and other programme staff, and ensure 
publication of results as appropriate. This model is 
based upon a hands-on modular approach that is 
practical, with strict criteria for candidate selection. 
Strong and sustained mentorship is provided 
by experienced facilitators, and candidates are 
offered long-term retention opportunities, such 
as operational research fellowships. Evaluation of 
training is performance-based, and candidates are 
required to fulfi l set milestones after each module 
in order to continue. Preliminary results of this 
approach are very encouraging, with the fi rst twelve 
candidates who started the course in 2009 having 
submitted a total of 14 papers for publication, of 
which, 11 were already published or in press within 
the twelve months of the course fi nishing.
3.3 Indicators for evaluation of capacity 
development:
Ideally, research capacity development should 
result in researchers who are able to independently 
develop, manage, and obtain funding for their own 
research programmes and ensure that their fi ndings 
are being disseminated and used as appropriate. 
Publication of research results in peer-reviewed 
journals is a crucial output of any research process, 
allowing dissemination of research fi ndings, and 
a good indicator of a successfully completed 
research study. In addition, the evaluation of 
capacity development can be carried out through 
a series of quantitative and qualitative indicators, 
as suggested in Table 5, although these would still 
need to be validated.
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TABLE 5: SUGGESTED INDICATORS FOR EVALUATION OF OPERATIONAL RESEARCH CAPACITY 
DEVELOPMENT WITHIN TB PROGRAMMES (FROM REFERENCE 25)
Quantitative indicators Qualitative indicators
• Presence of an operational research offi ce
• Presence of a research offi cer/focal point
• Ear-marked institutional or programme funding 
for operational research
• Evidence that operational research is in the 
annual budget and plans
• Number of publications in national and/or 
international peer-reviewed journals
• Number of conference presentations
• Number of degrees awarded (e.g. Masters, PhD, 
Post-doctoral)
• Number staff starting/completing graduate 
programme
• Number of research grants/other funding secured
• Number of trained staff employed for 
operational research with existing organisations 
and collaborators (e.g. government agencies, 
NGOs, etc.)
• Number of research/support staff
• Average time for PhD completion
• Career trajectories – number of promotions.
• Access to mentors
• Academic support (security of employment/
length of tenure)
• Programme quality (as judged by 
management quality indicators e.g. on 
leadership, team-working, decision-making)
• Teaching quality indicators (teaching 
effi cacy, teaching methods)
• Learning quality indicators (learning 
attitude, attendance rate)
• Learners’ confi dence and competence in 
research outcomes (i.e. attitudes, intentions).
Conclusion 
There is a need to rapidly and consistently develop 
capacity to conduct sustainable operational 
research at the programme level. The importance 
of operational research has been emphasized in the 
recent revision of the Global Plan to Stop TB 2011-
2015, that gives directions about the operational 
research needs towards the 2015 MDG targets and 
Stop TB Partnership goals. Development of capacity 
must be rapid as training models will need to deliver 
within the time frame of these targets. Approaches 
to training must be practical and target-oriented, 
with defi ned products and outputs that can 
infl uence policy and practice. The long-term vision 
is the development of leadership in operational 
research through collaborative networks in various 
parts of the world.
As it stands, capacity building is a paramount 
element of strengthening operational research at 
the programme level. In addition, there are a number 
of other enabling factors that foster a favourable 
environment for research within TB programmes.
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